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Abstract
RB has been shown to repress pol III transcription by targeting the pol III- 
specific general factor TFIIIB. Work presented here demonstrates that RB binds to 
the BRF subunit of TFIIIB. The binding interaction between these two proteins has 
been shown to require the RB large pocket domain and the amino-terminal repeats of 
BRF. In addition, the mechanism whereby RB represses pol III transcription has been 
established; namely, RB does not compromise the interactions within TFIIIB, but 
instead disrupts the association between TFIIIB and TFIIIC and between TFIIIB and 
pol III.
In human cancers, RB is generally inactivated by one of three means: 
hyperphosphorylation, mutation or viral oncoprotein sequestration. SV40- 
transformed cell lines displayed a diminished interaction between RB and BRF in 
comparison to the untransformed parental line. The association was also alleviated if 
RB was mutated or phosphorylated. In addition, mutant RB forms were unable to 
disrupt the interaction between TFIIIB and TFIIIC and between TFIIIB and pol III.
RB has also been shown to repress pol I transcription. The cunent work 
demonstrated an interaction between RB and the pol I transcription factors UBF and 
SLl. The human and Xenopus XJBF-binding domain in RB was identified as the large 
pocket, whilst xUBF was shown to bind RB through HMG boxes 1 and 2.
The RB-related proteins p i 07 and pi 30 were investigated for their ability to 
undertake RB functions. Indeed, p i07 and p i30 were both able to interact with the 
pol I transcription factor UBF and the BRF subunit of the pol III transcription factor 
TFIIIB.
m
Table of contents
Abstract ii
Table of contents iv
List of figures xi
Abbreviations xv
Declaration xx
Publications xxi
Aclcnowledgements xxii
Table of contents
1 Introduction 1
1.1 The retinoblastoma gene 2
1.2 Rbl is a tumour suppressor gene 3
1.3 The retinoblastoma protein 4
1.4 RB and the cell cycle 6
1.5 Phosphorylation of RB by cyclin-dependent kinases 8
1.6 Disruption of RB activity 10
1.7 RB regulates transcription factors 12
1.8 Other cellular functions of RB 14
1.9 The pocket proteins p i07 and p i30 16
1.9.1 Sequence homology between the pocket proteins 16
1.9.2 p 107 and p 13 0 interact with E2F family members 17
IV
1.9.3 p 107 and p 130 can induce cell cycle arrest when 
overexpressed 20
1.9.4 Analysis of pocket proteins in mutant mouse strains 20
1.9.5 Functional compensation by the pocket proteins 21
1.9.6 p i07 and p i30 have not been identified as tumour 
suppressor proteins 21
1.10 Nuclear RNA polymerases 22
1.11 RNA polymerase III transcription 24
1.11.1 Promoter structure of class III genes 24
1.11.2 Transcription factors utilised by pol III 27
1.11.2.1 TBP 27
1.11.2.2 TFIIIB 28
1.11.2.3 TFIIIC 34
1.11.2.4 TFIIIA 36
1.11.2.5 SNAPc 37
1.11.3 Transcription complex formation on class III genes 38
1.11.4 Regulation of RNA polymerase III transcription 41
1.11.5 Chromatin structure of class III genes 43
1.12 RNA polymerase I transcription 44
1.12.1 Promoter structure of class I genes 44
1.12.2 Transcription factors utilised by pol I 45
1.12.2.1 SLl 46
1.12.2.2 UBF 47
1.12.3 Transcription complex formation on class genes 47
1.12.4 Regulation of RNA polymerase I transcription by UBF 49
1.13 Regulation of pol III transcription by RB 51
1.14 Regulation of pol I transcription by RB 52
1.15 Aims and objectives of these studies 54
Experimental protocols 55
2.1 Molecular biology procedures 57
2.1.1 Determination of nucleic acid concentrations 57
2.1.2 Transformations 57
2.1.3 Large scale DNA preparations 59
2.1.4 Small scale DNA preparations 59
2.1.5 In vitro translation 60
2.1.6 Expression of GST fusion proteins 62
2.1.7 Expression of His-tagged RB (379-928) 64
2.2 Electrophoresis analysis 65
2.2.1 SDS-PAGE 65
2.2.2 Immunoblotting 67
2.3 Immunoprécipitations 70
2.3.1 Purification of antibodies 70
2.3.2 Mini bradford assays 71
2.3.3 Coupling of antibodies to protein A beads 71
2.3.4 Immunoprécipitations using reticulocyte lysate expressed
proteins 72
2.3.5 Immunoprécipitations involving reticulocyte lysate
vi
expressed proteins and cellular extract 72
2.3.6 Immunoprécipitations from cellular extract 73
2.4 GST-pull down assays 73
2.5 Random polymerisation assays 74
2.6 Oligonucleotide binding assay 76
2.6.1 Oligonucleotide binding assay 76
2.6.2 Manufacture of B-box probe 76
2.6.3 Oligonucleotides used in the oligonucleotide binding assay 77
2.7 Tissue culture 78
2.7.1 Passaging of cell lines 78
2.7.2 Cyro-storage of cells 78
2.7.3 Preparation of protein microextracts 79
2.7.4 Bradford assay 81
2.7.5 Transient transfections 81
2.8 Primer extension assays 83
2.8.1 Manufacture of probes 83
2.8.2 Primer extension reactions 83
2.8.3 Oligonucleotides utilised in primer extension analysis 85
Characterisation of the interaction between the pol III transcription 
factor TFIIIB and the tumour suppressor protein RB 86
3.1 Introduction 87
3.2 Results 92
3.2.1 Endogenous and recombinant RB associate with BRF-a
Vll
subimit of TFIIIB 92
3.2.2 The identification of the BRF"-binding domain in RB 95
3.2.3 Identification of the RB-binding region in hBRF 101
3.2.4 Identification of the RB-binding region in yBRF 106
3.2.5 Characterisation of the interaction between the components
of B ’, namely TBP and BRF 110
3.2.6 RB does not disrupt the interaction between BRF and TBP 120
3.2.7 Characterisation of the effects of RB upon the interaction 
between TFIIIB and TFIIIC 123
3.2.8 Characterisation of the affects of RB upon the interactions 
between TFIIIB and pol III 129
3.2.9 Model whereby RB represses pol III transcription 133
3.3 Discussion 133
Disruption of the interaction between BRF and RB in cancer cells 139
4.1 Introduction 140
4.2 Results 146
4.2.1 The interaction between TFIIIB and RB is deregulated 
following SV40 transformation 146
4.2.2 The interaction between TFIIIB and RB is diminished in 
SA0S2 cells but not U20S cells 150
4.2.3 A mutant form of RB from a cervical carcinoma does not 
interact with the BRF subunit of TFIIIB 152
4.2.4 The BRF subunit of TFIIIB does not interact with the
viii
RB null mutant A21 154
4.2.5 A RB null mutant A21 does not disrupt the interaction 
between TFIIIB and TFIIIC 156
4.2.6 RB null mutants do not disrupt the interaction between 
TFIIIB and pol III 158
4.2.7 Phosphorylation of RB prevents interaction with the BRF 
subunit of TFIIIB 163
4.3 Discussion 165
Characterisation of the interaction between the tumour suppressor 
protein RB and the pol I transcription factor UBF 170
5.1 Introduction 171
5.2 Results 175
5.2.1 Endogenous UBF interacts with endogenous RB 175
5.2.2 Identification of the UBF-binding domain in RB 175
5.2.3 The presence of a four amino acid deletion mutation 
in RB is sufficient to compromise its association
with UBF 180
5.2.4 Identification of the RB-binding region in xUBF 180
5.2.5 Endogenous SLl interacts with endogenous RB 187
5.3 Discussion 187
IX
6 The pocket proteins pl07 and pl30 interact with both BRF and UBF 193
6.1 Introduction 194
6.2 Results 196
6.2.1 Recombinant p 107 and p 130 interact with the BRF
subunit of TFIIIB 196
6.2.2 Endogenous p 107 and p 130 interact with the BRF
subunit of TFIIIB 198
6.2.3 Endogenous pl07 and pl30 interact with endogenous BRF 198
6.2.4 Recombinant p i30 interacts with hUBF 200
6.2.5 Endogenous p 107 and p 130 interact with endogenous UBF 202
6.3 Discussion 205
7 Conclusions 209
References 217
List of figures
1.1 Diagrammatic representation of the structure of RB 5
1.2 Diagram of the cell cycle 7
1.3 Diagram of RB inactivation observed in human cancer 13
1.4 Homologous domains between the pocket proteins 18
1.5 Promoter structure of class III genes 25
1.6 The structure of BRF 31
1.7 The order of complex assembly on class III genes 40
1.8 Diagrammatic representation of the structure of UBF 48
1.9 Complex assembly on class I promoters 50
3.1 Endogenous RB coimmunoprecipitates with the BRF subunit of TFIIIB 93
3.2 Endogenous RB coimmunoprecipitates with the BRF subunit of TFIIIB 94
3.3 Recombinant RB interacts with the BRF subunit of TFIIIB 96
3.4 A schematic representation of the GST-RB fusion proteins 98
3.5 Identification of the BRF-binding domain in RB 99
3.6 Overexpression of full-length RB inhibits pol III transcription in vivo 100
3.7 A schematic representation of the hBRF truncations generated 102
3.8 Identification of the RB-binding region in hBRF 104
3.9 Identification of the RB-binding region in hBRF 105
3.10 yBRF interacts with recombinant RB 107
3.11 Identification of the RB-binding region in yBRF 109
XI
3.12 The yeast truncation BRF(284-596) is able to bind TBP 111
3.13 Recombinant BRF interacts with recombinant TBP 113
3.14 Recombinant BRF interacts with recombinant TBP and
this interaction is stable to 400mM KCl 114
3.15 Recombinant TBP interacts with BRF truncations 116
3.16 Recombinant TBP interacts with BRF truncations 118
3.17 A BRF truncation which does not interact with TBP 119
3.18 RB does not disrupt the interaction between recombinant TBP and
recombinant BRF 121
3.19 RB does not abolish the interaction between endogenous TBP and
endogenous BRF 122
3.20 RB disrupts the interaction between endogenous TFIIIC2 and
recombinant BRF 124
3.21 RB disrupts the interaction between endogenous TBP and TFIIIC2 126
3.22 RB disrupts the interaction between endogenous TFIIIC2 and endogenous
TFIIIB 128
3.23 RB disrupts the interaction between pol III and BRF 130
3.24 RB disrupts the interaction between endogenous TFIIIB and
endogenous pol III 132
3.25 Model whereby RB represses pol III transcription 134
4.1 The BRF subunit of TFIIIB interacts with endogenous RB in A31
cell extract, but this interaction is compromised in extracts from 
SV3T3 C138 and C149 cells 147
xii
4.2 The association between endogenous TFIIIB and endogenous RB
is greater in A31 extracts compared to C138 and C149 149
4.3 The BRF subunit of TFIIIB interacts with endogenous RB in U20S
cell extract, but this interaction is compromised in SAOS2 cell extract 151
4.4 Endogenous BRF and RB interact in HeLa cell extract, but not in
C3 3 A cell extracts 153
4.5 The ability of the BRF subunit of TFIIIB to interact with a null
mutant form of RB is severely compromised 155
4.6 A null mutant form of RB is not able to disrupt the interaction between
TFIIIB and TFIIIC2 157
4.7 The RB null mutant A21 can not compromise the interaction between
TFIIIC2 and TFIIIB 159
4.8 Null mutant forms of RB are not able to disrupt the interaction
between TFIIIB and pol III 160
4.9 The RB null mutant A21 cannot compromise the interaction
between pol III and TFIIIB 162
4.10 Hypophosphorylated RB but not hyperphosphorylated RB interacts
with BRF 164
5.1 Endogenous UBF interacts with endogenous RB 176
5.2 Identification of the hUBF-binding domain in RB 177
5.3 Identification of the xUBF-binding domain in RB 179
5.4 Endogenous UBF and RB interact in HeLa cell extract, but this
X lll
interaction is compromised in C33A cell extract 181
5.5 Schematic representation of xUBF truncated mutants 183
5.6 Identification of the RB-binding region in xUBF 184
5.7 Identification of the RB-binding region in C-terminal truncated
xUBF 186
5.8 Endogenous SLl interacts with endogenous RB 188
6.1 Recombinant p 107 and p 13 0 interact with the BRF subunit of TFIIIB 197
6.2 Endogenous p 107 and p 130 interact with the BRF subunit of TFIIIB 199
6.3 Endogenous p 107 and p 130 interact with endogenous BRF 201
6.4 Recombinant p 130 interacts with the pol I transcription factor UBF 203
6.5 Endogenous p i30 interacts with endogenous UBF 204
6.6 Endogenous p i07 interacts with endogenous UBF 206
XIV
Abbreviations
aa
Ab
Amp
APS
ATP
bp
BRF
BSA
CAT
cdk/CDK
CKII
CTP
DEPC-H2O
DMSO
DNA
DTT
E. coli
EDTA
GST
rGTP
h
HDAC
amino acids
antibody
Ampicillin
Ammonium persulphate 
Adenosine triphosphate 
base pairs
TFIIB-related factor 
Bovine Serum Albumin 
chloramphenicol acetyltransferase 
cyclin dependent kinases 
caesin kinase II 
Cytosine triphosphate 
diethylpyrocarbonate water 
Dimethyl sulfoxide 
Deoxyribonucleic acid 
Dithiothreitol 
Escherichia coli 
Ethylenediaminetetraacetate 
Glutathione- S -transferase 
Guanine triphosphate 
human
histone deacetylase
XV
Hepes N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
His Histidine
HMG high mobility group
HPV-16 human papillomavirus type -16
ICR intragenic control regions
IGS intragenic spacer
INK4 inhibitor of cdk4
IP Immunoprécipitation
IPTG Isopropylthiogalactosidase
kD kilo Dalton
LB liquid broth
mA milliamps
Pg micrograms
mg milligrams
Hi micro litres
ml millilitres
mm millimeter
mM millimolar
M molar
mRNA messenger ribonucleic acid
nm nanometers
°C degrees centigrade
P plasmid
XVI
PBP 
PMSF 
pol I 
pol II 
pol III 
PSE 
PTF
rNTPs
Rb
RB
RCE
RNA
RNasin
rRNA
RT
SDS
SDS-PAGE
SINEs
SLl
snRNA
STEM
SV40
PSE binding protein
phenylmethyl sulphonyl fluoride
RNA polymerase I
RNA polymerase II
RNA polymerase III
proximal sequence element
proximal sequence element binding transcription
factor
ribonucleotidetriphosphates
Retinoblastoma gene
Retinoblastoma protein
retinoblastoma control elements
Ribonucleic acid
RNase inhibitor
ribosomal ribonucleic acid
room temperature
Sodium dodecyl Sulphate
Sodium dodecyl Sulphate polyacrylamide gel
electrophoresis
Short interspersed repeats
selectivity factor 1
small nuclear ribonucleic acid
scanning transmission electron microscopy
Simian Virus 40
X V ll
TAP TBP-associated factor
TBP TATA binding protein
TDF Translation dependent factor
TEMED N, N, N ’, N ’-tetramethylethylenediamine
TFIIIA Transcription factor IIIA
TFIIB Transcription factor IIB
TFIIIB Transcription factor IIIB
TFIIIC Transcription factor IIIC
TFIID Transcription factor IID
TFIIID Transcription factor HID
TFIIIE Transcription factor HIE
TIP-120 TBP-interacting protein-120
tis transcription initiation site
TGF transforming growth factor
Tris tris(hydroxymethyl)methylamine
tRNA transfer ribonucleic acid
Tween-20 Polyoxyethylene sorbitan monolaurate
U units
UBF upstream promoter element binding factor
UPE/UCE upstream promoter element
u v ultraviolet light
UTP uridine triphosphate
V Volts
v/v volume/volume
X V lll
w/v weight/volume
y yeast
XIX
Publications
The following publications were submitted during the course of the work presented in 
this thesis.
Sutcliffe, J.E., Cairns, C.A., McLees, A., Allison, S.J., Tosh, k. and White, R. J. 
(1999) RNA polymerase III transcription factor IIIB is a target for repression by 
pocket proteins p i07 and p i30. Mol. Cell Biol, 19, 4255-4261.
Larminie, C.G.C., Sutcliffe, J.E., Tosh, K., Winter, A.G., Felton-Edkins, Z. and 
White, R.J. (1999) Activation of RNA polymerase III transcription in cells 
transformed by simian virus 40. M ol Cell Biol, 19, 4927-4934.
Sutcliffe, J. E., Brown, T. R. P., Allison, S. J., Scott, P. H. and White, R. J. (2000) 
Retinoblastoma protein disrupts interactions required for RNA polymerase III 
transcription. M ol Cell Biol In press.
Scott, P. H., Cairns, C. A., Sutcliffe, J. E., Alzherri, H. M., McLees, A., Winter, A. 
G. and White, R. J. (2001) Regulation of RNA polymerase III transcription during 
cell cycle entry. J. Biol Chem. In press.
XXI
Acknowledgements
I would like to take this opportunity to thank various people for their help and 
support throughout my doctorate studies, without whom I dread to think what may 
have passed.
First and foremost, I would like to thank my supervisor Bob, for all his 
invaluable advice and input over the last three years. In particular, for proof-reading 
this manuscript. Past and present members of the lab for their help and sense of 
humour, in particular, Carol, Chris, Pam, Tim and Angie. The BBSRC for funding 
my PhD studentship. The Biochemistry department for allowing me to undertake my 
studies and also for providing me with numerous drinking partners. A special cheers 
to Sarah and Stephen.
I would also like to thank my brother Tim, for kindly allowing me endless use 
of his computer. In addition, my friends outside the department, in particular Helen, 
Maria and Mr Fury Murray, ah memories. Also my friends outside the university for 
being so supportive, dependable, and cooking dinner for me; it was very much 
appreciated.
Lastly but by no means least I would like to thank my parents for their 
unfailing love and belief in me, thankyou.
XXU
Chapter 1 Introduction
Chapter 1
Introduction
Chapter 1 Introduction
1 Introduction
The retinoblastoma tumour suppressor protein RB can repress transcription by 
all three eukaryotic nuclear RNA polymerases. This chapter shall discuss the cellular 
functions of RB, and the two proteins to which it is related p i07 and p i30. In 
addition, the properties of pol I and pol III will be described.
1.1 The retinoblastoma gene
The retinoblastoma susceptibility gene, Rb, encodes the retinoblastoma 
protein, RB. Retinoblastoma is a childhood cancer of the retina, which arises when 
both alleles o f Rb are inactivated. In 1971, Knudson proposed that for retinoblastoma 
to arise, two mutational events must occur at the same locus (Knudson, 1971). Loss 
of heterozygosity at the Rbl locus in conjunction with the development of 
retinoblastomas, pointed to the existence of a retinoblastoma susceptibility gene 
(Cavenee et ah, 1983). The human R67 gene was identified and isolated (Friend et ah, 
1986), and found to encode a protein of 928 amino acids (Friend et ah, 1987).
The Rbl gene has been found to be mutated in many cancers in addition to 
retinoblastomas, such as osteosarcomas, small-cell lung carcinomas, prostate 
carcinomas, breast carcinomas, some types of leukaemia and cervical carcinoma 
(Herwig and Strauss, 1997; Weinberg, 1995). Children who inherit a mutant Rbl 
allele often develop other cancers, such as osteosaromas, later in life when cured from
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retinoblastoma (Abramson et al., 1979). In mice the situation is altered. Homozygous 
null Rbl mice do not develop retinoblastoma; instead they die at mid-gestation with 
abnormalities in the haematopoietie and nervous system (Clarke et ah, 1992; Jacks et 
ah, 1992; Lee et ah, 1992). Mice displaying heterozygous mutations in Rbl develop 
pituitary and thyroid tumours (Jacks et ah, 1992; Mulligan and Jacks, 1998). These 
observations suggest a role for RB not only in cell growth, but also in development 
and differentiation (Herwig and Strauss, 1997).
1.2 R bl is a tumour suppressor gene
The link between inactivation or loss of the Rbl gene and the development of 
tumourigenesis classified Rbl as a tumour suppressor gene. For example, 
introduction of the wild type Rbl gene into cells lacking a functional RB suppressed 
cell growth and tumourigenicity, thereby verifying Rbl as a tumour suppressor gene 
(Bookstein et ah, 1990; Huang et ah, 1988; Qin et ah, 1992). The ability of RB to 
regulate cell cycle progression was also suggested by investigations demonstrating 
the ability of viral oncoproteins to deregulate cell cycle control. The SV40 T antigen 
(DeCaprio et ah, 1988), adenovirus ElA  (Whyte et ah, 1988) and human 
papillomavirus type-16 (HPV-16) E7 protein (Dyson et ah, 1989b) all interact with 
the hypophosphorylated form of RB. This has lead to a widely aceepted model, in 
which viral oncoproteins promote growth by sequestering RB, which normally acts as 
a brake of the cell cycle by binding E2F and preventing the expression of products 
required for S-phase entry (La Thangue, 1994). The inactivation of RB by mutation
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or phosphorylation was observed to have similar effects, namely the release of E2F 
(Herwig and Strauss, 1997).
1.3 The retinobiastoma protein
RB is a ubiquitously expressed nuclear phosphoprotein and is composed of 
928 amino acids (Lee et al., 1987b; Lee et al., 1987a). Within RB are two stretches of 
amino acids, the A-domain (aa 379-572) and the B-domain (aa 646-772), which have 
been termed the A/B or small pocket (Hu et al., 1990; Kaelin et al., 1990). The 
addition of the carboxy-terminal region (aa 768-928) gives rise to the large pocket 
domain (fig. 1.1). The small pocket is responsible for binding viral oncoproteins, such 
as adenovirus ElA, HPV-16 E7 and SV40 T antigen (Kaelin et al., 1991). The large 
pocket domain region is required for growth suppression and mediates the RB/E2F 
interaction (Qian et al., 1992; Qin et a l, 1992). This domain is also recognised by D- 
type cyclins and suffers the most mutations detected in human tumours (Weinberg, 
1995). There are two proteins that are related in sequence and function to RB, which 
have been called p i07 and p i30. Collectively these proteins are referred to as the 
pocket proteins and the family will be discussed in section 1.9.
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Fig. 1.1 Diagrammatic representation of the structure of RB.
RB is 928 amino acids long, with an A-domain (aa 379-572) and a B-domain (aa 646- 
772). Together these constitute the A/B pocket that is responsible for interacting with 
the viral oncoproteins SV40 Tag, E lA  and E7. A slight extension of the A/B pocket 
is recognised by E2F and cyclin D. The region encompassing aa 379-928 is referred 
to as the large pocket. This is the region which is responsible for growth suppression.
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1.4 RB and the cell cycle
The fundamental task of the cell cycle is to faithfully replicate DNA and 
ensure equal distribution of chromosomes to daughter cells. It is composed of 4 
phases, G l, S, G2 and M, and there is a resting GO phase. The G phases are gap 
phases, the S-phase is when DNA replication occurs and the M-phase is mitosis (fig. 
1.2).
The cell cycle has various check-points which function to ensure conditions 
are propitious for cell cycle progression. One such check-point occurs two-thirds into 
the Gl phase, and is called the restriction point in mammals (Pardee, 1989). The 
restriction point denotes the transition from serum-dependence to serum- 
independence; once cells pass this point, they are committed to enter S phase and no 
longer respond to mitogens (Pardee, 1989). There are alternative routes a cell may 
take, other than entry into S phase, such as differentiation, senescence, or cell death, 
subject to external signals (Herwig and Strauss, 1997).
RB undergoes alterations that coincide with the restriction point. Preceding 
G l, RB is found in a hypophosphorylated form. In contrast, RB isolated from cells in 
the last hours of Gl is hyperphosphorlyated, and remains so until exit from M 
(Buchkovich et al., 1989). There are several lines of evidence to suggest that upon 
phosphorylation RB is inactivated. Firstly, DNA tumour virus oncoproteins eliminate 
RB function by binding hypophosphorlyated but not hyperphosphorylated RB. 
Secondly, only the hypophosphorylated form of RB binds a variety of cellular
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Fig. 1.2 Diagram of the cell cycle.
The cell cycle is composed of four phases which are in sequential order G l, S G2 and 
M phases. Cells can withdraw from the cell cycle upon quiescence. They re-enter the 
cell cycle at Gl.
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proteins. Third, conditions which cause RB phosphorylation also favour cell 
proliferation. These observations allowed a model regarding RB and the regulation of 
cell cycle progression to be proposed; as a cell proceeds through Gl it encounters the 
restriction point, which is held shut by RB. Upon conditions becoming favourable for 
cell cycle progression, RB will be phosphorylated and inactivated. Hence, the arrest 
imposed by RB has been removed, and cells can now proceed into late G l.
1.5 Phosphorylation of RB by cyclin-dependent kinases
There is much evidence to suggest that components of the cell cycle mediate 
RB phosphorylation. Phosphopeptide analysis of RB identified multiple 
phosphorylation sites, which are typical of sites modified by cyclin-dependent 
kinases (-cdks). (Lees et al., 1991; Lin et al., 1991). Henee Gl cyclins, in conjunction 
with cdks, identify RB as a substrate for phosphorylation.
The prototype cdk, cdc2, regulates mitosis in all eukaryotic cells. It does this 
by complexing with its regulatory subunit cyclin B and subsequently phosphorylating 
mitotic proteins. Many proteins sharing sequence similarities to cdc2 have been 
identified, as have their regulatory cyclin subunits. D cyclins, D l, D2 and D3 
complex to their catalytic partners, cdk4/cdk6, and phosphorylate RB, as do cyclin 
E/cdk2 complexes (Weinberg, 1995). However, these complexes aet during 
temporally distinct phases during the cell cycle. Upon serum stimulation, a quiescent 
cell enters G l; this is accompanied by the synthesis of D-type cyclins. These subunits
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assemble with their catalytic partners and phosphorylate RB (Sherr, 1994). Cyclin D- 
cdk4/6 complexes first manifest in mid-Gl, and increase until the Gl/S transition. 
Cyclin D synthesis is halted upon mitogen withdrawal; hence, the associated kinase 
activity diminishes (Sherr, 1996). Cyclin E-cdk2 also contributes to RB 
phosphorylation, but recognises different sites from cyclin D-cdk4/6 (Connell- 
Crowley et al., 1997), but this complex is not prevalent until late Gl (Sherr, 1996). 
Unlike cyclin D-cdk4/6, cyclin E-cdk2 maintains the phosphorylated status of RB in 
a mitogen-independent fashion. RB remains phosphorylated throughout the cell cycle 
until emergence from mitosis. This is maintained by cyclin A-cdk2 in S phase, then 
cyclin A-cdc2 in late S and G2, followed by cyclin B-cdc2 until the cell completes 
mitosis and re-enters Gl (or GO).
The activity of the cyclin D-cdk4/6 complex can be blocked by proteins called 
inhibitors of cdk4 or INK4s. The four known INK4 proteins, p i6^"^^, pl5^^'^\ 
pjgiNK4c and Specifically inhibit cdk4/6. Furthermore, there is a
family of at least three proteins, p21^^\ p27^^ and p57^°"^, which negatively 
regulate cyclin D-, E- and A-dependent kinases. Of these, KIPl would appear to be 
most directly involved in restriction point control. This is underscored by the 
observation that in quiescent cells KIPl levels are high; upon entry into the cell cycle 
they fall. Hence, there is a pathway which regulates the phosphorylation of RB; it is 
called the RB pathway.
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1.6 Disruption of RB activity
To reprise the above introduction, a cell proceeding tlirough Gl will 
encounter the restriction point, which is governed by RB. If conditions are favourable 
the cell will pass into late Gl. However, cells lacking functional RB, as in cancer 
cells, will proceed blithely into late G l.
Hence, how is the activity of RB deregulated, so that it can no longer control 
progression through the restriction point?
The transforming proteins of DNA tumour viruses are known to compromise 
the activity of RB. These oncoproteins bind and inactivate RB. In cervical cancer, for 
example, RB is sequestered by the HPV E7 oncoprotein (Dyson et al., 1989b). Other 
oncoproteins, such as adenovirus E lA  and SV40 large T antigen, are also capable of 
binding and inactivating RB (DeCaprio et al., 1988; Whyte et al., 1988). These 
oncoproteins inactivate RB by disrupting its interactions with cellular proteins, such 
as the pol II transcription factor E2F (Bandara and La Thangue, 1991). Hence, upon 
DNA tumour virus transformation, the viral oncoproteins bind and inactivate RB by 
physically associating with the site of RB, the large pocket, that is recognised by 
many cellular proteins (Weinberg, 1995).
RB function can also be lost through mutation of the Rb gene, as is observed 
in a variety of cancers, such as retinoblastomas, small cell lung carcinomas and many 
sarcomas and bladder carcinomas (Weinberg, 1995). Two RB deletion mutants have
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been isolated from small cell lung carcinoma cell lines NCI-H1436 and NCI-H69C. 
These have been called, RBA21, which lacks 35 amino acids from exon 21, and 
RBA22, in which 38 amino acids from exon 22 are deleted. Studies involving these 
two mutants showed that neither are able to interact with adenovirus E lA  or SV40 T 
antigen (Horowitz et al., 1990). Another RB mutant, isolated from small cell lung 
carcinoma cell line NCI-H209, was also investigated for its ability to mimic the 
functions of wild type RB. This RB mutant contains a point mutation in exon 21 of 
residue 706, from cysteine to phenylalanine (Kaye et al., 1990). This mutant was not 
only unable to bind SV40 T antigen, but it was also underphosphorylated (Kaye et ah,
1990). The inability of mutant RB forms to mimic wild type RB is not a peculiarity of 
those isolated from small cell lung carcinomas. For example, the osteosarcoma cell 
line SA0S2 also contains mutant RB, in which exons 21-27 are removed (Shew et 
ah, 1990). This form is unable to bind SV40 T antigen and is also not phosphorylated. 
Moreover, the introduction of wild type RB suppresses the neoplastic phenotype of 
the SA0S2 cell line, thereby suggesting the endogenous RB to be inactive (Shew et 
ah, 1990).
As mentioned above, phosphorylation of RB results in its inactivation. Hence, 
another mechanism of inactivating RB found in human cancers is maintaining RB in 
a hyperphosphorylated state. This may be achieved by a variety of means, such as the 
amplification of cyclin D l, as observed in many esophageal, breast, and squamous 
cell carcinomas (Jiang et ah, 1992; Lammie et ah, 1991). In addition, the cdk4 gene 
can be overexpressed, as is found in glioblastomas and some gliomas (He et ah, 1994;
1 1
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Schmidt et ah, 1994). Furthermore, the genes encoding p i5 or p i6, inhibitors of 
cyclin D-cdk4/6, may be deleted resulting in the constitutive phosphorylation of RB, 
as observed in esophageal squamous cell carcinomas (Mori et al., 1994; Schmidt et 
al., 1994).
All of these mechanisms converge on the same point, that is the removal of 
RB activity, so that it can no longer function as a brake of the cell cycle, or bind 
cellular proteins (fig. 1.3).
1.7 RB regulates transcription factors
The importance of RB in controlling gene expression was suggested when it 
was shown that E lA  prevents RB from complexing with a cellular transcription 
factor (Bandara and La Thangue, 1991). It was proposed that transforming proteins 
inactivated the transcriptional-repression mediated by RB, and thereby indirectly 
activated the transcription of genes normally negatively controlled by RB. RB was 
subsequently shown to bind to a family of heterodimeric transcriptional regulators 
called E2F (Chellappan et al., 1991). Hence, RB binds E2F and disrupts its ability to 
promote transcription (Weintraub et a l, 1995; Weintraub et a l, 1992). The E2F 
family of transcription factors promotes the expression of genes whose products are 
important for S phase entry. Many are involved in cell cycle regulation, such as 
cyclin E (Geng et al, 1996), or DNA metabolism, such as dihydrofolate reductase 
(DHFR) (Slansky et a l, 1993).
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Fig. 1.3 Diagram of RB inactivation observed in human cancer.
RB can be inactivated by one of three means in human cancers: sequestration by viral 
oncoproteins, hyperphosphorylation and mutational inactivation. Upon inactivation, 
RB is no longer able to exert an effect on transcription factors.
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Through interaction with E2F, RB plays a central role in the control of cell 
division, by regulating cell cycle progression and DNA replication. Until recently it 
was believed that the ability of RB to mediate cell cycle arrest was solely via its 
interaction with E2F. However, recent studies suggest that there are alternative 
mechanisms which may contribute to this effect, such as the ability of RB to control 
cell growth by repressing both pol I and pol III transcription (Cavanaugh et al., 1995; 
White et al., 1996). These studies offer an explanation as to how tumour cells which 
lack RB can increase overall biosynthesis, without which an increase in the frequency 
of chromosome replication would be lethal (Nasmyth, 1996).
1.8 Other cellular functions of RB
Aside from interacting with E2F, and pol I and pol III transcription factors, 
which will discussed below, RB interacts with other cellular proteins, and is involved 
in variety of activities.
RB binds to a number of cellular proteins that may directly or indirectly be 
involved in transcriptional regulation of genes relevant for controlling the cell cycle. 
The promoters of growth control genes c-fos, c-myc, and transforming growth factor- 
pl (TGF-pi) contain sequences termed retinoblastoma control elements (RCE). Spl 
is one of three RCE-binding proteins. RB can interact with Spl, resulting in super­
activation of Spl-mediated transcription (Udvadia et al., 1993). RB can also activate
14
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transcription mediated by the AP-1 family of transcription factors by binding to c-Jun 
(Nead et ah, 1998).
RB has also been shown to repress pol II transcription by recruiting a histone 
deacetylase. RB binds histone deacetylase 1 (HDACl) through the pocket domain. 
HDACl and RB cooperate to repress the E2F-regulated promoter of cyclin E (Brehm 
et al., 1998; Magnaghi-1aulin et al., 1998). Hence, by recruiting HDACl, RB is able 
to halt cell cycle progression.
RB has also been shown to be required for differentiation of certain cell types. 
This is characterised by permanent cell cycle withdrawal, and the expression of genes 
required for the differentiated phenotype. The first evidence that RB was involved in 
differentiation came from Rb-!- knock-out mice, which die in utero due to defects in 
erythropoiesis and neural development (Clarke et al., 1992; Jacks et a l, 1992; Lee et 
a l, 1992). A role for RB in differentiation has been identified for various cell lines. In 
all systems studied, an early development is the dephosphorylation of RB, which 
correlates to cell cycle arrest in GO/Gl, and provides a prerequisite to enter the 
differentiation pathway. For example, in differentiating muscle cells RB complexes 
with myogenic transcription factors, such as MyoD. This interaction prevents RB 
from being rephosphorlyated and locks the cell in a differentiated state (Gu et al,
1993).
RB is involved in protecting against apoptosis (programmed cell death). 
Apoptosis is a genetically controlled process; genes involved have been identified,
15
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such as p53 and myc. The ectopic expression of wild type RB in SA0S2 cells 
increases radioresistance; that is, the ionising radiation induces less cell death in cells 
which express RB (Haas-Kogan et ah, 1995). The mechanism whereby RB protects 
cells from radiation-induced apoptosis is unclear. RB appears to be involved in 
regulating the apoptotic function of p53, as both of these tumour suppressor proteins 
are able to interact with the same oncoprotein MDM2. Indeed, RB can overcome the 
anti-apoptotic function of MDM2 on p53-induced apoptosis (Hsieh et al., 1999a).
1.9 The pocket proteins pl07 and pl30
RB belongs to a family of proteins, termed the pocket proteins, of which there 
are two other members, p i07 and p i30. These pocket proteins were identified as 
resembling RB in being able to physically associate with viral oncoproteins such as 
adenovirus ElA, SV40 and JC virus Tag, and HPV-16 E7 (Dyson et ah, 1989a; Ewen 
et ah, 1991; Hannon et ah, 1993; Li et ah, 1993; Mayol et ah, 1993). All three of 
these pocket proteins share sequence homologies and functional similarities.
1.9.1 Sequence homology between the pocket proteins
p i07 and p i30 are closely related to each other (-50% amino acid identity) 
and to RB (-30-35% amino acid identity) (Grana et ah, 1998; Mulligan and Jacks, 
1998). The structural conservation between RB, p i07 and p i30 is clustered into five
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regions, the majority of which is localised to the small pocket domain (Ewen et ah, 
1991; Hannon et al., 1993; Li et a l, 1993; Mayol et al., 1993) (fig. 1.4). The spacer 
region between the A- and B- domains is well conserved between p i 07 and p i30, but 
not between all three pocket proteins. It provides a site for interactions with cyclin A- 
cdk2 and cyclin E-cdk2 (Lees et al., 1992: Cobrinik et a l, 1993; Li et a l, 1993). 
Indeed, the pocket protein/cyclin-cdk complexes have been shown to display reduced 
kinase activity. It has been proposed that this contributes to the ability of p i07 and 
p i30 to arrest cell growth (De Luca et a l, 1997; Hauser et a l, 1997; Woo et al,
1997).
1.9.2 p i07 and pl30 interact with E2F family members
The E2F family of transcription factors provides an example of functional 
similarities between the pocket proteins. E2F1 can be detected in immunoprecipitates 
of RB, as can E2F2, E2F3 (Lees et a l, 1993) and to a lesser extent E2F4 (Morberg et 
a l, 1996). Whilst, pl07 and pl30 are not detected in the immunoprecipitates of 
E2F1-3, they are observed in those of E2F4 (Beijersbergen et a l, 1994; Dyson et al, 
1993; Ginsberg et a l, 1994; Vairo et a l, 1995). In addition, p i 30 can be found in 
complexes with E2F5 (Hijmans et a l, 1995). The coimmunoprecipitation data were 
substantiated by the finding that E2F4 relieves pl30-mediated Gl arrest more 
effectively than E2F1 (Vairo et a l, 1995). E2F4 and E2F5 lack the C-terminal RB- 
binding domain found in E2F1-3, but contain a DNA-binding and a transactivation 
domain (Beijersbergen et a l, 1994; Ginsberg et a l, 1994). All three pocket proteins
17
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Fig. 1.4 Homologous domains between the pocket proteins.
There are five domains of homology between RB, p i07 and p i 30, denoted as dark 
blue regions. Most of this homology is located within the large pocket domain. There 
is greater homology between p i07 and p i30, and these regions are coloured light 
blue.
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can interact with E2F family members. However, deregulation of E2F-target genes 
was observed in cells lacking RB or both p i07 and p i30, but not in cells lacking 
either pl07 or pl30. Interestingly, the genes deregulated under these two conditions 
were completely different. Hence, RB, p i07 and p i30 provide different functions in 
E2F regulation (Hurford et a l, 1997).
Like RB, pl07 and pl30 form a complex with their E2F partner at temporally 
distinct points during the cell cycle (Morberg et a l, 1996). RB associates with E2F 
mainly in Gl and S phase, p i07 forms two complexes with E2F, one with cdk2 and 
cyclin A that predominates in the S phase; the other complex consists of cdk2 and 
cyclin E and is found in the Gl phase (Lees et a l, 1992). pl30-E2F complexes are 
primarily found in cells in GO (Cobrinik et a l, 1993; Smith et a l, 1996); once the cell 
has passed into Gl, cyclin A- or cyclin E- cdk 2 enters the complex (Li et a l, 1993).
It is of interest to note that the major pocket protein/E2F complexes observed 
in the cell cycle coincide with the expression of p i07 and p i30, which fluctuate 
throughout the cell cycle. When cells enter quiescence, the level of p i30 rises; as a 
cell passes towards S phase, the level of p i30 sharply declines, then increases again 
as a ceil exits the cell cycle (Mayol et a l, 1996). The levels of p i07 expression follow 
a near opposite trend; little p i07 is detected in quiescent cells, but p i07 accumulates 
sharply as cells progress through the cell cycle (Beijersbergen et a l, 1995; Cobrinik 
et a l, 1993). It would appear that the increase in p i07 is accompanied by an increase 
in pl07 mRNA (Hurford et a l, 1997). The regulation of pl30 expression is post- 
transcriptional, as there is little variation in p i30 mRNA levels (Grana et a l, 1998).
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1.9.3 pl07 and pl30 can induce cell cycle arrest when overexpressed
As mentioned above, the overexpression of RB in cells results in an increase 
in the number of cells in Gl phase of the cell cycle (Goodrich et ah, 1991; Qin et al., 
1992). As pl07 and pl30 were shown to display considerable homology to RB, it was 
investigated if they could also arrest cell cycle progression. Upon overexpression 
pl07 arrests progression through the cell cycle (Zhu et al., 1993), as does pl30 
(Claudio et al., 1994).
1.9.4 Analysis of pocket proteins in mutant mouse strains
Analyses of Rb family mouse mutants demonstrate an important in vivo role 
of these genes in regulatory functions. Homozygous Rb knock-out mice die between 
13 and 15 days of gestation with defective neurogenesis and erythropoiesis, whilst 
heterozygous mice develop tumours of the pituitary and thyroid, but do not display 
retinoblastoma (Clarke et ah, 1992; Jacks et al., 1992; Lee et al., 1992). In contrast, 
animals lacking functional p i07 or p i30 develop normally, with no observed 
predisposition to tumours. Animals lacking both p i07 and p i30 are bom with 
shortened limbs and rib bones, fail to respire and die rapidly (Cobrinik et al., 1996). 
Interbreeding of the Rb and p l0 7  mouse strains points to species-specific 
susceptibility to retinoblastoma, which might be related to differential requirements 
for gene mutation. Rb+/- p i 07-/- animals display lesions characterised by severe 
dismption of normal retinal stmcture, but these are not observed in other
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combinations {Rb+I- pîSOd-, pl30+l- plOJd- or pl07-\-l- pl30-l-). The retinal 
phenotype of Rb+I- p i 07-/- animals suggests that p i07 and RB have overlapping 
functions in the control of cell growth in the murine retina.
1.9.5 Functional compensation by the pocket proteins
As has been mentioned, the functions of the pocket proteins may overlap, but, 
there also appears to be functional compensation. This is illustrated by peripheral T 
lymphocytes from pl30-deficient mice. As mentioned above, the pl30-E2F4 
complex is most prevalent in quiescent cells, suggesting a role for p i30 in the resting 
status of a cell; disruption of this complex causes the cell to enter the cell cycle. 
However, in p i  30-/- T lymphocytes the quiescence status and re-entry into the cell 
cycle are identical to p i 30-^/+ and p i 30+/-. The levels of p i07 in these mutant cells 
are significantly elevated, and mobility shift analyses indicate that p i07 has replaced 
p i30 in the E2F regulatory complex. In T lymphocytes deficient in both p i30 and 
p i07, there are elevated levels of free E2F and also a RB-E2F4 complex (Mulligan et 
a l, 1998), which suggests functional compensation.
1.9.6 pl07 and pl30 have not been identified as tumour suppressor proteins
The role of p i07 and p i30 in tumour suppression remains unclear. RB is 
mutated in a variety of human cancers (Weinberg, 1995). However, no mutant forms
2 1
Chapter 1 Introduction
of pi 07 have been reported, and only one mutant form of p i 30 has been detected in a 
small-cell lung cancer cell line (Helin et ah, 1997). It could be that one compensates 
for the others absence, and that both need to be inactivated to reveal their tumour 
suppressing functions. However, both pl30+/-/pl07-/- and pl30-/-/pl07+/- mice 
failed to exhibit an obvious tumour phenotype, suggesting that loss of both p i30 and 
p i07 is insufficient for tumour progression in murine tissues. In addition, p i07 has 
been mapped to a chromosome region not altered in human cancers (Ewen et al., 
1991). p i30, however, mapped to a chromosome region which is deleted in a variety 
of cancers (Yeung et al., 1993). This suggests a possible role for pl30 as a tumour 
suppressor protein in humans.
As discussed above, p i07 and p i30 are able to mimic some of the functions 
performed by RB; for example, they are recognised by viral oncoproteins, they bind 
various E2F family members and they can arrest cell growth when overexpressed. 
Between the three pocket proteins there appears to be some functional overlap and 
compensation. However, unlike RB, p i07 and p i30 are not regarded as tumour 
suppressor proteins.
1.10 Nuclear RNA polymerases
Eukaryotic organisms have three nuclear RNA polymerases, namely RNA 
polymerase (pol) I, pol II and pol III. Each RNA polymerase synthesises a unique set 
of products; pol I synthesises the 5.8S, 18S and 28S ribosomal RNAs (rRNA). pol II
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synthesises messenger RNA (mRNA) and most small nuclear RNA (snRNA), whilst 
pol III synthesises transfer RNA (tRNA), 5S rRNA and various small nuclear RNAs 
and viral RNAs. Below, the properties of pol I and pol III transcription shall be 
discussed, as will the ability of ÈB to regulate them.
The three classes of RNA polymerases that occur in eukaryotes were 
originally separated by chromatography on DEAE Sephadex (Roeder and Rutter, 
1969). They were classified according to chromatographic properties, salt 
requirements, template preferences and their sensitivity to the toxin a-amanitin, a 
cyclic octapeptide produced by the poisonous Amanita mushrooms (Chambon, 1975; 
Kedinger et al., 1970; Roeder and Rutter, 1969). In mammals, pol II is the most 
sensitive (50% inhibition at 25ng/ml), with pol III displaying intermediate sensitivity, 
(50% inhibition at 20pg/ml), whilst pol 1 is completely resistant (Schwartz et al., 
1974).
There are five subunits which are found in all three nuclear RNA polymerases 
(ABC 27, 23, 14.5, 10a and lOp, in S. cerevisiae). Pol I and pol III share two 
additional subunits (AC 19 and AC40 in S. cerevisiae) (Mann et al., 1987). These 
subunits are not present in pol II, but, B12.5 and B44 are functionally equivalent 
(Paule and White, 2000).
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1.11 RNA pol III transcription
1.11.1 Promoter Structure of Class III genes
The majority of class III genes include discontinuous intragenic structures 
termed internal control regions (ICRs). There are three types of class III gene 
promoter, called type I, II, and III. Each is composed of specific sequences and is 
present in particular genes (as summarised in fig. 1.5).
The ICRs of 5S rRNA genes are unique and are often referred to as type I. 
They are composed of two functional domains located within the transcribed region; 
an A-block, and a second domain consisting of an intermediate element and a C- 
block; a prime example is Xh^Xenopus laevis 5S rRNA gene. The location of the ICR 
lies between base pairs +50 and +97; the A-block lies between +50 and +64, the 
intermediate element +67 and +72 and the C-block +80 and + 97 (Pieler et al., 1987). 
The bases between these regions serve as spacers, but their sequence does not 
influence transcription efficiency (Pieler et ah, 1987).
The majority of class III genes display a type II promoter, such as tRNA, VA, 
Alu and 7SL genes. These promoters are located downstream of+I and are composed 
of two domains of 10 base pairs, termed the A- and B-blocks. The sequences of the 
A- and B-blocks of many eukaryotic tRNA genes have been determined, allowing a 
consensus sequence for each block to be derived; namely TGGCNNAGTGG for the 
A-block and GGTTCGANNCC for the B-block (Galli et al., 1981). The A-blocks of
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Fig. 1.5 Promoter structure of class III genes.
Diagrammatic depiction of the three types of class III promoters, which are 
characterised by particular sequences. An example of a type I promoter is found in 
Xenoptis somatic 5S rRNA genes. It is characterised by three promoter elements, an 
A-block (+50 to +60), an intermediate element (~ +70) and a C-block (+80 to +97). 
Type II promoters, such as the SUP4 tRNA promoter of S. cerevisiae, display two 
conserved sequences, an A-block (+8 to +19) and a B-block (+52 to +62). Human U6 
snRNA genes have a type III promoter structure, consisting of a DSE (-244 to -214), 
a FSE (-66 to -47) and a TATA box (-30 to -25). The site of transcription initiation is 
denoted by a bent anow.
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type II promoters are located closer to +1 then those of type I promoters. For 
example, in the S. cerevisiae SUP4 tRNA^^' promoter, the A-block is positioned from 
+8 to +19, whilst the B-block encompasses bp +52 to +62 (Allison et al., 1983). The 
location of the B-block varies. An interblock separation of 30-60 bp is optimal for 
transcription. However, a distance of 365 bp can be tolerated (Baker et al., 1987; 
Fabrizio et al., 1987). This is quite remarkable, when one considers that both of these 
blocks are contacted by the same transcription factor TFIIIC (Schultz et al., 1989).
The final promoter type is independent of intragenic elements and is located 
within 5’ flanking regions; an example is provided by the human U6 gene. The 
human U6 promoter consists of a TATA box, between -30 and -25, a proximal 
sequence element (PSE) located between -60 and -47, and a distal sequence element 
(DSE) between -244 and -214 (Das et al., 1988; Kunkel and Pederson, 1989; Lobo 
and Hernandez, 1989). The U6 PSE and DSE are homologous and interchangeable 
with elements at similar positions in the class II U2 snRNA gene (Lobo and 
Hernandez, 1989). A TATA box is not found in the U2 promoter, which is surprising 
as TATA sequences are normally associated with class 11 gene promoters. Moreover, 
the insertion of a TATA box into the U2 promoter converts it to a pol 111 promoter, 
and removal of the TATA sequence from the U6 promoter allows it to be transcribed 
by pol II (Lobo and Hernandez, 1989; Mattaj et ah, 1988).
There are other class 111 genes, whose promoter types do not fall into any of 
the above classifications, such as the Epstein-Barr virus EBER2 gene (Howe and Shu, 
1989).
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1.11.2 Transcription factors utilised by pol HI
Purified pol III initiates transcription randomly (Hammond and Holland, 
1983). In order for accurate and specific transcription to occur, the assistance of 
transcription factors is required.
1.11.2.1 TBP
TBP was originally thought to be restricted to the expression of class II genes. 
Upon elucidation of the U6 promoter sequence, it was proposed that a TATA-binding 
factor is utilised for expression of U6 snRNA (Mattaj et al., 1988). Observations by 
Margottin and co-workers (Margottin et al., 1991) showed that TBP was indeed able 
to support U6 transcription by pol III. It was subsequently shown, by competition and 
reconstitution analyses, to be required for the expression of pol III genes whose 
promoters did not contain a TATA-box (White et al., 1992a; White et al., 1992b).
TBP was originally purified (Buratowski et al., 1988; Cavallini et al., 1988; 
Horikoshi et al., 1989a) then cloned, (Cavallini et al., 1989; Fikes et al., 1990; Hahn 
et al., 1989; Hoffinann et al., 1990; Horikoshi et al., 1989b; Schmidt et al., 1989) 
from yeast. TBP encoding genes give rise to a protein of 27-38kD. The N-tenninal 
region is variable in both size and sequence; in contrast, the C-terminal domain is 
highly conserved. For example, the C-terminal 180 residues of TBP isolated from
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human, mice and frog are 100% identical (Hashimoto et a l, 1992; Tamura et a l,
1991), and at least 80% conserved to TBP isolated from yeast (Fikes et a l,  1990).
Upon chromatography, TBP fractionates heterogeneously, suggesting its 
inclusion in various complexes (Timmers and Sharp, 1991). Proteins which associate 
with TBP are called TBP associated factors or TAFs (Hernandez, 1993; Rigby, 1993; 
White and Jackson, 1992c). In the pol 11 system the TBP-TAF complex is TFllD. In 
pol I it is referred to as SLl or TIF-IB, it is composed of TBP and three TAFs, 
(Comai et a l, 1992; Zomerdijk et a l, 1994). The TBP containing complexes of pol 
111 transcription are TFIIIB and SNAPc.
1.11.2.2 TFIIIB
TFIllB alone is sufficient to recruit the polymerase and specify the start site of 
transcription (Kassavetis et a l, 1990). Kassavetis et a l, (Kassavetis et a l, 1989) split 
a TFIIIB fraction into two components called B’ and B” by chromatography on 
Mono S. Both of these fractions were shown to be necessary for the transcription of 
tRNA in the presence of purified TFlllC and pol 111. TFIIIB does not bind to TATA- 
less class 111 genes directly (Johnson et a l, 1991), instead it is recruited into the 
vicinity of DNA by interacting with TFllIC (Kassavetis et a l, 1989), Bartholomew 
et. a l (Bartholomew et a l, 1990) exploited this property to probe the polypeptide 
composition of TFIIIB by photocross-linking. This approach detected two 
polypeptides of 70 and 90 kD within the TFIIIB fraction which are recruited to the
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promoter by TFIIIC (Bartholomew et ah, 1991). The 70kD polypeptide was found in 
the B’ Mono S fraction and the 90kD polypeptide in the B” fraction (Bartholomew et 
ah, 1991).
The gene encoding the 70kD subunit of yeast TFIIIB was cloned. The gene 
has been named BRFl (Colbert and Hahn, 1992), TDS4 (Buratowski and Zhou, 1992) 
and PCF4 (Lopez-de-Leon et al., 1992), here it will be referred to as BRFl and its 
product yBRF. BRFl has been shown to be essential for growth (Buratowski and 
Zhou, 1992; Colbert and Hahn, 1992). Introduction of mutations induce a rapid 
decline in the in vivo expression of tRNA, but not of class 1 or class II genes 
(Buratowski and Zhou, 1992; Lopez-de-Leon et ah, 1992). BRFl encodes a protein of 
596 amino acids, with a predicted molecular mass of 67kD and a pi of ~ 6.9 
(Buratowski and Zhou, 1992; Colbert and Hahn, 1992; Lopez-de-Leon et ah, 1992). 
Its structure can be split down the middle. There is a zinc ribbon at the extreme 
amino-terminus. The remainder of the amino half displays two highly conserved 
imperfect repeats of 76 amino acids (Buratowski and Zhou, 1992; Colbert and Halm, 
1992; Lopez-de-Leon et ah, 1992). In contrast, the carboxy-terminal half has no 
homology to any known protein. However, three regions of conservation have been 
identified between BRF cloned from evolutionarily diverse yeast species (Khoo et ah,
1994).
yBRF and TBP were both identified in the B’ fraction by western analysis 
(Buratowski and Zhou, 1992; Colbert and Hahn, 1992; Kassavetis et ah, 1992). This 
was confirmed as antibodies raised against recombinant TBP or yBRF were
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specifically able to super shift a TFIIIB/DNA complex in a gel retardation assay 
(Buratowski and Zhou, 1992; Kassavetis et ah, 1992). Furthermore, Kassavetis et al, 
(Kassavetis et ah, 1992) showed that recombinant TBP and recombinant BRF was 
sufficient to reconstitute all the known properties of the B ’ fraction, thereby providing 
strong evidence that TBP and BRF interact to form part of TFIIIB. GST pull down 
analyses showed that within BRF there are two TBP binding sites (Khoo et ah, 1994). 
One mapped to the direct repeat region; the other, which showed the greatest affinity, 
was the H2 region in the carboxy terminal half (Andrau et ah, 1999; Kassavetis,
1998)(see fig. 1.6 for the binding regions identified in BRF).
The other TFIIIB fraction observed by Kassavetis et al was B” (Kassavetis et 
ah, 1991), the activity of which was found to co-migrate with the 90kD polypepetide 
in a SDS-polyacrylamide gel (Kassavetis et ah, 1992). Definite evidence that the 
90kD subunit is responsible for B” activity came with the cloning of its gene 
(Kassavetis et ah, 1995; Roberts et ah, 1996; Ruth et ah, 1996). It encodes a 594 
amino acid protein with a calculated mass of ~ 68 kD, but which migrates at ~ 90kD 
(Kassavetis et ah, 1995; Roberts et ah, 1996; Ruth et ah, 1996). B” displays little 
homology to other known proteins, expect for a putative SANT domain (Aasland et 
ah, 1996).
B” can retain its activities when extensively truncated (Kassavetis et ah, 1995; 
Kumar et ah, 1997). A core domain of 176 residues (residues 224-400) is sufficient to 
support U6 transcription (Kumar et ah, 1997). Two distinct regions, residues 224-305 
and 390-460 are both necessary for tRNA synthesis but can function on an either/or
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Fig. 1,6 The structure of BRF.
The N-terariinal half of BRF consists of an N-terminal Zn ribbon and two imperfect 
repeats. The N-terminal 320 amino acids of yBRF are 23% identical to either human 
or yeast TFIIB. The TFIIIC binding domain in BRF has been identified as 
encompassing much of the N-terminal half. TBP has two binding sites within BRF: 
one located in each half, the site in the C-terminal half is the strongest. The region 
responsible for binding pol III is the carboxy teiminus of the imperfect repeat.
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Chapter 1 Introduction
basis for U6  snRNA expression (Kumar et ah, 1997). Protein footprinting suggests 
that B” is folded such that these two domains are in close proximity when TFIIIB is 
assembled onto DNA (Kumar et al., 1997). The resilience of B” to deletion 
mutagensis may be accounted for if the multiple protein/protein and protein/DNA 
interactions made by this polypeptide allow it to compensate for the loss of any 
individual contact. Recombinant B” binds weakly to TBP, but this binding can be 
greatly enhanced by the presence of yBRF. In contrast, no interaction is observed 
between yBRF and B” in the absence of TBP (Roberts et al., 1996).
S. cerevisiae TFIIIB can be reconstituted from recombinant TBP, BRF and B” 
(Kassavetis et al., 1995; Roberts et al., 1996; Ruth et al., 1996). The activity observed 
for the recombinant complex is lower than that for native TFIIIB (Kassavetis et al., 
1995; Ruth et al., 1996). This might be because the recombinant TFIIIB complex 
lacks some post-translational modifrcation(s) that are present in the native complex, 
or perhaps an essential component is missing (Kassavetis et ah, 1995).
A putative gene encoding a homologue of yBRF has been identified in 
Caenorhabditis elegans (Larminie and White, 1998). The CeBRF protein is predicted 
to be 26% identical and 35% similar to yBRF from S. cerevisiae. It is much longer, 
consisting of 759 residues (Larminie and White, 1998). The greatest homology lies in 
the N-terminal half, which contains a putative zinc ribbon and two imperfect direct 
repeats (Larminie and White, 1998). The C-terminal half bears two of the three 
regions of homology that are shared by the yBRFs (Larminie and White, 1998).
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Mammalian TFIIIB is less well understood. It has been purified using various 
chromatography techniques. Using anti-TBP antibodies, a TAF of 88-90kD could be 
immunoprecipitated fi-om fractions containing TFIIIB (Mital et al., 1996; Wang and 
Boeder, 1995). The cDNA encoding this TAF was isolated by peptide sequencing, 
and the product was found to contain 677 residues (Mital et al., 1996). The N- 
terminal 280 residues are 24% identical to human TFIIB and 41% identical to yBRF 
from S. cerevisiae', hence it was called BRF (Mital et al., 1996). Like the other BRF 
sequences, the N-terminal half of human BRF or hBRF contains a zinc ribbon and 
two imperfect direct repeats (Mital et al., 1996). The C-terminal half displays little 
homology to yBRFs, except for the residues which constitute the H2 region (Mital et 
ah, 1996), but shows more homology with CeBRF (Larminie and White, 1998). 
Transcription of VA, 5S and tRNA genes is compromised following 
immunodepletion of hBRF, but expression can be restored by the addition of 
recombinant TBP and hBRF (Mital et ah, 1996; Wang and Roeder, 1995). Recently 
another mammalian TFIIIB TAF was described. It displays homology to yeast B”, 
and is necessary for the transcription from both TATA-less and snRNA-type 
promoters (Schramm et ah, 2000).
The requirement of TFIIIB for type III promoters is different than that of type 
I and type II promoters (Lobo et ah, 1992). BRF may not be involved in U6  
transcription, as immunodepletion of BRF inhibits VA transcription but does not 
affect U6  transcription, (Mital et ah, 1996). Hence, it was proposed that type III 
promoters utilise a modified form of BRF. Lately, various splice variants of hBRF 
have been cloned; all of these can complex with TBP. However, they are required for
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transcription at structurally distinct promoter types; hBRFl is required for 
transcription from 5S, VAl, 7SL and EBER2 promoters, whilst hBRF2 is recruited to 
the U6  promoter (McCulloch et ah, 2000). Schramm and co-workers have also 
observed the presence of hBRF splice variants. They identified a factor related to 
BRF, hBRFU, which is required for transcription from snRNA-type TATA- 
containing promoters (Schramm et ah, 2000).
1.11.2.3 TFIIIC
TFIIIC is another general transcription factor of pol III transcription. Like 
TFIIIB it was first purified from yeast, by a combination of ion-exchange and affinity 
chromatography on specific tDNA or B-block columns (Kassavetis et ah, 1989; 
Parsons and Weil, 1990; Swanson et ah, 1991). Polypeptides of approximately 138, 
131, 95, 91, 60 and 55 kD copurify with TFIIIC transcription and DNA-binding 
activity (Bartholomew et ah, 1990; Braun et ah, 1992; Gabrielsen et ah, 1989; 
Parsons and Weil, 1990; Swanson et ah, 1991). As yeast TFIIIC is sometimes 
referred to as x, its subunits have been named xl38, xI31, x95, x91, x60 and x55. 
Visualisation studies using scanning transmission electron microscopy (STEM) 
showed that TFIIIC/tDNA complexes appear dumbbell shaped, with individual 
protein domains bound to the A- and B- blocks, which are referred to as the xA and 
xB domains, respectively (Schultz et ah, 1989). xB has been demonstrated to be 
recognised by an anti-xl38 antibody, but not an anti-x95 antibody, indicating that
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t138 is part of the xB domain (Gabrielsen et al., 1989). In contrast, xl31, x95 and x55 
can be crosslinked to NsRdU residues in and around the A-block (Bartholomew et al., 
1990).
Whereas yeast and human TFIIIB appear to be similar, human and yeast TFIIIC 
are different. Human TFIIIC was first resolved into two components, TFIIIC 1 and 
TFIIIC2 (Dean and Berk, 1987; Yoshinaga et al., 1987). Whereas TFIIIC 1 is ill- 
defined, TFIIIC2 is far more characterised. The binding activity of TFIIIC2 to VA is 
localised to fractions containing five polypeptides, of 240, 110, 100, 80 and 60 kD, 
referred to as a , p, y, Ô and 8  respectively (Yoshinaga et ah, 1989). These fractions 
display transcriptional activity in the presence of TFIIIB, TFIIIC 1 and pol III 
(Yoshinaga et ah, 1989). TFIIIC2 binds to the B-block regions of VAl and tRNA 
genes (Boulanger et ah, 1989; Wang and Roeder, 1996; Yoshinaga et ah, 1987). The 
addition of TFIIIC 1 increases the intensity of the footprint generated by TFIIIC2 and 
extends it to include the A-block (Wang and Roeder, 1996; Yoshinaga et ah, 1987). 
HeLa cell TFIIIC2 was resolved into two DNA binding forms on non-denaturing gels 
(Hoeffler et ah, 1988). The slower migrating one has been named TFIIIC2a, whereas 
the high mobility form is referred to as TFIIIC2b (Sinn et ah, 1995). These two forms 
have identical footprints on VAl and have similar DNA binding activities (Hoeffler 
et ah, 1988; Kovelman and Roeder, 1992). Transcriptional activity, however, is only 
associated with TFIIIC2a (Hoeffler et ah, 1988; Kovelman and Roeder, 1992). Silver 
staining revealed that TFIIIC2b was missing the TFIIICP, 110 kD subunit, and 
instead a band of 77 kD was present (Kovelman and Roeder, 1992; Sinn et ah, 1995).
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Phosphatase treatment of TFIIIC2a converted it into inactive TFIIIC2b, suggesting 
that the transcriptional activity of TFIIIC can be modulated by phosphorylation 
(Hoeffler et a l, 1988).
The genes for the subunits of TFIIIC2 have been cloned. Three of them, 
hTFIIIC220, hTFIIICllO and hTFIIIC90 display no homology to S. cerevisiae 
TFIIIC. The other two display some weak homology to yeast TFIIIC; hTFIIIC63 
shows 22% homology to x95, whilst hTFIIICI02 is 31% identical to xI31, and both 
these subunits contain 11 copies of a tetratricopeptide repeat (Hsieh et al., 1999b).
TFIIIC plays a pivotal role by recruiting TFIIIB to the promoter. However, 
there are other transcriptional activities involving TFIIIC. For example, it relieves 
chromatin repression of S. cerevisiae U6  snRNA transcription (Bumol et al., 1993). 
hTFIIIC is also able to relieve chromatin-mediated repression, as it displays an 
intrinsic histone acetyltransferase activity (Hsieh et a l, 1999b; Kundun et a l, 1999).
1.11.2.4 TFIIIA
The expression of 5S genes requires an additional factor called TFIIIA 
(Engelke et a l, 1980; Segall et al, 1980). TFIIIA was the first eukaryotic 
transcription factor to be purified to homogeneity (Engelke et a l, 1980), and have its 
gene cloned (Ginsberg et a l, 1984). This was probably facilitated by its abundance in
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early Xenopus oocytes. The predicted TFIIIA protein is 344 amino acids in length, 
the majority of which constitutes 9 tandem repeats of 27 amino acids. These repeats 
are called zinc fingers (Miller et al., 1985), and are essential for DNA binding 
activities (Hanas et al., 1983). The DNA binding domain consists of three distinct 
regions; those composed of fingers 1-3 and 7-9 are compact, whereas the region 
composed of fingers 4-6 is extended (Hayes and Clemens, 1992; Hayes and Tullius, 
1992). Fingers 1-3 bind to the C-block, finger 5 binds the intermediate element, 
fingers 7-9 bind the A-block, whilst fingers 4 and 6  span these promoter regions 
(Hayes and Clemens, 1992; Hayes and Tullius, 1992). Mutation of finger 3 has the 
most detrimental effect upon binding to the 5S ICR (Del Rio and Setzer, 1993), 
whilst mutation of finger 9 causes a severe loss in transcriptional activity (Del Rio 
and Setzer, 1993). In addition to the transcripton of 5S genes, TFIIIA plays an 
important role in the storage and transport of 58 rRNA; fingers 4-7 display the 
greatest importance in binding RNA (Friesen and Darby, 1997).
1.11.2.5 SNAPc
Another gene-specific factor recognises the PSE of type III promoters. This 
factor is known as PBP, PTF and SNAPc (Henry et al., 1995; Sadowski et al., 1993). 
It has a mass of -  200 kD (Sadowski et al., 1993), and contains polypeptides of 190, 
50, 45 and 43 kD, which correlates to those previously observed (Henry et al., 1995; 
Sadowski et al., 1996). Recently, an additional subunit has been identified, called 
SNAP 19 (Henry et al., 1998). Immunodepleting against SNAP50, SNAP43 or SNAP45,
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specifically repressed transcription from U6  and 7SK promoters, but not transcription 
from VA or AdML promoters (Bai et al., 1996; Henry et al., 1996; Henry et al., 1995; 
Sadowski et al., 1996; Yoon and Roeder, 1996). SNAPc interacts with TBP, but the 
amount of TBP that copurifies with SNAPc is variable (Henry et al., 1995; Sadowski 
et al., 1993).
1.11.3 Transcription complex formation on class III genes
In yeast, the positions of TFIIIC subunits with respect to a tRNA gene have 
been deduced by photocross-linking (Bartholomew et al., 1990). t138 is located 
around the B-block, whilst t95 and t55 are associated with the A-block region 
(Bartholomew et al., 1990). The x91 subunit is located downstream of class III genes 
(Braun et al., 1992) and cooperates with tI 38 to bind DNA (Arrebola et ah, 1998), 
t131 is the only subunit to be located upstream of the transcription start site 
(Bartholomew et al., 1994; Bartholomew et al., 1991). The footprint of xl3I is 
extended upon the addition of TFIIIB (Braun et ah, 1989; Kassavetis et ah, 1990; 
Kassavetis et ah, 1989). As x 131 extends upstream of the transcription start site, it is 
likely to recruit TFIIIB to the promoter (Bartholomew et al., 1991). Indeed, 
recombinant yBRF has been shown to bind to x 131 via its amino-terminal half 
(Chaussivert et ah, 1995; Khoo et ah, 1994). Once yBRF is brought into the complex, 
TBP is then recruited, followed by B” (Kassavetis et ah, 1992). Pol III is brought into 
the initiation complex via an interaction between its C34 subunit and the amino
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terminal imperfect repeats of yBRF (Khoo et al., 1994; Werner et al., 1993). (see fig. 
1.6 for schematic representation of binding sites in BRF).
In vertebrates, TFIIIC binds predominantly to the B-block of tRNA and VA 
genes (Carey et a l, 1986a; Cromlish and Roeder, 1989; Fuhrman et al., 1984; Wang 
and Roeder, 1996). TFIIIC2 binds to the B-block (Dean and Berk, 1988). TFIIIC I is 
then recruited, resulting in the footprint of TFIIIC2 being extended to encompass the 
A-block (Oettel et al., 1997; Wang and Roeder, 1996; Yoshinaga et al., 1987). TFIIIB 
is then brought into the complex. hBRF can bind the pol III subunit C39, the human 
homologue of yeast C34 (Wang and Roeder, 1997), thereby bringing pol III to the 
start site (fig. 1.7.A).
TFIIIA binding to the promoter is the first step in transcription complex 
formation on type I promoters. TFIIIA binds to the 5S ICR, with its amino-terminus 
pointing towards the 3’ end of the gene (Bieker and Roeder, 1984; Smith et a l, 1984; 
Taylor et a l, 1986; Vrana et a l, 1988). The TFIIIA/5S DNA complex is relatively 
unstable (Bieker et a l, 1985), but stabilisation occurs upon binding by TFIIIC 
(Bieker et a l, 1985; Oettel et a l, 1997). Once both TFIIIC and TFIIIA have been 
recruited, XFIIIB can be brought into the initiation complex (Bieker et a l, 1985). 
Upon TFIIIB recruitment, pol III can then be assembled onto the preformed 
TFIIIC/TFIIIA/5S gene complex (Bieker et a l, 1985) (fig. 1.7.B).
Type III promoters lack ICRs, and so there is no need for TFIIIA or TFIIIC2. 
The expression of genes with type III promoters requires TFIIIC 1 (Yoon et a l, 1995),
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Fig. 1.7 The order of complex assembly on class III genes.
A. On tRNA genes the first transcription factor to bind to the promoter is TFIIIC, 
which then recruits TFIIIB and lastly pol III
B. To initiate transcription from 5S rRNA genes, TFIIIA is first recruited to the 
promoter, then TFIIIC, TFIIIB and finally pol III.
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an alternative form of TFIIIB (Mital et al., 1996), and the PSE-hinding factor (Reddy, 
1988; Waldschmidt et al., 1991).
1.11.4 Regulation of RNA polymerase III transcription.
Pol III transcription is regulated by a variety of means, such as virally 
encoded proteins and various cellular proteins.
During mitosis pol III transcription is repressed (Hartl et al., 1993). TBP is 
subject to hyperphosphorylation, but this does not appear to be sufficient for the 
reduction in TFIIIB activity observed (White et al., 1995a). It is proposed that another 
subunit of TFIIIB is also modified (Leresche et a l, 1996; White et a l, 1995a). 
Indeed, pol III transcription appears to be regulated throughout the cell cycle, which 
is reflected by the activity of TFIIIB, which is low in early G1 phase, but increases as 
cells reach S phase. The change in activity is apparently due to an alteration of the 
activity of a TFIIIB-TAF (White et a l, 1995b).
The level of pol III transcription varies during the cell cycle and also when 
cells take an alternative route such as differentiation. For example, when F9 
embryonal carcinoma cells differentiate into parietal endoderm there is a down- 
regulation of pol III transcription (White et a l, 1989). This is reflected by a decrease 
in TFIIIB activity, which is due to a reduction in the abundance of TBP and to a 
greater extent BRF (Alzuherri and White, 1998).
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The level of transcription can be modulated by a variety of virally encoded 
proteins and cellular proteins. For example, the Tax protein of Human T-cell 
leukemia virus type I induces a higher level of pol III transcription, and TFIIIB is 
believed to be the principal target of this effect (Gottesfeld et al., 1996). The ability of 
a virally encoded protein to enhance pol III transcription is not unique to Tax; for 
example, adenovirus El A protein can also up-regulate pol III transcription (Hoeffler 
et al., 1985).
Cellular proteins can also regulate pol III transcription. For example, Drl is a 
highly conserved 19kD nuclear phosphoprotein (Inostroza et al., 1992). It inhibits 
transcription upon binding its co-repressor DRAPl (Mermelstein et al., 1996). Drl 
represses transcription via TBP, and deletion of the TBP binding domain within Drl 
forfeits its ability to repress transcription (Yeung et al., 1994). The binding of Drl to 
TBP does not prevent TBP from binding DNA; instead it prevents TBP from 
interacting with other transcription factors, such as BRF (White et al., 1994).
The retinoblastoma suspectibility gene and the p53 gene both encode 
important tumour suppressors. The repression mediated by retinoblastoma gene 
product shall be discussed later; at present the properties of p53 shall be summarised 
briefly.
The tumour suppressor protein p53 is lost or mutated in more than half of all 
human tumours, and its inactivation is considered an important step in carcinogenesis 
(Hollstein et al., 1991). p53 can arrest cell growth, but it is not required for passage
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through the cell cycle. Mice which are homozygously null for the p53 gene develop 
normally, but display a greater predisposition to cancer (Donehower et al., 1992). It 
has been shown to be a general repressor of pol III transcription, as it inhibits 
transcription from all class III promoter types (Cairns and White, 1998; Chesnokov et 
al., 1996).
Kinases and phosphatases can also regulate pol III transcription, such as the 
kinase cdc2 which is complexed to cyclin B. This kinase is active as cells enter 
mitosis, and inactivates TFIIIB specifically when incubated with fractionated factors 
(Gottesfeld et al., 1994). The highly conserved serine/threonine protein kinase CKII 
may be involved in growth and cell cycle control (Pepperkok et al., 1994). In yeast 
CKII has been shown to stimulate tRNA and 5S RNA transcription, but the 
mechanism for this activation has yet to be elucidated (Hockman and Schultz, 1996).
1.11.5 Chromatin structure of class III genes
The chromatin structure of a gene can often determine its transcriptional 
activity (Wolffe, 1994). The structure of chromatin is as follows: 146bp of DNA is 
wrapped approximately twice around a nucleosome core comprising two molecules 
each of H2A, H2B, H3 and H4 histones. These are arranged as two H2A/H2B dimers 
associated with a central H3/H4 tetramer (Richmond et ah, 1984). The flanking DNA 
is bound by a single molecule of histone HI (Pruss et al., 1995). The presence of
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histones can often inhibit transcription. For example, a nucleosome on or near a 
Xenopus 5S ICR inhibits transcription initiation in Xenopus oocyte nuclear extract 
(Morse, 1989). The ability of histones to inhibit both initiation and elongation is 
directly proportional to the density of the nucleosomes (Hansen and Wolffe, 1992).
1.12 RNA polymerase I transcription
1.12.1 Promoter structure of class I genes
Pol I transcription, unlike that displayed by pols II and III, exhibits species 
specificity. This results from the interaction between transcription factors and the 
promoter, and between the transcription factors themselves. Very little sequence 
similarity is observed in pol I promoters from different species, but, the general lay­
out is conserved from yeast to human (Paule and White, 2000).
Ribosomal genes are found as multiple copies in head-to-tail clusters. The 
DNA intervening between these repeats is known as the intergenic spacer (IGS) and 
contains most of the promoter (Reeder, 1984). 50bp upstream from the initiation site 
is the core promoter, which is necessary and sufficient for initiation of basal 
transcription in most species (Paule and White, 2000). The core promoter contains the 
only conserved rRNA promoter element, the ribosomal initiator or rinr (Pema et al., 
1992). This is an AT-rich sequence which surrounds +1 (Radebaugh et al., 1997). 
Although it resembles a TATA box, it is not an interaction site for TBP.
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In most species there are additional elements and factors to help stabilise or 
assemble the complex formed on the core promoter. One such example is the 
upstream promoter element (UPE), which extends 150-200 bp upstream of +1 (Paule 
and White 2000; Reeder, 1984). UPE stimulates transcription driven by the core, but 
it is not absolutely required for transcription initiation. The UPE binds a factor that 
mediates the recruitment of the core factor to the promoter. Non-essential DNA 
separates the core and the UPE; the spacing and helical orientation, however, are 
important; half helical insertions or deletions are severely compromised in 
comparison to unaltered promoters (Pape et al., 1990).
In addition to the core and UCE, the IGS contains other sequence elements 
such as the proximal terminator (Bateman and Paule, 1988), enhancers (Paule and 
White, 2000), and spacer promoters (Morgan et al., 1983).
1.12.2 Transcription factors utilised by pol I
Two transcription factors are utilised by RNA polymerase I: SLI, which binds 
the core promoter, and UBF, upstream binding factor, which recognises the UCE. 
Together they recruit pol I to the initiation site of ribosomal promoters.
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1.12.2.1 SLl
In humans the factor which recognises the core promoter is called SLl, It is 
referred to by other names in different species, for example TIF-IB in mouse 
(Eberhard et al., 1993), and Ribl in Xenopus (McStay et al., 1991b). It is also the 
TBP-containing pol I transcription factor. SLl and TBP were found to co-fractionate. 
Furthermore, immunodepletion with antibodies against TBP inactivated pol I activity, 
which could not be restored by recombinant TBP, suggesting the presence of TAFs 
(Comai et al., 1992). It was subsequently shown that SLl was composed of TBP and 
three TAFs of 110, 63 and 48kD (Comai et al., 1992). Each TAF is able to bind TBP, 
and the two other TAFs (Comai et al., 1994; Paule and White, 2000).
The transcriptional activity of SLl in an in vitro transcription assay can be 
reconstituted from purified TBP, TAFi48, TAFi63 and TAFillO in the presence of 
UBF and pol I, but not in the absence of TAFi63 and TAFillO (Zomerdijk et al., 
1994). SLl has been demonstrated by coimmunoprecipitation analysis to interact 
with UBF (Hempel et al., 1996); this interaction is directed by TAFi48 (Beckmann et 
al., 1995). The subunits of SLl TAFi63 and TAFillO have been shown by cross- 
linking experiments to contact DNA (Beckmann et al., 1995). The inability of SLl to 
recognise and bind to TATA boxes in promoters is believed to be due to the ability of 
TAFi48 to alter the DNA binding properties of TBP, either by blocking the DNA 
binding surface or changing its conformation (Beckmann et al., 1995).
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1.12.2.2 UBF
UBF binds the UPE and aids core factor assembly of SLl onto the promoter. 
The actual requirement for UBF is species dependent; in some species the core factor 
alone can mediate basal transcription. In human and Xenopus are reliant upon UBF 
(Bell et al., 1988; McStay et al., 1991a).
Vertebrate UBF is a dimer of 90-100 kD (O'Mahony and Rothblum, 1991). It 
has an amino-terminal dimérisation domain (McStay et al., 1991a), followed by four 
to six HMG box DNA-binding domains and a carboxy-terminal acidic serine-rich tail 
(fig. 1.8) (Bachvarov and Moss, 1991; Jantzen et al., 1990). The UBF variants result 
from differential splicing of the UBF message (O'Mahony and Rothblum, 1991). The 
region spliced is not conserved between species; in Xenopus a 22 amino acid region 
between HMG domains 3 and 4 is spliced from xUBF2, but not xUBFl (Guimond 
and Moss, 1992). In mammals, 37 amino acids of HMG domain 2 is spliced from 
UBF2 but not UBFl. These splice valants have specific functions; UBFl functions in 
transcription, whilst UBF2 has a role in enhancer function (McStay et al., 1997).
1.12.3 Transcription complex formation on class I genes
The first step in the transcription of ribosomal genes is the binding of UBF to 
the promoter, thereby establishing an interaction between dimerised UBF and both 
the core and UCE promoter elements. UBF is able to bind both the core and UCE
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Fig. 1.8 Diagrammatic representation of the structure of UBF.
A diagram depicting the two forms of human UBF: UBFl and UBF2, which has 22 
amino acids deleted from its HMG2 box. The N-temiinus of UBF is the dimerization 
domain, whilst the HMGl box promotes sequence specific DNA binding, and HMG 
boxes 2-6 are responsible for non-specific DNA binding.
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elements because the HMG boxes within UBF can bend the DNA sharply. Alone 
UBF is sufficient to direct initiation, but instead functions to recruit SLl to the 
promoter, via protein-protein interactions involving the TBP and the TAFi48 subunits 
of SLl. Once SLl is recruited to the vicinity of the promoter it is able to bind to the 
DNA. The final step is the positioning of RNA pol I over the transcription start site 
(fig. 1.9) (Paule and White, 2000).
1.12.4 Regulation of RNA polymerase I transcription by UBF
The regulation of rRNA transcription reflects the growth and protein synthetic 
requirements of a cell. One way to modulate the expression of rRNA genes would be 
to regulate the activity of UBF and this can be achieved by at least three mechanisms; 
i) regulation of the amount of UBF, ii) regulation of the phosphorylation status of 
UBF and iii) sequestration of UBF into inactive complexes.
Sells et al. demonstrated that upon differentiation of L6  myoblasts the rate of 
rDNA transcription decreased, which was accompanied by a reduction in the amount 
of UBF in the cells, suggesting a possible casual relationship between the two events 
(Larson et al., 1993). Upon serum starvation of Chinese hamster ovary cells, a 
reduction in the level of phosphorlyated UBF was observed in comparsion to growing 
cells. These findings suggest that the phosphorylation of UBF is a prerequisite for the 
activation of pol I transcription (O' Mahony et al., 1992). An example of a kinase 
capable of recognising UBF is CKII (Voit et al., 1992). A third means by which the
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Fig. 1.9 Complex assembly on class I promoters.
The first step in complex assembly is the recruitment of UBF to the promter, which in 
turn recruits SLl and then lastly pol I.
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activity of UBF can be regulated is by being sequestered by RB, which will be 
discussed in more detail below.
1.13 Regulation of pol IH transcription by RB
The ability of RB to regulate pol III transcription was discovered by White et 
al (White et al., 1996). They showed that synthesis of pol III products, VA, 5S rRNA 
and tRNA was greater in fibroblasts derived from Rb-l~ mice than fibroblasts from 
mice (White et a l, 1996). In addition, KB was shown to inhibit pol III 
transcription in a reconstituted system (White et a l, 1996). This repression required 
an intact large pocket domain; RB with deletions within the large pocket was unable 
to repress transcription (White et a l, 1996). RB was shown to inhibit transcription 
from all pol III promoter types, suggesting that RB targets a general factor of pol III 
transcription (Lanninie et a l, 1997). Indeed, RB binds and inactivates the pol III 
transcription factor TFIIIB (Larminie et a l, 1997). RB has also been shown to bind 
TFIIIC2, however, this association is less than that observed with TFIIIB (Chu et a l, 
1997).
The physical association between TFIIIB and RB was demonstrated by pull­
down assays, coimmunopreipcipitations and cofractionation analyses. (Larminie et 
a l, 1997). As TFIIIB is a multisubunit complex, the next question to ask is which 
subunit RB targets in order to exert its effect. TBP has been shown not to bind RB 
(Weintraub et a l, 1995) and is unable to relieve RB-mediated pol III repression
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(Larminie et al., 1997), and so it is not a likely candidate. However, an affinity 
purified TFIIIB-TAF fraction is able to relieve such repression (Larminie et al., 
1997), suggesting that a TAF subunit of TFIIIB is the target of RB-mediated 
repression.
1.14 Regulation of pol I transcription by RB
In addition to being able to repress pol II and pol III transcription, RB has also 
been demonstrated to repress pol I transcription (Cavanaugh et al., 1995). Upon 
differentiation of a monocyte-like cell line U937, a decline in pol I transcription is 
observed, as is the accumulation of RB in the nucleoli, the site of pol 1 transcription 
(Cavanaugh et al., 1995). Hence, experiments were undertaken to determine if RB 
was able to regulate pol I transcription. RB was shown to inhibit pol I transcription in 
an in vitro transcription system (Cavanaugh et al., 1995). The target of this 
repression was UBF, and the effect was mediated by the large pocket of RB 
(Cavanaugh et al., 1995).
The ability of RB to repress pol I transcription was supported by observations 
of Voit et al (Voit et al., 1997). Like Cavanaugh and co-workers, they showed that 
UBF was targeted in order to exert this effect. However, they proposed that the 
repression was mediated by the C-terminus of RB (Voit et al., 1997). They showed 
that the RB-binding site in UBF is HMG boxes 1 and 2 (Voit et al., 1997). In 
addition, they presented a model of how RB is able to inhibit pol I transcription. RB 
binds UBF, thereby preventing UBF from binding the pol I promoter. However, it
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does not prevent UBF from interacting with either pol I or the TAF subunits of SLl 
(Voit et al., 1997).
Hannan et al, have also undertaken investigations to further understand RB- 
mediated pol I repression. They showed that the A/B pocket of RB is required for its 
association with UBF. In contrast to Voit et a l, they found thet RB binding did not 
abolish the ability of UBF to bind DNA, but rather its interaction with SLl (Hannan 
et a l, 2000a). In addition, pl30 but not pl07 was found to bind UBF. Furthermore, 
the overexpression of p i30 represses ribosomal transcription (Hannan et a l, 2000a).
Other circumstances under which RB downregulates pol I transcription have 
also been investigated. Studies show that upon confluence-induced cell cycle arrest 
the amount of UBF complexed to RB rises (Hannan et a l, 2000b).
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1.15 Aims and objectives of these studies
The aim of these studies is to identify the subunit of TFIIIB that RB targets to 
exert its inhibitory effect on pol III transcription, and to determine the regions of each 
protein required for this interaction. Also, to determine the effect RB binding to 
TFIIIB has upon its interaction with other components of the pol III machinery, 
establishing a mechanism of RB-mediated repression.
In the majority of human cancers RB is inactivated. The effects this has upon 
the RB/TFIIIB interaction are to be determined.
The physical association between RB and UBF is to be investigated. Also the 
binding sites responsible in each protein are to be identified.
Lastly, the ability of the other pocket proteins, p i07 and p i 30, to interact with 
the targets of RB-mediated repression of pol I and pol III transcription, namely UBF 
and TFIIIB respectively, is to be determined.
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2 Experimental protocols
All chemicals, unless otherwise stated, were supplied by Sigma (Sigma-Aldrich 
Company Ltd, Poole, Dorset, UK), BDH Laboratory Supplies (Merck House, Poole, 
Dorset, UK) or GibcoBRL (Life Technologies Ltd, Paisley, Renfrewshire, UK). 
Protein A sepharose was obtained from Amserham Pharmacia Biotech AB. 
Radiochemicals were provided by Amserham International, UK.
Plasmids used 
yBRF plasmid constructs
The in vitro translatable yBRF and mutant derivatives were kindly provided by 
George Kassavetis (Kassavetis, 1998).
hUBF and xUBF plasmid constructs
In vitro translatable hUBF, xUBF and xUBF mutant forms were a generous gift from 
Brain McStay (McStay et al., 1991a).
hBRF plasmid construct
The in vitro translatable hBRF plasmid construct contains the full length sequence 
and was generously donated by Nouria Hernandez (Mital et al., 1996).
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RB plasmid contracts
The RB constructs were kindly provided by Dennis McCance (Kaelin et a l, 1991)
2.1 Molecular biology procedures
2.1.1 Determination of nucleic acid concentration
The concentrations of nucleic acid solutions were determined 
spectrophotometrically using a quartz cuvette (Sambrook, 1989).
1 A260 = 50|ug/ml dsDNA 
1 A260 = 40pg/ml ssRNA
2.1.2 Transformations
20jul of competent cells (XLl Blue for DNA preparations and BL21 (DE3) 
pLysS for GST fusion and His-tagged protein preparations) were thawed on ice. 
After thawing, 0.2|Lig of the appropriate DNA was added and the mixture was placed 
on ice for 30 minutes. The mixtures were heat-shocked at 42°C for 45 seconds and 
then cooled on ice for two minutes. 900jul of LB (containing no amp) was added to 
the cells, which were then incubated at 37°C for 30 minutes. After incubation, the
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cells were pelleted and the majority of supernatant aspirated off The cells were then 
resuspended in the remaining supernatant, spread on a LB plate (amp. lOOpg/ml) 
and incubated at 37°C overnight.
E. coli strains:
XLl Blue,
racAl endAl gyrA96 thi-1 hsdRl? supe44 relAl lac[F'proAB lacfZAM lS TnlO 
(Tett^)]
BL21(DE3)pLysS,
B E  dem opmT hscB^BmE) galX(DES) [pLysS Can{]
LB: stored at RT
20g of LB mix was dissolved and autoclaved in IL H2O, to give 
1 % Bacto-tryptone (w/v),
0.5 % Bacto-yeast extract (w/v), 
l%N aCI (w/v).
Amp. was added as required after autoclaving to give lOOpg/ml.
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Agar Plates: stored at 4°C
1 X LB,
1 .2  % (w/v) agar.
The solution was autoclaved. When it was cool enough to be held, amp. was added 
to give a final concentration of lOOpg/ml. The solution was mixed and poured into 
100mm diameter plates. Immediately after the surface was flamed with a bunsen 
burner, and the lids set ajar to allow the plates to dry at RT.
2.1.3 Large scale DNA preparations
Large scale preparations of plasmid DNA was carried out as described in the 
manufacturers’ protocol (Qiagen).
2.1.4 Small scale DNA preparations
Small scale preparations of plasmid DNA were carried out as described in 
the manufacturers’ protocol (Promega).
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2.1.5 In vitro translation
In vitro transcription/translation reactions were carried out as specified in the 
manufacturers’ protocol (Novagen). Ipg of plasmid DNA was added to 8 pi of the 
transcription mixture and incubated at 30°C for 30 minutes. To the transcription 
mixture, 30pl of translation mixture, 40pCi Met and Cys and 6 pl dH2 0 , was 
added. The mixture was then incubated at 30“C for one hour.
The in vitro translation of the truncated BRF proteins was undertaken by 
linearising the construct containing BRF cDNA. These forms were made by 
incubating lOpg of the BRF construct with lU  of the appropriate restriction 
endonuclease, either Stu I, Bgl II, Xcm I, Hinc II or EcoR I, for one hour at 37°C. 
Completion of endonuclease digestion was determined by analysing Ipl of the 
reaction mixture on a 1% agarose gel at 80V for one hour. The agarose gel was 
stained with ethidium bromide and viewed with U.V. light. .Upon completed 
endonuclease digestion, the DNA was phenoFchloroform extracted, ethanol 
precipitated and resuspended in 1 x TE to give a concentration of 0.2pg/pl. The 
truncated template was in vitro transcribed by adding 1 pg of endonuclease digested 
template DNA with ImM NTPs, 1 x TSC buffer (Promega), 5mM DTT, 40U 
RNasin (Promega), 8 OU T7 RNA polymerase (Promega) and H2O to 50 pi, then 
incubating at 31^C for 90 minutes. After incubation, the reaction mixture was 
phenol/chloroform extracted, and the RNA ethanol precipitated with 1/10 volume 
7.5M NH4OAC. The RNA was resuspended in 50pl DEPC-H2O; this was aided by
60
Chapter 2 Experimental Protocols
incubating at 65°C. The RNA samples (2pl) were added to an in vitro translation 
system composed of 35pl reticulocyte lysate (Promega), 7pl DEPC-H2O, Ipl amino 
acid mixture minus Met and Cys (Promega), 40U RNasin (Promega) and 40pCi 
Met and Cys. The mixture was then incubated at 30°C for 90 minutes. Expression of 
the truncated protein was analysed by resolving 2pl aliquots by SDS-polyacrylamide 
gel electrophoresis.
Reticulocyte lysate containing in vitro expressed radiolabelled RB was 
phosphorylated by incubating the RB expressing reticulocyte lysate with lOOng of 
cdk 4/cyclin D l, cdk 2/cyclin E and cdk 2/cyclin A (a gift from Prof. R. White), for 
30 minutes at 30"’C. Successful phosphorylation was determined by resolving 2pi 
aliquots by SDS-polyacrylamide gel electrophoresis and looking for a shift in 
electrophoretic mobility.
1 % Agarose Gel:
1 % (w/v) agarose,
IxTA E.
Agarose Gel Running Buffer:
1 xTAE.
1 X TAE: stored at RT
0.04M Tris-acetate,
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O.OOIM EDTA.
2.1.6 Expression of GST fusion proteins
GST fusion proteins were prepared as previously described (Smith and 
Johnson, 1988). 40ml of LB (amp. lOOpg/ml) was inoculated with a single colony 
from a streaked plate, or from a loopful of glycerol stock, and incubated at 37°C 
overnight. The following day the overnight culture was diluted 1:10, by adding it to 
400ml LB (amp. lOOpg/ml), and this culture was then incubated at 30°C. Samples of 
the culture were taken and the optical density at 600nm was read. Upon the culture 
reaching an optical density >0.4, the cultures were induced with IPTG to a final 
concentration of O.lmM. The cultures were then grown at 30°C for 6  hours. 
Following incubation, the cells were pelleted by centrifugation at 1367g for 15 
minutes, in a Sorvall centrifuge. The supernatant was aspirated off and the bacterial 
pellet resuspended in 9ml ice-cold PBS, 1% triton, O.OOIM PMSF. The resuspended 
cells were sonicated on ice (2 x 60W), after which the bacterial debris was pelleted 
by eentrifugation at 17,522g, for 5 minutes in a Sorvall centrifuge. The resulting 
supernatant was removed and incubated with 400pl of packed glutathione-agarose 
beads for 30 minutes at 4®C. Following binding, the glutathione-agarose beads were 
pelleted by centrifugation at 828g for 3 minutes at 4°C in a bench top Sorvall. The 
supernatant was removed and the glutathione-agarose beads washed twice with 50ml 
of ice-cold PBS, 1% triton, then twice with 50ml of ice-cold PBS. The remaining
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glutathione-agarose beads were then transferred to an Eppendorf tube. Successful 
expression was confirmed by analysing 20pl of bound GST-fusion protein by SDS- 
PAGE and staining with coomassie blue. The remaining GST-fusion protein was 
snap frozen on dry-ice and stored at -80°C.
In some instances the GST-fusion protein was eluted from the glutathione- 
agarose beads. This was achieved by adding one bead volume of 25mM glutathione, 
0.05mM Tris-HCl pH 8.0 to the glutathione-agarose beads and vigorously vortexing 
the mixture at RT for 10 minutes; this procedure was repeated twice. Again, 
successful expression and elution was confirmed by resolving lOpl aliquots on a 
SDS-polyacrylamide gel and then staining with coomassie blue. The remaining 
protein was snap frozen on dry-ice and stored at -80°C.
PBS: stored at 4°C
1 PBS tablet (Sigma), was dissolved in 200ml of water to give 0.01 M phosphate
buffer,
0.0027M KCl,
0.137MNaCl, pH 7.4,
4mM Na2HP0 4 ,
1.8mM KH2PO4.
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2.1.7 Expression of His-tagged RB (379-928)
40ml of LB (amp. lOOpg/pl) was inoculated with a single colony from a 
streaked plate, and incubated at 37°C overnight. The following day the overnight 
culture was diluted 1:10 by adding it to 400ml of LB (amp. lOOpg/pl). It was then 
incubated at 30°C. Samples of the culture were taken periodically and the optical 
density at 600nm was determined. Upon reaching an optical density >0.4, the 
cultures were induced with IPTG to a final concentration of 0.15mM. The eultures 
were then grown at 30°C for six hours. Following incubation, the cells were pelleted 
by centrifugation at 1367g for 15 minutes at RT in a Sorvall centrifuge. The 
supernatant was removed and the pelleted cells resuspended in 9ml 1 x TBS, 1 % 
Triton, O.OOIM PMSF. The resuspended cells were sonicated on ice (2 x 60W), then 
the bacterial debris was pelleted by centrifugation at 17,522g for 5 minutes at RT, 
again in a Sorvall centrifuge. The supernatant was then incubated with 300pl of 
packed Ni-NTA beads (Qiagen) with imidazole to a final concentration of lOmM, 
for 30 minutes at 4°C. Following binding, the Ni-NTA beads were pelleted in a 
bench top Sorvall at 828g for 3 minutes at 4°C and the supernatant removed. The Ni- 
NTA beads were then washed five times with 20 bead volumes of 5 x TBS, lOmM 
imidazole, then five times with 20 bead volumes of 5 x TBS, 40mM imidazole. The 
bound protein was eluted with 1 bead volume of 1 x TBS, 150mM imidazole with 
vigorous vortexing at RT for 10 minutes. Successful expression was determined by 
analysing a lOpl aliquot of the purified protein by 7.8 % SDS-PAGE and then 
staining with coomassie blue.
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2.2 Electrophoresis analysis
2.2.1 SDS-PAGE
SDS-PAGE analysis was carried out based on a protocol described 
previously (Laemmli, 1970), using Biorad Mini-Protean II systems. 7.8%/10%/12% 
denaturing polyacrylamide gels were poured with low acrylamide/low pH stacking 
gels. Prior to loading, the samples were prepared in 4 x protein sample buffer, and 
boiled for 4 minutes. Apart from samples that were immunoprécipitations of solely 
cell extract, these were vigorously vortexed instead of being boiled. The loaded 
samples were resolved at 70V, until the dye front had gathered, and then at 140V 
until the dye front had run off the bottom of the gel. Full range molecular weight 
rainbow markers (Amersham) were run alongside the samples. Those gels 
containing radioactive samples were vacuum dried at 80°C. Those containing large 
amounts of specifically purified proteins were stained in coomassie blue for 1 hour, 
then destained. Other gels were immunoblotted.
4 X Protein Sample Buffer: stored at RT
250mM Tris-HCl pH6 .8 ,
2% SDS,
2 0 % p-mercaptoethanol,
40% glycerol,
0.5% bromophenol blue.
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10 X Protein Running Buffer:
O.IM Tris-HCl,
0.768M glycine,
20% SDS, pH 8 .8 .
stored at RT
4 X Upper Buffer:
1.5M Tris-HCl, pH 8 .8 , 
0.4% SDS.
stored at RT
4 X Lower Buffer:
0.5M Tris-HCl pH 6 .8 ,
0.4% SDS.
SDS-PAGE composition table:
stored at RT
4 X lower buffer 
4 X upper buffer 
30% acrylamide 
dHiO
Stacking buffer
1.25ml 
0.7ml 
3 ml
7.8%
1.25ml
1.3ml
2.4ml
10%
1.25ml
1.7ml
2 .0 ml
12%
1.25ml
2 .0 ml
1.7ml
+ l lp l  TEMED 
30pl 10% (w/v) APS
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Staining and destaining of polyacrylamide gels
Polyacrylamide gels were stained by placing them in a plastic box containing 
coomassie blue, then placing that on a tilting platform for one hour. In order to 
visualise the protein bands, the coomaasie blue was drained off, and destain was 
added to the box, whieh was returned to the tilting platform for another hour. After 
destaining, the polyacrylamide gel was removed fi*om the box and vacuum dried.
Coomassie Blue:
1% (w/v) Coomassie Blue, 
50% (v/v) Methanol,
10% (v/v) Glacial acetic acid.
stored at RT
Destain:
30% (v/v) Methanol, 
10% (v/v) Acetic acid.
stored at RT
2.2.2 Immunoblotting
Immunoblotting was carried out as described previously (Burnette, 1981; 
Towbin, 1979). Samples were transferred onto 0.2pM pore nitrocellullose (Biorad) 
in 1 X Western Blotting Buffer, using a Biorad Mini-Protean II system. The samples
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were blotted at 37V, with a set limit of 1 mA for 30 minutes. The transblotter was 
kept cool by an ice block. Upon completion of transfer, the nitrocellolose filter was 
washed in 1 x TBS, then transferred into Milk Buffer (MB) for three washes of two 
minutes, after which the primary antibody diluted 1:1000 in MB was added and the 
filter probed overnight at 4°C. The following day the filter was washed three times 
for two minutes each in MB, after which the secondary antibody, either rabbit 
polyclonal or mouse monoclonal depending on the primary antibody, again diluted 
1:1000 in MB, was added to the filter, and further probed at RT for 1 hour. After 
this, the filter was washed three times for two minutes each with MB, then twice for 
15 minutes with MB. It was then transferred into 1 x TBS for 5 minutes before being 
developed by ECL (Amersham), apart from fig. 6.3.B which was developed by 
alkaline phosphatase. Both methods were undertaken as instrueted in the 
manufacturers’ protocols.
50 X Western Blotting Buffer: stored at RT
IM Na2HP0 4  was brought to pH 6.7 by the addition of IM NaH2P0 4 .
10 X TBS: stored at RT
25mM Tris-HCl pH 7.6,
150mM NaCl.
Milk Buffer: made as required
1 X TBS,
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0.5% (v/v) Tween-20,
4% (w/v) powdered milk.
Antibodies
M19 aTAFi48 (Santa Cruz)
M18 aTAFi95/110 (Santa Cruz)
C15 aRB (Santa Cruz)
CIS apl07 (Santa Cruz)
C19 aXAFi48 (Santa Cruz)
C20 apl30  (Santa Cruz)
C21 aOCT-1 (Santa Cruz)
SD9 apl07 (Santa Cruz)
XZ91 aRB (Santa Cruz)
IF8 aRB (Santa Cruz)
G99-549 aRB (Pharminogen)
G3-245 aRB (Pharminogen)
MTBP- 6 aTBP (Pruzan et al., 1992)
SL30 ahTBP (Ruppert et al., 1996)
ahUBFAb ahUBF (Santa Cruz)
aRb2mAb apl30  (Affiniti)
4286-4 aTFIIICp (Generated against a peptide encompassing 
residues 897-911 of TFIIICP)
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BN51 113 apol III subunit (Ittmann et al., 1993)
128-4 aBRF (Generated against a peptide encompassing
amino acids 533-547 of BRF)
330-4 aBRF (Generated against a peptide encompassing the
residues 664-677 of BRF)
2.3 Immunoprécipitations
2.3.1 Purification of antibodies
lOOpl of packed protein A sepharose was washed twice with 1ml of ice cold 
PBS, and poured into a column (Biorad). The pH of the antibody preparation was 
adjusted to pH 8.0, then poured into a Bio-rad column. Once the antibody solution 
had passed through the column it was recycled five times. After recycling the 
sample, the column was washed with 10 column volumes of lOOmM Tris-HCl pH 
8.0, then with 10 column volumes of lOmM Tris-HCl, pH 8.0. The antibody was 
eluted 5 times with 1 column volume of lOOmM glycine pH 3.0, into eppendorf 
tubes containing 1/10 column volume IM Tris pH 8.0. The fractions containing the 
antibody were identified by mini bradford assays.
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2.3.2 Mini bradford assays
Bradford reagent was diluted 10 fold with CIH2O, lOOpl aliquots were added 
to the wells of a 96 well ELISA assay tray to which lOpl of eluted antibody was 
added. The intensity of colour change related to the amount of protein in that 
fraction.
2.3.3 Coupling of antibodies to protein A beads
20pl of packed protein A sepharose beads (Pharmacia) was washed twice 
with lOOpl ice-cold LDB (LDB is 20mM Hepes pH 7.0, lOOmM KCl, 12mM 
MgCh, O.lmM EDTA, 17% glycerol, 2mM DTT). The beads were pelleted in a 
microfuge at 16,060g for 30 seconds, and the supernatant removed. The beads were 
then coupled to the appropriate antibody, by adding 2 pl of the antibody of choice 
and 18pl of LDB; coupling was commenced by placing the mixture on a vibrating 
platform at 4°C for one hour. After coupling, the beads were washed twice with 
lOOpl of ice-cold LDB, then pelleted in a microfrige at 16,060g for 30 seconds, and 
the supernatant decanted.
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2.3.4 Immunoprécipitations using reticulocyte lysate expressed proteins
20pl of protein A sepharose beads (Pharmacia) conjugated to an anti-TBP 
antibody were washed twice with 200pl LDB, the beads were pelleted in a 
micro fuge at 16,060g for 30 seconds, and the supernatant decanted. 20pl of 
reticulocyte lysate (Novagen) containing in vitro expressed radiolabelled hTBP 
or hBRF from the T7 expression vectors pARFLIID and pCITEDl, respectively, 
were added as indicated to the beads. Alternatively, as specified, reticulocyte lysate 
containing truncated forms of hBRF were analysed. In one experiment a third 
protein was included in the immunoprécipitation namely RB purified from 
baculovirus Sf9 cells, a generous gift from S. Mittnacht. The immunoprécipitation 
reactions were placed on a vibrating platform for 3 hours at 4°C. After which they 
were washed five times with 150pl LDB. The beads were pelleted in a micro fuge at 
16,060g for 30 seconds and the supernatant was aspirated off. 16pl of 1 x protein 
sample buffer was added and the samples were boiled for 4 minutes, prior to being 
loaded onto a 7.8% SDS-polyacrylamide gel and visualised by autoradiography.
2.3.5 Immunoprécipitations involving reticulocyte lysate expressed proteins 
and cellular extract
150|Lig of the desired cellular extract was mixed with 15pl of the reticulocyte 
lysate expressing the desired labelled protein and, as indicated, 2 0 0 ng of eluted
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GST fusion protein or His-tagged RB. These mixtures were added to the beads 
coupled to the antibody of choice, and were placed on the vibrating platform for 3 
hours. After binding, the beads were washed five times with 150pl LDB. 16pl of 1 x 
protein sample buffer was added and the samples boiled prior to being resolved by 
SDS-polyacrylamide gel electrophoresis and visualised by autoradiography.
2.3.6 Immunoprécipitation from cellular extract
ISOjLig of the cellular extract of choice, and as specified 200ng of the 
appropriate eluted GST-fusion protein or His-tagged RB, were added to the antibody 
coupled beads, and the mixture placed on a vibrating platform for 3 hours. 
Following incubation, the beads were washed five times with 150pl LDB. 16pl of 1 
X protein sample buffer was added, and the samples vigorously vortexed, before 
being resolved on a SDS-polyacrylamide gel and visualised by western analysis.
2.4 GST-fusion protein pull down assays
Equal volumes of purified GST proteins were resolved by SDS- 
polyacrylamide gel electrophoresis and stained with coomassie blue. The relative 
amounts of GST proteins present were estimated, and equal amounts of GST-fusion 
proteins were compared in the pull-down assays. The reticulocyte lysate expressing
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the required -labelled protein was added to the beads and the mixture incubated 
on a vibrating platform at 4°C for 3 hours. After vibrating, the samples were washed 
five times with 700pl LDB. 16pl of 1 x protein sample buffer was added, the 
sampled boiled and the reactions resolved by SDS-polyacrylamide gel 
electrophoresis and visualised by autoradiography.
2.5 Random polymerisation assays
The desired immunoprécipitation reactions were set up as described above. 
After washing with LDB, the random polymerisation assays were carried out, as 
described previously (Boeder, 1974). 25pl of incubation buffer was added to each 
sample, which were then mixed thoroughly and incubated at 30°C for 20 minutes. 
After incubation, the mixture was bound to DEAE discs and the discs washed for 
five minutes with 0.5M Na2HP0 4 . This wash step was repeated five times. The discs 
were then washed twice for 5 minutes each with dH2 0 , then 2 x 5  minutes with 96% 
ethanol, and lastly with diethyl ether. After the last wash, the discs were blotted with 
Whatman paper and left to air-dry. Once the discs were dry, they were placed in 
scintillation vials containing 5ml of scintillation fluid, and the incorporated 
counted in a scintillation counter.
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TC(NE):
6.25mM rATP, 
6.25mM rCTP, 
6.25mMrGTP, 
1.75mM EDTA.
stored at -80°C
Polymerase Buffer:
0.7M Tris-HCl pH 7.9, 
0.9M NH4SO4 ,
28mM MnCl.
stored at 4°C
Incubation mixture:
240fil polymerase buffer, 
78pl TC(NE),
40nM UTP,
80pg polydAdT, 
leOnCi a “ P UTP,
0.08% (w/v) BSA.
made fresh as required
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2.6 Oligonucleotide binding assay
2.6.1 Oligonucleotide binding assay
The immunoprécipitation reactions of interest were set up as described 
above. After the immunoprécipitation reactions had been washed five times with
LDB, Ing of ^^P-radiolabelled B-box probe, Ipg of polydldC, and as indicated
lOOng of specific or non-specific competitor oligonucleotide were added to the 
reaction samples. The samples were mixed well and incubated at 30“C for 30 
minutes. After incubation, the samples were washed five times with 15Dpi LDB. The 
probe retained on the beads was eluted by the addition of 20pl of IM KCl, and then 
bound to DEAE discs. The discs were blotted dry with whatman paper. Once dry, 
they were placed in a scintillation vial containing 5ml scintillation fluid and bound 
^^ P was measured in a scintillation counter.
2.6.2 Manufacture of B-box probe
The oligonucleotide RJWl contains the upper strand of the B-block t FIIIC 
recognition sequence from a B2 gene (White et al., 1989). It was labelled by 
incubating 40ng of the oligonucleotide with 20pCi of y-^^P ATP, lOU of T4 
polynucleotide kinase (Promega) and 1 x T4 buffer (Promega), at 37°C for 1 hour. 
The reaction was heat inactivated at 65°C for 10 minutes. After heat inactivation, the
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probe was phenol/chloroform extracted and ethanol precipitated, washed five times 
with 70% ethanol, and resuspended in 20pl of 1 x TE. lOOng of the complementary 
oligonucleotide RJW2 was added and the nucleic acids denatured at 90°C for 2 
minutes; the probe was then cooled overnight to allow annealing to occur. The 
following day, the sample was diluted with 1 x TE to give a final concentration of 
0.5ng/pl.
2.6.3 Oligonucleotides used in the oligonucleotide binding assay
RJWl
5 ’-AGAGGTCCTGAGTTCAAATCCCAGC AACC-3 ’
RJW2
5’-GGTTGCTGGGATTTGAACTCAGGACCTCT-3’
RJWl 9
5 ’ -CCGTGCCTGATC ATGATATTCTTTGGG-3 ’
RJW20
5 ’ -CCC AAAG AATATC ATGATC AGGC ACGG-3 ’
1 X TE: stored at RT
lOmM Tris-HCl pH 7.5,
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ImMEDTA pH 8.0.
2.7 Tissue culture
2.7.1 Passaging of cell lines
SA0S2 and C33A cells were cultured as adherent monolayers in Dulbeccos’ 
modification of Eagles Medium (DMEM) supplemented with 10% (v/v) foetal calf 
serum (FCS-GiboBRL), 4mM L-glutamine (GibcoBRL), antibiotics; lOmg/ml 
streptomycin and lOOU/ml penicillin (GibcoBRL). The cells were grown at 37‘^ C, in 
5 % CO2/H2O saturated atmosphere. The cells were cultured in 75 cm^ tissue 
culture flasks (NUNC) and seeded at one in four. Cells were passaged by treatment 
with trypsin (Gibco BRL, dissolved in FCS-free DMEM, 0.05% (w/v)) at 37°C for 1 
minute to dislodge the cells from the polystyrene. Trypsinisation was arrested by the 
addition of complete media, in which the cells were resuspended.
2.7.2 Cyro-storage of cells
Live cells were subjected to long term storage by resuspending near 
confluent 75cm^ flasks in 2ml media containing 10% DMSO. The suspension was
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aliquoted into cryotubes (NUNC) and placed at -80°C overnight to ensure slow 
freezing, before being transferred to liquid nitrogen.
Cells were thawed at RT and poured into a 50ml tube, 30ml of complete 
media was added to the cells, the mixture was then centrifuged at 298g for 5 minutes 
at RT. After centrifugation, the supernatant was aspirated off and the cells 
resuspended in 12ml of complete media before being transferred to a 75 cm^ flask. 
Recovery was almost 100% and cells were always passaged once before being used 
after thawing.
2.7.3 Preparation of protein microextracts
Preparation of protein microextracts was based on a protocol described 
previously (Scholer, 1989). C33A cells were harvested when cells were near 
confluence. The plates were washed twice with 6 ml of ice-cold PBS; then harvested 
in 6 ml of ice-cold PBS, with plate scraping. The PBS/cell mixture was placed in a 
50ml tube and centrifuged at 298g for 8  minutes at 4°C in a bench top Sorvall. The 
supernatant was aspirated off, and the pellet transferred to an eppendorf tube. The 
pellet was resuspended in 1 volume of microextraction buffer, and immediately snap 
frozen on dry ice. After freezing, the cells were thawed at 30°C and the freeze/thaw 
process was repeated twice. After the last thawing process, the mixture was 
centrifuged in a microfuge at 16,060g for 10 minutes at 4°C. After centrifugation,
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stored at RT
the supernatant was collected and the protein concentration measured by a bradford
assay.
Microextraction stock:
0.02M Hepes-HClpH7.8,
0.45MNaCl,
25% (v/v) Glycerol,
0.05MNaF,
0.2mMEDTA.
Microextraction buffer:
974jLil microextraction stock,
0.5mMPMSF,
ImMDTT,
20|li1 PIM.
made fresh as required
PIM:
1.6ml Bestatin (2.5mg/ml),
50pl Leupeptin (Img/ml), 
lOOpl Trypsin inhibitor (Img/ml), 
24pl Aprotinin (2.2mg/ml),
70pl Pepstatin (Img/ml),
150pl E-64 (2mg/ml).
stored at -20°C
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2.7.4 Bradford assay
A standard Bradford assay curve was constructed by determining the optical 
densities at 595nm of Opg, 2pg, 4pg, 6 pg, Spg, lOpg, 12pg, 14pg, lôpg, and ISjag 
of BSA in 1ml of Bradfords reagent (Bio-Rad) diluted 1:5 with dH2 0 . The readings 
were plotted on a graph, (x-axis protein concentrations, y-axis absorbency readings) 
and a standard curve fitted. 4pl aliquots of the microextraction samples were taken 
and diluted 1:4 with dH2 0 . 2|l i 1, 4pl and 8 pl of the diluted microextraction samples 
were added to 1ml of Bradfords reagent diluted 1:5 with (IH2O, and the optical 
density at 595nm determined. These readings were then converted into protein 
concentrations by reading from the standard curve. For those readings obtained from 
2  pi of diluted microextraction buffer the reading was doubled, that obtained for the 
4pi sample was left unaltered, whilst those for the 8 pl sample was halved. These 
figures were then averaged to find the protein concentration of the microextraction 
samples.
2,7,5 Transient transfections
SA0S2 cells were transiently transfected using the calcium-phosphate- 
precipitate method. Cells were plated at a density of 1 x 1 0  ^ cells in a 100mm 
diameter dish (NUNC) and incubated at 37"C for 24 hours. 4 hours prior to the
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addition of the precipitated DNA, the medium was aspirated off and 6ml of fresh 
medium was added.
The donor DNA was placed in a plastic bijou flask and the volume made up 
to 450pl with O.lmM EDTA pH 8.0, ImM Tris-HCl pH 8.0. 1/10 volume of CaCb 
was added, and the solution mixed. The DNA mixture was then added a drop at a 
time, with continuous vortexing to 500pl 2 x Hepes buffer saline in a second plastic 
bijou. When the addition was completed, the mixture was further vortexed for 15 
seconds, then left to stand for 30 minutes at RT. After precipitation, the DNA was 
added a drop at a time to a plate of SAOS2 cells. The cells were incubated at 37”C 
overnight to allow absorption of the DNA-calcium phosphate precipitate into the 
cells. The following morning, the cells were washed twice with 6ml PBS, fresh 
medium was added, and the transfected cells incubated at 37“C for 72 hours. Total 
RNA was harvested from the cells using TRI-reagent (Sigma), according to the 
manufacturer’s protocol. To assess for the expression of the transfected genes, 
parallel plates were harvested for protein by the addition of lOOjal 1 x protein sample 
buffer, in which the cells were resuspended. Harvesting was quantitated by resolving 
lOpl of the suspension by 7.8% SDS-polyacrylamide gel electrophoresis, followed 
by staining with coomassie blue. Relative amounts of protein were estimated by 
visual comparsions. Equal amounts of protein were subsequently resolved by 7.8% 
SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane 
and probed with the appropriate antibody.
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2 X Hepes Buffer Saline:
0.28M NaCl,
50mM Hepes, 
1.5m M Na2H PO 4.2H 20.
stored at 4°C
2.8 Primer extensions assays
2.8.1 Manufacture of probes
 ^The VA] and CAT probes were both radiolabelled by incubating 50ng of the 
appropriate oligonucleotide with 40U T4 polynucleotide kinase (Promega), 1 x T4 
kinase buffer (Promega), and 80pCi y-^^P ATP, in DEPC-H2O, at 37°C for 1 hour. 
Upon completion of the reaction, the samples were heat inactivated at 65°C for 10 
minutes.
2.8.2 Primer extension reactions
To each primer extension reaction, containing up to lOpg of RNA (but not 
exceeding a final volume of lOpl), Ipl of probe and 9pl of strand buffer 
(Promega) was added. The nucleic acids were denatured at 80°C for 10 minutes, 
then annealed at 50°C for 2 hours. Following annealing, 1.7mM DTT, 0.83mM
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dNTPs, 2nM actinomcyin D, 20U RNasin (Promega), lOOU superscript (Promega) 
and dH^O to a final volume of 30pl were added to each reaction, and the mixtures 
incubated at 42°C for 1 hour. After extension, the samples were ethanol precipitated 
at -20°C, then centrifuged in a microfuge at 16,060g for 15 minutes at RT. The 
pellets were washed with 75% ethanol and centrifuged at 16,060g for 5 minutes at 
RT. The pellets were dried at 50°C for 5 minutes and resuspended in 4pl of 
formamide running buffer by vortexing vigorously for 30 minutes. Prior to 
resolution on a 7% sequencing gel for 1 hour at 40V, the samples were boiled for 2 
minutes and then immediately placed on ice.
Formamide running buffer:
98% formamide,
0.01% Bromophenol blue, 
0.01% Xylene cyanol pp, 
5mM EDTA.
stored at RT
7 % sequencing gel mix:
7 % (v/v) acrylamide,
46 % (w/v) urea, 
0.5XTBE.
stored at RT (in foil)
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The mixture for one gel consisted of 5Omis of 7 % sequencing gel mix, to which 
300pl of 10% (w/v) APS and SOpl TEMED were added. Prior to loading of the 
samples, the gel was pre-run for 30 minutes at 40V.
7 % sequencing gel running buffer:
0.5 X TBE.
0.5 X TBE: stored at RT
0.045M Tris-borate,
O .O OlMEDTApHS.O .
2.8.3 Oligonucleotides used in primer extension analysis
VAi specific
5 ’-CACGCGGGCGGTAACCGCATG-3 ’
CAT specific
5’-CGATGCCATTGGGATATATCA-3’
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Chapter 3
Characterisation of the interaction between the pol III transcription 
factor TFIIIB and the tumour suppressor protein RB
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3 Characterisation of the interaction between the pol III transcription 
factor TFIIIB and the tumour suppressor protein RB
3.1 Introduction
The retinoblastoma protein (RB) is a lOSkDa nuclear phosphoprotein that is 
encoded by the important tumour suppressor gene Rb (Weinberg, 1995; Herwig and 
Strauss, 1997; Grana et al., 1998; Mulligan and Jacks, 1998), In normal cells RB 
provides a mechanism for constraining cell growth and proliferation. In the absence 
of RB, the ability of a cell to regulate these functions is compromised (Weinberg, 
1995; Whyte, 1995). RB is found mutated in many human tumours, such as 
retinoblastomas, small cell lung carcinomas, sarcomas and bladder carcinomas 
(Weinberg, 1995; Herwig and Strauss, 1997; Grana et al., 1998; Mulligan and Jacks, 
1998). In many other tumours, the pathway by which the activity of RB is regulated 
is aberrant (Pines, 1995; Weinberg, 1995). It is therefore of great importance to 
understand how RB influences cellular activity.
In 1996, White et al. (White et al., 1996) demonstrated that RB is capable of 
suppressing pol III transcription both in vitro and in vivo. Initial investigations 
demonstrated that bacterially purified RB could inhibit pol III transcription from a 
system reconstituted from fractionated factors. In addition, overexpression of RB 
repressed transcription from pol III templates in transfected cells (White et al., 1996). 
Primary fibroblasts from Rb-I- mice and mice were analysed for pol III
activity. Such studies revealed that the fibroblasts derived from Rb-I- mice had
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greater pol III activity than fibroblasts derived from Rb-\-l+ mice (White et a l, 1996). 
Comparison of the osteosarcoma cell lines U20S, which is RB positive, and SA0S2, 
which lacks a functional RB protein, demonstrated that the RB-deficient cells 
displayed increased pol III activity relative to the RB-positive cells (White et al,
1996). The ability of RB to repress pol III activity was alleviated by mutations in the 
RB pocket domain, such as RB null mutants isolated from small cell lung carcinomas 
(Horowitz et a l, 1990). RB repression was also abolished by the presence of the 
adenoviral transforming protein El A, which binds and inactivates RB (DeCaprio et 
a l, 1988; Dyson et a l, 1989b; Munger et al, 1989).
Transcription by pol III involves at least two general factors, named TFIIIB 
and TFIIIC (Willis, 1993; Geiduschek and Kassavetis, 1995; White, 1998). TFIIIB 
has been shown to be a multisubunit complex, which consists of the TATA-binding 
protein TBP (Hernandez, 1993; Rigby, 1993), and at least two TBP-associated factors 
or TAFs. One of these TAFs has been shown to be homologous to the pol II 
transcription factor TFIIB; because of this similarity, this subunit has been named 
TFIIB-Related Factor, or BRF (Buratowski and Zhou, 1992; Colbert and Hahn, 1992; 
Lopez-de-Leon et a l, 1992; Khoo et al, 1994; Wang and Roeder, 1995; Mitai et al,
1996), the other TFIIIB-TAF is called B” (Kassavetis et a l, 1995). Yeast TFIIIB has 
been reconstituted from recombinant polypeptides (Kassavetis et a l, 1995; Roberts et 
a l, 1996; Ruth et a l, 1996), in contrast to mammalian TFIIIB, which is far less well 
characterised.
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The majority of pol III templates lack a TATA box and so in these cases 
TFIIIB is not brought to the promoter by DNA-protein interactions instigated by 
TBP. Instead, TFIIIB is recruited by protein-protein interactions with the DNA- 
binding protein TFIIIC (Willis, 1993; Geiduschek and Kassavetis, 1995; White, 
1998).
Investigations by Larminie et. al. shed some light upon the mechanism 
whereby RB regulates pol III transcription (Larminie et al., 1997). Work undertaken 
showed that the activity of a pol III preinitiation complex, reconstituted from 
fractionated factors, was inactivated by the addition of bacterially purified RB, 
irrespective of being added before, during or after preinitiation complex assembly 
(Larminie et al., 1997).
In vitro transcription assays illustrated the ability of RB to repress pol III 
transcription from all three pol III promoter types, suggesting that RB is a general pol 
III repressor (Larminie et al., 1997). The ability of RB to repress pol III transcription 
was further localised to the large pocket domain. The GST fusion protein GST-RB 
(379-928) encompasses the large pocket domain and is able to repress pol III 
transcription. In contrast, the GST fusion protein GST-RB (612-711), which 
encompasses much of the B domain of the RB large pocket, was not able to repress 
pol III transcription in this assay (Larminie et al., 1997).
As RB can inactivate pol III transcription from all pol III promoter types, the 
ability of RB to target a general component of pol III transcription, such as the pol III
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enzyme or the general pol III transcription factors TFIIIB and TFIIIC, was examined 
by add-back experiments. VAi transcription was reconstituted using partially purified 
factors; upon the addition of recombinant RB to this reconstituted system, 
transcription was repressed. The repression mediated by RB could be relieved by the 
addition of TFIIIB, but not by the addition of TFIIIC or pol III. Therefore, the add- 
back experiments demonstrated that TFIIIB is the target of RB repression, as only the 
addition of TFIIIB could relieve RB-mediated inhibition of pol III (Larminie et al,
1997).
The ability of RB to interact with endogenous TFIIIB was suggested by the 
fact that a population of RB molecules cofractionates with TFIIIB through a variety 
of purification steps, including phosphocellulose and DEAE-Sephadex columns and 
glycerol gradients. In contrast, RB did not cofractionate with TFIIIC or pol III. When 
phosphocellulose fractions containing TFIIIB were applied to a heparin-sepharose 
column and the bound protein eluted in a linear salt gradient, close cofractionation 
was observed between TFIIIB and RB. These observations suggest that there is a 
stable and specific interaction between endogenous TFIIIB and RB (Larminie et al,
1997).
The ability of TFIIIB and RB to interact was also analysed by 
immunoprécipitations. Antiserum against RB was found to be able to co-precipitate 
TBP and BRF. The presence of a specific competitor abolished the co-precipitation of 
TBP and BRF by the anti-RB antibody. These immunoprécipitation data provide
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further evidence that endogenous TFIIIB interacts with endogenous RB at 
physiological ratios (Larminie et al., 1997).
The ability of RB to target TFIIIB was further established by studying extracts 
from primary cells isolated from wild-type or RB-knockout mice. The RB-negative 
extracts displayed elevated levels of pol III transcription when compared to RB- 
positive extracts. The level of TFIIIC and pol III activity between these two extract 
types varied only slightly. However, the activity of TFIIIB was found to be much 
greater in the RB-deficient extracts when compared to the RB-positive extracts, again 
suggesting that RB targets TFIIIB specifically (Larminie et al., 1997).
Additional add-back experiments were undertaken in order to determine 
which subunit of TFIIIB is targeted by RB to repress pol III transcription. VAi 
transcription was reconstituted using partially purified factors, and again repressed by 
the addition of recombinant RB. The ability of recombinant TBP and affinity-purified 
TFIIIB-TAFs to reverse this inhibition was examined. It was shown that TBP was 
unable to reverse repression, whereas the affinity-purified TFIIIB-TAFs were able to 
reverse inhibition in a dose-dependent manner. These add-back experiments suggest 
that RB targets one or more of the TFIIIB-TAFs to repress pol III transcription 
(Larminie et al., 1997).
The next step was to determine more precisely how RB interacts with TFIIIB. 
As mentioned above, TBP does not relieve RB-mediated pol III repression whereas a 
TFIIIB-TAF does (Larminie et al., 1997). Also, TBP has previously been reported to
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be unable to bind RB (Weintraub et al., 1995). Hence it was decided to determine if 
RB targeted the BRF subunit of TFIIIB. Work presented here shows that recombinant 
and endogenous RB interact with BRF. The binding interfaces of these interactions 
were mapped. In addition, the interactions between TBP and BRF were characterised 
and found not to be disrupted by the addition of bacterially purified RB. In contrast, 
the interactions between TFIIIB and TFIIIC and between TFIIIB and pol III were 
both found to be disrupted by the presence of RB. These observations culminated in 
the proposal of a model for how RB represses pol III transcription.
3.2 Results
3.2.1 Endogenous and recombinant RB associate with BRF - a subunit of 
TFIIIB
Immunoprécipitations were undertaken in order to determine if endogenous 
RB could interact with BRF. HeLa cell extract containing wild type RB was mixed 
with reticulocyte lysate containing radiolabelled BRF. The mixtures were 
immunoprecipiated using a variety of anti-RB antibodies immobilised on protein A 
beads. The immunoprecipitated complexes were washed extensively, and the 
precipitated material examined by SDS-PAGE and autoradiography (fig. 3.1. and 
3.2), Both antisera against RB were found to coprecipitate detectable amounts of BRF 
(lane 2 in both figures). The interaction was dependent on the presence of cell extract
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FIG. 3.1 Endogenous RB coimmunoprecipitates with the BRF subunit of 
TFIIIB.
Reticulocyte lysate (15pl) containing in vitro-translated BRF was 
immunoprecipitated (IP) in the presence of 20pl LDB (lane 1), or 150pg HeLa 
whole-cell extract (lane 2) using anti-RB antibody G3-245. Precipitated material was 
resolved on a 7.8% SDS-polyacrylamide gel and visualised by autoradiography.
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FIG. 3.2 Endogenous RB coimmunoprecipitates with the BRF subunit of 
TFinB.
Reticulocyte lysate (15pl) containing in vitro-translated BRF was mixed with 20jul 
LDB (lane 1) or 150pg of HeLa whole cell extract (lane 2) and immunoprecipitated 
(IP) in the presence of anti-RB antibody G99-549, Proteins retained after extensive 
washing were resolved on a SDS-7.8% polyacrylamide gel and visualised by 
autoradiography.
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and presumably the RB within, since on replacing the extract with buffer the amount 
of BRF precipitated was greatly reduced (lane 1 in both figures).
To determine if recombinant RB could interact with BRF and if this was a 
stable interaction, a variety of GST fusion proteins were purified and immobilised on 
glutathione-agarose beads. GST alone and GST-RB (379-928) were incubated with 
radiolabelled BRF that had been translated in vitro using reticulocyte lysate. The 
beads were washed with buffer containing 200mM, 300mM and 400mM KCl, the 
protein retained on the beads was resolved by SDS-PAGE and visualised by 
autoradiography (fig. 3.3). GST alone brought down a low, background amount of 
BRF (lane 1) in contrast to GST-RB (379-928), which brought down considerably 
more BRF (lanes 2-4). The ability of GST-RB (379-928) to pull down BRF is 
specific to the RB portion of the GST fusion protein, as GST alone pulled down only 
a small amount of BRF. The interaction between RB and BRF is demonstrated to be 
stable, as it can withstand washes of increased stringency (up to 400mM KCl) (lanes 
2-4). These immunoprécipitation data and pull down assay suggest that RB and BRF 
interact with one another, and that this interaction is stable.
3,2.2 The identification of the BRF-binding domain in RB
The BRF-binding domain in RB was identified by the use of a variety of 
GST-RB fusion proteins, namely GST-RB (379-928), which encompasses the large 
pocket domain of RB, GST-RB (379-792) which contains only the small pocket,
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FIG. 3.3 Recombinant RB interacts with the BRF subunit of TFIIIB.
Reticulocyte lysate containing in vitro-translated BRF (15p,l) was incubated in the 
presence of glutathione-agarose beads carrying equal amounts of GST (lane 1) or 
GST-RB (379-928) (lanes 2-4). Proteins retained after washing with 200mM KCl 
(lanes 1 and 2), 300mM KCl (lane 3) and 400mM KCl (lane 4) were resolved on a 
SDS-7.8% polyacrylamide gel and visualised by autoradiography.
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and lastly GST-RB (763-928), which contains the C-domain. These proteins are 
represented in a schematic diagram (fig 3.4). Each of these GST fusion proteins were 
purified and immobilised on glutathione-agarose beads, and incubated with 
reticulocyte lysate containing radiolabelled BRF. The proteins retained on the beads 
were resolved by SDS-PAGE and visualised by autoradiography (fig. 3.5). As can be 
seen, the GST alone pulled down a minimal background amount of BRF (lane 2), 
whereas GST-RB (379-928) brought down substantially more BRF (lane 3). The 
ability of GST-RB (379-792) (lane 4) and GST-RB (763-928) (lane 5) to retain BRF 
is reduced compared to that observed for GST-RB (379-928) (lane 3). Indeed, the 
amount of BRF that is bound by GST-RB (379-792) is only slightly greater than the 
background observed with GST alone (lane 4 versus lane 2). These pull down data 
therefore suggest that the large pocket of RB is the binding domain for BRF.
Transient transfection assays were carried out to test if  the region of RB that 
binds to BRF is the same as the region required to repress pol III transcription in vivo. 
The human osteosarcoma cell line SAOS2, which lacks wild-type RB (Shew et al., 
1990), was transfected with expression vectors encoding the large or small pocket of 
RB. Primer extension analysis was used to determine the levels of transcription of a 
co-transfected VAi gene, which is used as a pol III reporter. A control plasmid was 
included to normalise for transfection efficiency; this contained the CAT gene, driven 
by the simian virus 40 early promoter. VAi and CAT RNA levels were assayed by 
primer extension (fig 3.6.A). From the VAi transcripts resolved on a sequencing gel, 
it can be seen that the transfected RB large pocket had a far greater ability to repress 
pol III transcription than the RB small pocket (lane 2 compared to lane 3). The primer
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FIG. 3.4 A schematic representation of the GST-RB fusion proteins.
The diagram illustrates the regions of RB encompassed by the various GST-fusion 
proteins employed.
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FIG. 3.5 Identification of the BRF-binding domain in RB.
Glutathione-agarose beads carrying equal amounts of GST alone (lane 2), GST-RB 
(379-928) (lane 3), GST-RB (379-792) (lane 4), and GST-RB (763-928) (lane 5) 
were incubated with 15pi of reticulocyte lysate containing expressed BRF. Proteins 
remaining after extensive washing were resolved on a SDS-7.8% polyacrylamide gel 
and visualised by autoradigraphy. Lane 1 shows 10% of the input reticulocyte lysate 
containing in vitro-translated BRF.
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FIG. 3.6 Overexpression of full length RB inhibits pol III transcription in vivo.
(A) SA0S2 cells were transfected with pVAi (4 pg), pCAT (4 pg), pSG5 (lOpg lane 
1, 2pg lanes 2 and 3), pRBSP (8 pg lane 2) and pRBWT (8 pg lane 3). VA% and CAT 
levels were assayed by primer extension analysis.
(B) The primer extension was quantitated by phosphorimager. The values shown for 
VAi have been nonnalised to the levels of CAT to correct for transfection efficiency, 
and are expressed relative to the value obtained for pSG5 control.
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extension was quantified by using a phosphorimager and then normalising to the 
levels of CAT to correct for transfection efficiency. It can be observed that whilst 
small pocket of RB is able to repress pol III transcription 
very slightly, the greatest effect is observed with the large pocket of RB (fig. 3.6.B 
lane 2 compared to lane 3). The primer extension analysis in conjunction with the 
pull down assays therefore indicate that the large pocket domain of RB is not only the 
domain responsible for binding BRF, but also for repressing pol III transcription. 
The data described above provide a correlation between the ability of RB to bind 
BRF and the ability of RB to repress pol III transcription.
To ensure that the differences in pol III transcript abundance were not due to 
variation in the expression of the RB proteins after transfection, protein was harvested 
from parallel transfections, resolved by SDS-PAGE, and probed for the presence of 
RB by western analysis. The untransfected cells have little RB, whereas those which 
have been transfected with RB-containing vectors have much greater amounts of RB 
(data not shown). The full-length and small pocket RB were both expressed with 
equal proficiency, thus indicating that the difference in pol III repression was due to 
the difference in the encoded proteins and not their levels of expression.
3,2.3 Identification of the RB-binding region in hBRF
Once the BRF-binding domain in RB had been identified, the inverse was to 
be determined, namely the RB-binding domain in BRF. In order to do this, a variety
101
Chapter 3 Results
FIG 3.7 A schematic representation of the hBRF truncations generated.
A diagrammatic representation of the conserved regions of BRF present in the 
truncations generated by endonuclease digestion.
1 0 2
f:
so
’■ CG
Of)CO
U
QQ
X I
I
Sjd_o
"o
Bo
X
PQ
wL&
H
2
&
-oc<N
I
I
&
fi
c
s
N
I
rs
%
§;
%
I
I
PQ
e
PQ
Tf
Ew
PQ
JS
m
PQxi
On
QQ
2
PQ
PQ
J B
Chapter 3 Results
of BRF truncated proteins were expressed (see fig. 3.7 for a schematic 
representation). The truncated proteins were generated by incubating the vector 
pCITE D l, which contains the cDNA sequence of hBRF, with various endonuclease 
restriction enzymes whose cleavage sequences were unique in hBRF. Complete 
cleavage was confirmed by analysing a sample on a 1% agarose gel. The cleaved 
DNA was then purified and the encoded transcript generated by transcription with T7 
RNA polymerase. The RNA generated was purified and the protein expressed and 
radiolabelled using rabbit reticulocyte lysate. Successful expression was confirmed 
by resolving an aliquot by SDS-PAGE and visualising by autoradiography. The 
ability of the truncated proteins to bind to RB was determined by incubating the 
proteins with GST alone or GST-RB (379-928) purified and 
immobilised on glutathione-agarose beads. After incubation, the beads were washed 
extensively and the protein remaining bound to the beads was resolved by SDS- 
PAGE and visualised by autoradiography (fig. 3.8). As can be seen, the cleavage of 
BRF with either Stu I, which removes most of the C-terminal tail, or Bgl II, which 
removes the H3 region, does not abolish the ability of BRF to interact with RB (lanes 
3 and 4 respectively). These GST pull down assays suggest that neither the C- 
terminal tail or H3 region of BRF contribute to the RB binding domain in BRF. To 
further define the RB-binding domain of BRF, alternative unique endonuclease 
restriction sites were identified, from which truncated proteins were expressed and 
their ability to interact with RB assessed (fig. 3.9). As is observed, cleavage of the 
BRF gene with Hinc II, which removes the entire BRF conservation domain, and 
EcoR I, which also removes the majority of the 2"  ^ N-terminal imperfect repeat, 
generated truncated proteins which were able to interact with RB (lanes 6 and 9
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FIG. 3.8 Identification of the RB-binding region in hBRF.
Reticulocyte lysate (15pl) containing in vitro-translated BRF (lanes 1 and 2), 
BRF/StuI (lane 3) or BRF/Bglll (lane 4), were incubated in the presence of 
glutathione-agarose beads carrying equal amounts of GST (lane 1) or GST-RB (379- 
928) (lanes 2, 3 and 4). Proteins retained after extensive washing were resolved by 
SDS-7.8% polyacrylamide gel electrophoresis and then visualised by 
autoradiography.
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FIG. 3.9 Identification of the RB-region domain in hBRF.
Glutatliione-agarose beads caiTying equal amounts of GST (lanes 2, 5, and 8) or GST- 
RB (379-928) (lanes 3, 6 and 9) were incubated with reticulocyte lysate (15pl) 
containing BRF (lanes 2 and 3), BRF/HincII (lanes 5 and 6) or BRF/EcoRI (lanes 8 
and 9). Proteins remaining on the beads after extensive washing were resolved by 
SDS-7.8% polyacrylamide gel electrophoresis and visualised by autoradiography. 
Lanes 1, 4 and 7 all show 10% of the input reticulocyte lysate containing the relevant 
in vitro-translated BRF or BRF truncations.
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respectively). These GST pull down assays suggest that the RB-binding domain in 
BRF resides upstream of the 2"  ^N-terminal imperfect repeat. Within the BRF cDNA 
sequence, there are no more unique endonuclease restriction sites upstream of the 
EcoR I site; hence an alternative means of determining the RB binding domain in 
BRF was sought. Fortunately, an extensive collection of yBRF truncations was 
available. These yBRF truncations had been previously characterised (Kassavetis et 
ah, 1998), and were so comprehensive in their design, that every conserved domain 
within BRF could be assayed for its contribution towards the binding of RB.
3.2.4 Identification of the RB-binding region in yBRF
The first step in employing the yBRF truncations was to determine if yBRF 
could bind to human RB. To investigate this, yBRF was radiolabelled in vitro using 
reticulocyte lysate and incubated with GST alone and GST-RB (379-928) 
immobilised on glutathione-agarose beads. After incubation, the proteins retained on 
the beads were resolved by SDS-PAGE and visualised by autoradiography. As is 
shown (fig. 3.10), yBRF is able to bind GST-RB (379-928) to a far greater extent 
than yBRF binds GST. This is an important observation, as the yBRF truncations can 
consequently be employed to determine the RB binding domain in yBRF.
To determine where RB binds to in yBRF, the collection of yBRF truncations 
were expressed and radio labelled in vitro using reticulocyte lysate. The expression of 
these proteins was confirmed by resolving 2pl aliquots by SDS-PAGE, and visualised
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FIG. 3.10 yBRF interacts with recombinant RB.
Reticulocyte lysate containing yBRF (15pl) was incubated with glutathione-agarose 
beads carrying equal amounts of GST (lane 2) or GST-RB (379-928) (lane 3). After 
extensive washing, the retained proteins were resolved on a SDS-7.8% 
polyaciylamide gel and visualised by autoradiography. Lane 1 shows 10% of the 
input reticulocyte lysate containing in vitro-translated yBRF.
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by autoradiography. Once the proteins had been successfully expressed, they were 
incubated with GST alone or GST-RB (379-928) immobilised on glutathione-agarose 
beads. After incubation, they were extensively washed and the bound protein was 
resolved by SDS-PAGE and visualised by autoradiography. The results of these GST 
pull down assays are summarised in figure 3.11.A, and the pull down assay data from 
the most informative truncations are shown in fig. 3.1 l.B. As can be seen from the 
pull down analysis, the yBRF truncations which were able to bind RB contained 
either part or all of the N-terminal TFIIB homology domain of yBRF (lanes 3, 6, 12, 
15). Those yBRF truncations which are composed solely of the C-terminal BRF 
homology domain and lack any part of the TFIIB homology domain are unable to 
bind RB (lane 9). These data demonstrate that the N-terminal TFIIB homology 
domain of yBRF is responsible for binding to RB. This confirms the result obtained 
using hBRF. Although many yBRF truncations were available, we were unable to 
localise more precisely the RB-binding domain within the N-terminal half of BRF 
since it was not possible to identify any sequence that was essential for interaction. 
Although yeast residues 1-165 proved sufficient to bind to RB, binding was also 
obtained with residues 164-438. These observations might be explained if the two 
direct repeats (aa 119-159 and aa 217-257) each provide a region that can interact 
with RB. Further experiments will be required to test this possibility.
It was important to confirm that the failure of the C-terminal domain to 
interact with RB was not due to its dénaturation. To ensure the viability of the yBRF 
truncation, BRF (aa 284-596), a control experiment was undertaken. Previous work 
(Kassavetis et al., 1998) and work that will be discussed in section 3.2.5 show that
108
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FIG. 3.11 Identification of the RB-binding region in yBRF.
(A) A schematic representation of the collection of yBRF truncations, and their 
ability to interact with RB.
(B) Glutathione-agarose beads carrying equal amounts of GST (lanes 2, 5,8,  11 and 
14) or GST-RB (379-928) (lanes 3, 6, 9, 12 and 15) were incubated with reticulocyte 
lysate (15pl) containing BRF (1-165) (lanes 2 and 3) , BRF (1-282) (lanes 5 and 6), 
BRF (284-596) (lanes 8 and 9), BRF (164-320) (lanes 11 and 12), or BRF (69- 
365) (lanes 14 and 15). Retained protein was resolved on a SDS-12% polyarcylamide 
gel and visualised by autoradiography. Lanes 1 ,4 ,7 ,  10, and 13 shows 10% of the 
input reticulocyte lysate containing the appropriate in vitro-translated yBRF 
truncations.
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the main TBP-binding domain in BRF is the H2 region, which is located in the C- 
terminal half of BRF. A variety of GST fusion proteins were expressed, purified and 
immobilised on glutathione-agarose beads, namely, GST alone, GST-RB (379-928), 
and qsx-TBP. A s  the main TBP binding region in BRF is the H2 region, present in 
BRF(284-596), it is expected that BRF(284-596) will be able to bind GST-TBP if it 
has retained its structure. BRF(284-596) was expressed and radiolabelled in vitro 
with reticulocyte lysate and incubated with each of the aforementioned GST fusion 
proteins. After incubation, the beads were washed and retained protein resolved by 
SDS-PAGE and visualised by autoradiography, (fig. 3.12). As can be seen BRF(284- 
596), did not bind either GST alone, or GST-RB (379-928) (lane 2 and 3 
respectively); however it was retained by GST-TBP (lane 4). These GST pull down 
data demonstrate that this yBRF truncation has retained its structure, as it is able to 
bind to TBP. Collectively, the pull down assays demonstrate that the RB binding 
domain lies in the N-terminal half of BRF.
3.2.5 Characterisation of the interactions between the components of B’, 
namely TBP and BRF
As discussed above, the RB-binding domain in BRF resides in the N-terminal 
half of the protein. To determine if RB binding to BRF could affect the ability of 
BRF to bind TBP, the TBP/BRF interaction was investigated.
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FIG. 3.12 The yeast truncation BRF (284-596) is able to bind TBP.
Reticulocyte lysate containing BRF (284-596) (15pl), was incubated with 
glutathione-agarose beads carrying equal amounts of GST (lane 2), GST-RB (379- 
928) (lane 3) and GST-TBP (lane 4). Retained protein was resolved on a SDS-12% 
polyacrylamide gel and visualised by autoradiography. Lane 1 shows 10% input of 
the reticulocyte lysate containing BRF(284-596).
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The initial experiment undertaken was to show that TBP and BRF interact. 
TBP and BRF were expressed and radiolabelled in vitro by reticulocyte lysate, and 
immunoprecipitated with TBP antiserum immobilised on protein A beads. After 
incubation, the coprecipitate was resolved by SDS-PAGE and visualised by 
autoradiography (fig. 3.13). As is observed, no TBP is retained by protein A beads 
alone (lane 1), but TBP is coprecipitated with the antiserum raised against TBP (lane 
2), thus illustrating that the coprecipitation of TBP is dependent on the TBP 
antiserum immobilised on the protein A beads. In the absence of TBP, BRF is not 
immunoprecipitated (lane 3), but in the presence of TBP, BRF is coprecipitated (lane 
4), thus demonstrating that TBP and BRF interact.
The ability of TBP and BRF to interact was further confirmed by GST pull 
down assays. In this instance, GST alone and GST-TBP were expressed, purified and 
immobilised on glutathione-agarose beads. Each of these fusion proteins were 
incubated with reticulocyte lysate containing radiolabelled BRF. After extensive 
washing, the bound protein was analysed by resolving on a SDS-polyacrylamide gel 
and visualised by autoradiography (fig. 3.14). As can be seen, BRF is not brought 
down with GST alone (lane 1) but it is pulled down with GST-TBP (lanes 2-4). This 
experiment also shows that the interaction between BRF and TBP is stable, as 
increasing the stringency of the washes, by raising the ionic concentration of the 
washing buffer, did not disrupt the ability of TBP and BRF to interact (lanes 2-4). 
Thus, from these GST pull down data it can be concluded that TBP and BRF form an 
interaction stable to high ionic strength.
112
Chapter 3 Results
FIG. 3.13 Recombinant BRF interacts with recombinant TBP.
Reticulocyte lysate (15 pi) containing either in vitro-translated TBP (lanes 1 and 2), or 
in vitro-translated BRF (lane 3) or both (lane 4), were immunoprecipitated with the 
anti-TBP antibody, MTBP-6 (lanes 2-4) or incubated with only protein A beads (lane
1). The precipitated material was resolved on a SDS-7.8% polyarcylamide gel and 
visualised by autoradiography.
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FIG. 3.14 Recombinant BRF interacts with recombinant TBP and this 
interaction is stable to 400mM KCI.
Reticulocyte lysate containing in vitro-translated BRF (15pl), was incubated with 
glutathione-agarose beads carrying equal amounts of GST alone (lane 1), or GST- 
TBP (lanes 2-4). The protein retained on the beads were washed with lOOmM KCI 
(lanes 1 and 2), 200mM KCI (lane 3), and 400mM KCI (lane 4), and resolved on a 
SDS-7.8% polyacrylamide gel and visualised by autoradiography.
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Having demonstrated the interaction between TBP and BRF, the next step was 
to identify the TBP binding domain within BRF. This was undertaken by incubating 
pCITE D l, a construct containing the cDNA sequence of BRF, with various 
restriction endonucleases, whose cleavage sites were unique in hBRF. Completion of 
cleavage was confirmed by analysing an aliquot on a 1% agarose gel. Once the DNA 
was completely cleaved, it was purified and transcribed using T7 RNA polymerase. 
The RNA was then purified and the encoded protein expressed and radiolabelled in 
vitro by reticulocyte lysate. Protein expression was confirmed by resolving a 2pi 
aliquot by SDS-PAGE, followed by autoradiography. The ability of these BRF 
truncated proteins to interact with TBP was determined by immunoprécipitations. 
Reticulocyte lysate containing either radiolabelled BRF truncations or TBP were 
incubated with TBP antiserum immobilised on protein A beads. After incubation the 
beads were washed and the coprecipitated material was examined by resolving on a 
SDS-polyacrylamide gel and autoradiography (fig. 3.15). Again it was found that the 
coprecipitation of BRF is dependent on the presence of TBP (lanes 1-4). Furthermore, 
the truncated proteins BRF/Stu I, which lacks the C-terminal tail of BRF (lane 5), and 
BRF/Bgl II, which lacks the H3 region (lane 7), are both able to bind TBP. These 
immunoprécipitation data indicate that the C-terminal tail and the H3 region are not 
required for BRF to bind TBP.
The ability of these BRF truncations to interact with TBP was confirmed by 
GST pull down assays. GST alone and GST-TBP were expressed, purified and 
immobilised on glutathione-agarose beads. Each of these fusion proteins was
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FIG 3.15 Recombinant TBP Interacts with BRF truncations.
Reticulocyte lysate (15pl) containing in vitro-translated BRF (lanes 3 and 4), 
BRF/Stu I (lanes 5 and 6) or BRF/Bgl II (lanes 7 and 8), with the addition of 
reticulocyte lysate containing in vitro-translated TBP (lanes 1, 2, 4, 5 and 7), were 
immunoprecipitated using the anti-TBP antibody MTBP-6. The precipitated protein 
was washed extensively, resolved on a SDS-7.8% polyacrylamide gel and visualised 
by autoradiogiaphy.
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incubated with reticulocyte lysate containing radiolabelled full length BRF or a 
truncated form of BRF. The beads were extensively washed, and the retained protein 
resolved by SDS-PAGE and visualised by autoradiography (fig 3.16). As is shown, 
GST alone retains a minimal background amount of BRF (lanes 1-3). However, there 
is a much stronger interaction between all of the BRF forms and TBP (lanes 4-6), It 
can be concluded from these immunoprécipitation data and GST pull down analysis 
that neither the C-terminal tail nor the H3 region contribute to the ability of BRF to 
interact with TBP.
The TBP-binding domain in BRF was further analysed by generating another 
BRF truncation using restriction enzyme Xcm I, in which the H2 region had been 
removed. Again the ability of this truncation to interact with TBP was determined by 
immunoprécipitation. Various truncations of BRF were expressed and radiolabelled 
in reticulocyte lysate, and incubated with TBP antiserum immobilised on protein A 
beads. TBP expressed in reticulocyte lysate, but not radiolabelled was also added; in 
this instance expression was confirmed by resolving an aliquot by SDS-PAGE, and 
staining with coomassie blue. After incubation and washing, the coprecipitate was 
resolved by SDS-PAGE and visualised by autoradiography (fig. 3.17). From the 
autoradiogram, it can be seen that the truncated forms of BRF previously examined 
were capable of binding TBP (lanes 4-7). However the truncated form in which the 
H2 region was removed, namely BRF/Xcm I, is not capable of binding TBP (lanes 8 
and 9). Therefore it can be concluded from these immunoprécipitation data that the 
TBP binding domain in BRF resides in the H2 region. The TBP-binding domain in 
BRF is therefore separate from the domain responsible for interacting with RB.
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FIG. 3,16 Recombinant TBP interacts with BRF truncations.
Glutathione-agarose beads carrying equal amounts of GST alone, (lanes 1, 2, and 3) 
or GST-TBP (lanes 4, 5 and 6) were incubated with reticulocyte lysate (15pl) 
containing in vitro-translated BRF (lanes 1 and 4), BRF/Stu I (lanes 3 and 6) or 
BRF/Bgl II (lanes 2 and 5). The retained protein was washed extensively, and 
resolved by SDS-7.8% polyacrylamide gel and visualised by autoradiography.
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FIG. 3.17 A BRF truncation which does not interact with TBP.
Reticulocyte lysate (15pl) containing in vitro-translated BRF/Stu I (lanes 4 and 5), 
BRF/Bgl II (lanes 6 and 7) or BRF/Xcm I (lanes 8 and 9), with the addition of 
reticulocyte lysate containing in vitro-translated but not radiolabelled TBP (lanes 5, 7, 
and 9), were immunoprecipitated with the anti-TBP antibody MTBP-6. The 
precipitated protein was washed and resolved on a SDS-7.8% polyacrylamide gel and 
visualised by autoradiography. Lanes 1, 2, and 3 show 10% of the input reticulocyte 
lysate containing in vitro-translated BRF tmncations.
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Hence it was decided to investigate the effect of RB upon the interaction 
between TBP and BRF.
3.2.6 RB does not disrupt the interaction between BRF and TBP
As it has previously been demonstrated that TFIIIB is the target for RB 
repression of pol III transcription (Larminie et al., 1997), it was decided to test if  RB 
exerts its effect by disrupting the TFIIIB complex. This was investigated by 
immunoprécipitations. Reticulocyte lysates containing radiolabelled BRF and TBP 
were incubated with TBP antiserum immobilised on protein A beads, in the absence 
or presence of RB purified from baculovirus cells. After incubation, the coprecipitate 
was resolved by SDS-PAGE and visualised by autoradiography (fig. 3.18). It can be 
seen that TBP and BRF can coprecipitate (lane 4) and the ability of TBP and BRF to 
coprecipitate is not affected by the presence of RB (lane 5). These 
immunoprécipitation data suggest that RB does not disrupt the interaction between 
TBP and BRF.
The effect of RB upon the interaction between endogenous TBP and BRF was 
also investigated by immunoprécipitations. HeLa extracts were incubated with 
protein A beads coupled to BRF antiserum or its corresponding preimmune as the 
negative control. After incubation, the coprecipitate was extensively washed and 
resolved by SDS-PAGE. The presence of TBP was determined by western blotting 
(fig.3.19). As can be observed, the preimmune serum does not coprecipitate TBP
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FIG. 3.18 RB does not disrupt the interaction between recombinant TBP and 
recombinant BRF.
15 pi of reticulocyte lysate containing in vitro-translated TBP (lanes 1 and 2), or in 
vitro-translated BRF (lane 3), or both (lanes 4 and 5), with the addition of baculovrius 
purified RB (lane 5) were immunoprecipitated by the anti-TBP antibody MTBP-6 
(lanes 2-5) or incubated with protein A beads (lane 1). The precipitated protein was 
washed and resolved by on a SDS-7.8% polyacrylamide gel and visualised by 
autoradiography.
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FIG. 3.19 RB does not abolish the interaction between endogenous TBP and 
BRF.
HeLa cell extract (150 pg) alone (lanes 2 and 3), or mixed with 200ng of GST (lane 
4) or GST-RB (379-928) (lane 5) was immunoprecipitated (IP) using BRF 128 
antiserum (lanes 3-5) and the corresponding preimmune (lane 2). The precipitated 
material was resolved on a SDS-7.8% polyacrylamide gel. The presence of TBP was 
deteimined by western analysis with the anti-TBP antibody SL30. Lane 1 shows 25% 
input of the HeLa extract.
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(lane 2), whereas the BRF antiserum does, demonstrating the specificity of this 
interaction (lanes 3). The presence of GST alone does not affect the interaction 
between TBP and BRF (lane 4), and neither does the addition of GST-RB (379-928) 
(lane 5). These observations lead to the conclusion that RB does not affect the 
interaction between TBP and BRF. It was therefore decided to determine if RB 
represses pol III transcription by preventing TFIIIB from interacting with TFIIIC, the 
pol III enzyme or both.
3,2.7 Characterisation of the effects of RB upon the interaction between 
TFIIIB and TFIIIC
The effect of RB upon the interaction between TFIIIB and TFIIIC2 was 
investigated by immunoprécipitations. HeLa extract was mixed with in vitro 
translated BRF in the presence of His-tagged RB (379-928). The mixtures were then 
incubated with TFIIIC2 antiserum immobilised on protein A beads. After incubation 
and extensive washing, the coprecipitated material was resolved by SDS-PAGE and 
visualised by autoradiography (fig. 3.20,A). The antiserum raised against TFIIIC2 
coprecipitates BRF (lane 3); however, the addition of His-tagged RB (379-928) 
greatly reduces the level of BRF coprecipitated by the TFIIIC2 antiserum (lane 4).
To ensure these observations were not a peeuliarity of His-tagged fusion 
proteins, an alternative bacterially expressed RB protein was utilised in additional 
immunoprécipitation experiments. HeLa extract was mixed with radiolabelled BRF,
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FIG. 3.20 RB disrupts the interaction between endogenous TFIIIC2 and 
recombinant BRF.
(A) HeLa cell extract (150 pg) (lanes 3 and 4) or buffer (lane 2) was mixed with 
reticulocyte lysate containing in vitro-translated BRF, with the addition of lOOng of 
His-tagged RB (lane 4), was immunoprecipitated using TFIIIC2 antiserum 4286 
(lanes 2-4). The precipitated material was resolved on a SDS-7.8% polyacrylamide 
gel and visualised by autoradiography. Lane 1 shows 10% input of the reticulocyte 
lysate containing in vitro-translated BRF.
(B) Reticulocyte lysate containing in vitro-translated BRF (ISpl), was mixed with 
buffer (lane 2) or HeLa cell extract (150 pg) (lanes 3 and 4), and 200ng of GST alone 
(lane 3) or 200ng of GST-RB (379-928) (lane 4), then immunoprecipitated with 
TFIÎIC2 4286 antiserum (lanes 2-4). The precipitated material was resolved on a 
SDS-7.8% polyacrylamide gel and visualised by autoradiography. Lane 1 shows 10% 
input of reticulocyte lysate containing in vitro-translated BRF.
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with the addition of either GST, or GST-RB (379-928), then incubated with TFIIIC2 
antiserum immobilised on protein A beads. The coprecipitate was resolved by SDS- 
PAGE and visualised by autoradiography (fig. 3.20.B). The antiserum against 
TFIIIC2 once again coprecipitated BRF in the presence of GST (lane 3); however, the 
addition of GST-RB (379-928) greatly reduces the amount of BRF retained (lane 4). 
These data suggest that the presence of RB compromises the interaction between 
TFIIIB and TFIIIC.
The effect of RB upon the interaction between endogenous TFIIIB and 
TFIIIC was also examined by immunoprécipitations. HeLa extract was mixed with 
GST alone or GST-RB (379-928) and incubated with TFIIIC2 antiserum immobilised 
on protein A beads. After incubation, the coprecipitate was extensively washed and 
resolved by SDS-PAGE, and the presence of TFIIIB was determined by probing for 
TBP by western analysis (fig. 3.21). The preimmune does not coprecipitate TBP (lane
2), in contrast to the TFIIIC2 antiserum which does coprecipitate TBP, and is capable 
of doing so in the presence of GST alone (lane 3). The addition of GST-RB (379-928) 
greatly reduces the amount of TBP coprecipitated by the TFIIIC2 antiserum (lane 4). 
These immunoprécipitations therefore demonstrate that RB is able to disrupt the 
interaction between TFIIIB and TFIIIC.
An alternative means of assessing the effect of the RB upon the interaction 
between TFIIIB and TFIIIC was provided by assaying the DNA-binding activity of 
precipitated material. These oligonucleotide binding assays involve
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FIG. 3.21 RB disrupts the interaction between endogenous TBP and TFIIIC2.
HeLa cell extract (150 pg) alone (lanes 2 and 3), or mixed with 200ng of GST-RB 
(379-928) (lane 4) was immunoprecipitated using a column purified TFI1IC2 4286 
antiserum, (lanes 3 and 4), or the corresponding preimmune serum (lane 2). The 
precipitated material was resolved by SDS-7.8% polyacrylamide gel electrophoresis. 
The presence of TBP was determined by western analysis using anti-TBP antibody 
SL30. Lane 1 shows 20 % input of HeLa extract.
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immunoprécipitations as before, then incubating the coprecipitated material with a 
radiolabelled DNA probe, and then removing unbound probe by washing. The 
amount of probe bound was subsequently determined by scintillation counting. 
The initial oligonucleotide binding assay was to determine if such an experimental 
approach was viable. TFIIIC2 4286 antiserum and its corresponding preimmune were 
immobilised on protein A beads and incubated with HeLa extract. After incubation, 
the beads were extensively washed and incubated with a radiolabelled B box probe, 
that contains a recognition sequence of the internal pol III promoter bound by 
TFIIIC2. After the second incubation, the beads were again washed, the retained 
DNA eluted, bound to DEAE discs, and scintillation counted (fig 3.22.A). As can be 
seen, significantly more B box binding activity is immunoprecipitated by the TFIIIC2 
anti serum than the corresponding preimmune (compare lane 2 to lane 1). The ability 
of the immunoprecipitated material to bind the B box probe is partially specific (fig. 
3.22.B), as the introduction of unlabelled B box competitor oligonucleotide greatly 
reduces the amount of probe immunoprecipitated (lane 2). In contrast, incubation 
with a non-specific competitor oligonulceotide does not have such a great effect (lane
3). The effect of RB upon the interaction between TFIIIC and TFIIIB was determined 
by immunoprecipitating HeLa extract with the BRF antiserum 330 immobilised on 
protein A beads (fig. 3.22.C). As can be seen, the presence of GST-RB (379-928) 
greatly reduces the ability of the complex coprecipitated by the BRF antiserum to 
retain the radiolabelled B box probe (lane 3), in contrast to GST alone which had 
much less effect (lane 2). In order to confirm that the inclusion of RB specifically 
affected the TFIIIC/TFIIIB interaction and not the ability of precipitated TFIIIC2 to 
bind the B-box probe, TFIIIC2 antiserum was used to
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FIG. 3.22 RB disrupts the interaction between endogenous TFIIIC2 and 
endogenous TFIIIB.
(A) HeLa cell extract (150 pg) was immunoprecipitated with TFIIIC2 antiserum 4286 
(lane 2) and the conesponding preimmme (lane 1). The precipitated material was 
incubated with radiolabelled B box probe. After extensive washing, the amount of 
retained probe was measured by scintillation counting.
(B) HeLa cell extract (150 pg) was immunoprecipitated with TFIIIC2 antiserum 4286 
(lanes 1-3). The precipitate was incubated with radiolabelled B box probe, with the 
addition of a specific competitor oligonucleotide (lane 2), and a non-specific 
competitor oligonucleotide (lane 3). After incubation, the precipitate was washed and 
the amount of probe retained determined.
(C) HeLa cell extract (150 pg) alone (lane 1), or mixed with 200ng of GST (lane 2) or 
GST-RB (379-928) (lane 3) was immunoprecipitated with BRF antiserum 330 (lanes 
1-3). The precipitate was incubated with radio labelled B box probe; retained probe 
was measured.
(D) HeLa cell extract (150 pg) with addition of 200ng of GST alone (lane 1) or GST- 
RB (379-928) (lane 2) was immunoprecipitated with TFIIIC2 antiserum 4286 (lanes 
1 and 2). The precipitate was incubated with radiolabelled probe and the retained 
probe was measured
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immunoprecipitate HeLa extract in the presence of recombinant RB (fig. 3.22.D). The 
addition of GST-RB (379-928) only slightly reduces the ability of the TFIIIC2 
antiserum to immunoprecipitate a complex which has the capacity to bind the B box 
probe. The immunoprécipitation data and oligonucleotide binding assays suggest that 
RB compromises the ability of TFIIIC2 to coimmunoprecipitate with BRF, indicating 
that RB disrupts the interaction between TFIIIB and TFIIIC.
3.2.8 Characterisation of the effect of RB upon the interaction between TFIIIB 
and pol III
The ability of RB to disrupt the pol III/TFIIIB interaction was investigated by 
immunoprécipitations. Pol III antiserum was immobilised on protein A beads and 
incubated with HeLa extract mixed with reticulocyte lysate containing radiolabelled 
BRF, with the addition of GST alone or GST-RB (379-928). After incubation, the 
coprecipitate was washed and resolved by SDS-PAGE and visualised by 
autoradiography (fig. 3.23.A). As is shown, the pol III antiserum is able to 
coprecipitate BRF (lane 3) and this ability is not negated by the presence of GST 
alone (lane 4). However, when GST-RB (379-928) was added to the 
immunoprécipitation reaction the ability of the pol III antiserum to coprecipitate BRF 
was reduced (lane 5). These immunoprécipitation data suggest that RB disrupts the 
interaction between TFIIIB and pol III.
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FIG. 3.23 RB disrupts the interaction between pol III and BRF.
(A) 15pi of reticulocyte lysate containing in vitro-translated BRF, was mixed with 
buffer (lane 2) or HeLa extract (lanes 3-5), with the addition of 200ng of GST alone 
(lane 4) or GST-RB (379-928) (lane 5), then immunoprecipitated with column 
purified pol III antiserum BN51 (lanes 2-5). The precipitate was resolved on a SDS- 
7.8% polyacrylamide gel and visualised by autoradiography. Lane 1 shows 10% input 
of reticulocyte lysate containing in vitro-translated BRF.
(B) HeLa cell extract (150 pg) (lanes 2-5) mixed with lOOng of His-tagged RB (379- 
928) (lane 5), was immunoprecipitated with the BRF antiserum 330 (lane 2), the 
corresponding preimmune (lane 3), and the pol III antiserum BN51 (lanes 4 and 5). 
The precipitate was resolved on a SDS-7.8% polyacrylamide gel. The presence of 
TBP was determined by western analysis with the anti-TBP antibody SL30. Lane 1 
shows 25% input of HeLa.
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The effect of RB upon the interaction between endogenous TFIIIB and 
endogenous pol III was also investigated by immunoprécipitations. Pol III and BRF 
antisera immobilised on protein A beads were incubated with HeLa extract, in the 
absence or presence of His-tagged RB (379-928). After incubation, the coprecipitate 
was washed and resolved by SDS-PAGE, The presence of TFIIIB was determined by 
probing for TBP by western analysis (fig. 3.23.B). As is shown, the preimmune 
serum (lane 2) does not precipitate TBP, but the BRF antiserum does (lane 3). The 
pol III antiserum coprecipitates TBP (lane 4), but upon the addition of His-tagged RB 
(379-928) this effect is abolished (lane 5). These observations suggest that the 
presence of RB disrupts the interaction between TFIIIB and pol III.
An alternative means of detecting RNA polymerase was employed, namely 
polymerisation assays using poly(dA-dT) as template. This experimental approach 
allowed for further assessment of the TFIIIB-pol III interaction. Anterisera against 
BRF and pol III, along with the corresponding preimmunes as negative controls, were 
immobilised on protein A beads, incubated with HeLa extract, then assayed for 
polymerase activity (fig. 3.24A). As is shown, both antisera immunoprecipitated 
more pol III activity than their corresponding preimmune^{ 
To determine the effect of RB upon the interaction between TFIIIB and pol III, BRF 
antiserum was immobilised on protein A beads and incubated with HeLa extract with 
the addition of GST alone or GST-RB (379-928). The coprecipitate was washed and 
assayed for polymerase activity. It can be seen that (fig. 3.24.B), the presence of 
GST-RB (379-928) greatly reduced the ability of pol III and TFIIIB to
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FIG. 3.24 RB disrupts the interaction between endogenous TFIIIB and 
endogenous pol III.
(A) HeLa cell extract (150 pg) was immunoprecipitated by the pol III antiserum 
BN51 (lane 2) and the corresponding preimmune (lane 1), and the BRF antiserum 
330 (lane 4) and its corresponding preimmune (lane 3). The presence of pol III was 
detected by a polymerisation assay.
(B) HeLa cell extract (150 pg) mixed with 200ng of GST alone (lane 1) or GST-RB 
(379-928) (lane 2) was immunoprecipitated with BRF antiserum. Again, pol III was 
detected by a polymerisation assay.
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interact. Thus, these assays again demonstrate that RB is capable of disrupting the 
interaction between TFIIIB and pol III.
3.2.9 Model whereby RB represses pol III transcription
The observations discussed above culminate in the following model: RB 
represses pol III transcription by targeting the BRF subunit of the pol III general 
transcription factor TFIIIB; RB exerts this effect not by disrupting the TFIIIB 
multisubunit complex, but instead RB prevents TFIIIB from interacting with both 
TFIIIC and pol III (fig. 3.25).
3.3 Discussion
Relatively recently it was discovered that RB is able to inhibit pol III 
transcription (White et al., 1996; Larminie et al., 1997). The work presented above 
has elucidated a mechanism for this repression; namely, that RB interacts with the 
BRF subunit of TFIIIB and prevents it from physically associating with the other 
components of the transcription machinery. The domain of RB responsible for 
binding BRF and repressing pol III transcription is the large pocket of RB (White et 
al., 1996). Since this is also the domain necessary for growth inhibition (Qin et al., 
1992), perhaps a correlation exists between these events.
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FIG. 3.25 Model whereby RB represses pol III transcription.
RB targets the BRF subunit of TFIIIB, thereby making it unavailable to interact with 
both TFIIIC and pol III.
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The RB-binding domain in BRF was elucidated. Truncations of yeast and 
human BRF identified the region as being in the TFIIB homology half. Since deletion 
of either imperfect repeat did not abolish RB binding, it could be that both of these 
repeats is a RB-binding region. The stiochiometry of the RB/BRF interaction is not 
known and it could be that RB binding to BRF is cooperative, resulting in two RB 
molecules being bound to a BRF protein by virtue of the imperfect repeats. Whether 
this is spatially feasible will only be apparent upon determination of the tertiary 
structure of BRF.
RB represses pol III transcription via two effects. Firstly, it prevents TFIIIB 
from interacting with TFIIIC2, the DNA binding protein which acts to recruit TFIIIB 
to most class III promoters. However, there are some genes that are transcribed by pol 
III in a TFIIIC2-independent fashion, such as human U6 snRNA genes (White, 
1998). These genes, unlike other pol III templates, have an upstream TATA sequence 
which can be recognised directly by the TBP subunit of TFIIIB (White, 1998). If RB 
only affected the interaction between TFIIIB and TFIIIC2, then this could not account 
for the ability of RB to repress class III promoter types. However, there is another 
means by which RB represses pol III transcription, namely by disrupting the 
interaction between TFIIIB and pol III. The ability of RB to disrupt this interaction 
provides a mechanism for RB to be a general repressor of pol III transcription, as the 
recruitment of pol III by TFIIIB is an essential step in the transcription of all pol III 
genes (Willis, 1993; Geiduschek and Kassavetis, 1995; White, 1998).
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The ability of RB to disrupt the interaction between TFIIIB and pol III is 
unlike the mechanism of RB-mediated repression reported for the other transcription 
systems, pol I (Cavanaugh et al., 1995; Voit et al., 1997) and pol II (Ross et al, 1999). 
For example, RB does not disrupt the interaction between the pol I transcription 
factor UBF and the pol I enzyme (Voit et al., 1997). However, there would appear to 
be an analogy between the pol II and pol III systems, regarding the ability of RB to 
prevent a physical association between a TBP-containing complex and a promoter- 
recognising protein. Thus, RB binds XFIIIB and prevents it from interacting with the 
promoter-recognition factor TFIIIC2, whilst in the pol II system RB binds E2F, a 
promoter-recognising factor, and prevents it from associating with TFIID, a TBP- 
containing complex (Ross et al., 1999).
Although it appears that RB represses pol III transcription by two distinct 
mechanisms, why this is so is not clear. The ability of RB to disrupt the interaction 
between TFIIIB and pol III would suffice to repress transcription from all pol III 
promoter types. As mentioned above, the RB binding site has been located to the 
TFIIB-homology half of BRF, more precisely the imperfect repeats. It could be that 
RB binding to BRF covers the regions needed for BRF to interact with both TFIIIC2 
and pol III. In yeast, the domains in BRF that interact with TFIIIC and pol III have 
been identified as being situated around the 2 N-terminal repeats (Khoo et a l, 1994; 
Chaussivert et a l, 1995; Kassavetis et a l, 1997), the same region which has been 
shown to be responsible for binding RB. It is likely that the same regions are 
responsible for such interactions in human BRF. Hence, upon binding to BRF, RB
136
Chapter 3 Results
disrupts the interaction between BRF and TFIIIC and pol III by masking the binding 
sites of these two proteins.
The model proposed above does not fully comply with previous observations 
regarding RB-mediated pol III repression. Previous work has suggested that RB 
targets two general pol III transcription factors, TFIIIC and TFIIIB (Chu et al., 1997). 
Other studies (Larminie et al., 1997) and the work presented above imply that TFIIIB 
is the specific target of repression, and that upon addition of RB the interaction 
between TFIIIB and TFIIIC is abolished.
Larminie et al. suggested that RB represses pol III transcription by disrupting 
the TFIIIB complex (Larminie et al., 1997). Work presented here demonstrates that 
RB does not disrupt the physical association between TBP and BRF, unlike Drl, 
which represses pol III transcription by competing with BRF for binding sites on TBP 
(White et al., 1994). This is consistent with the fact that TBP and BRF can be 
coimmunoprecipitated with antibodies against RB (Larminie et al., 1997). However, 
mammalian TFIIIB is believed to be composed of at least one more subunit besides 
TBP and BRF, probably one which shows homology to the B” subunit of yeast 
TFIIIB (Lobo et al., 1992; Teichmann and Seifart, 1995; Mital et al., 1996; 
Teichmann et al., 1997). It cannot be ruled out that RB disrupts the interactions 
between the components of B’ and an as of yet unidentified subunit(s) of TFIIIB. At 
present the molecular reagents are not available for such investigations to be 
undertaken. They are also not available to examine the possible interaction between 
RB and the ill-defined TFIIIC 1 component of TFIIIC.
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In conclusion, it appears that RB represses pol III transcription by disrupting 
the initiation complex, preventing TFIIIB from interacting with TFIIIC and pol III.
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Chapter 4
Disruption of the interaction between BRF and RB in cancer cells
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4 Disruption of the interaction between BRF and RB in cancer cells
4.1 Introduction
A hallmark of cancer is uncontrolled proliferation and deregulation of the cell 
cycle. The fundamental task of the cell cycle is to faithfully replicate DNA, and 
ensure equal distribution of the chromosomes between two daughter cells (Heichman 
and Roberts, 1994). During Gl, cells are receptive to extracellular stimuli, which 
signal to the cells to either proceed towards division by transit through S, G2, and M- 
phases or to withdraw from the cell cycle into a resting state called GO (Pardee,
1989). Cancer cells differ from normal cells by being unreceptive towards many 
extracellular stimuli; these signals are ignored and the cells tend to remain cycling, 
rather than going into a resting state that may facilitate differentiation. There are 
various control or check-points throughout the cell cycle, an example of which occurs 
during late Gl and is known as the restriction or R point. Once a cell passes the 
restriction point it is committed to cycling (Pardee, 1989). As the restriction point 
constitutes a major regulatory feature of the cell cycle, it is of considerable 
importance to understand the mechanisms which act at the restriction point, and if 
deregulation of this machinery allows cancerous cells to continuously cycle.
A means of regulating the passage of cells through the restriction point is by 
the cyclin-dependent protein kinases (cdks). The activity of cdks requires cyclin 
binding; which occurs in a progressive fashion through the cell cycle by cyclins D, E, 
A and B. (Morgan, 1995; Resnitzky et al., 1994). cdk activity also depends on both
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positive and negative regulatory phosphorylation and can be compromised by cdk 
inhibitory proteins (Sherr and Roberts, 1995). A target of cyclin-dependent kinases is 
RB; this gives rise to the RB pathway which converges on the restriction point 
(Weinberg, 1995).
As the activity of the cdks is controlled by various cyclins throughout the cell 
cycle, so is the phosphorylation status of RB. Upon the appropriate extracellular 
signals, cyclin D is expressed giving rise to the formation of a cdk4/6-cyclin D 
complex by mid-Gl. The cdk4/6-cyclin D l complex phosphorylates RB, preventing 
it from acting as a cell cycle brake; hence cells can pass through the restriction point 
and exit Gl (Sherr, 1993). At the Gl-S transition, cyclin E is the most predominant 
cyclin and maintains the hyperphosphorylation status of RB in a mitogen-independent 
fashion (Sherr, 1993). The other cyclins, A and B, maintain the hyperphosphorylated 
status of RB as cells proceed through the cell cycle. RB-dephosphorylation does not 
occur until cells complete mitosis and re-enter Gl phase (or GO) (Sherr, 1996). A 
pattern for RB phosphorylation throughout the cell cycle can be proposed: RB is 
hypophosphorylated in Gl phase; as cells enter S phase, RB is hyperphosphorylated; 
it remains in this state until end of M phase, whereupon it is dephosphorylated 
(Weinberg, 1995). Like RB, pol III transcription levels fluctuate as a cell passes 
through the cell cycle; pol ill transcription increases gradually through G l, reaching a 
maximal level during S and G2, then decreasing as cells enter M (White et a i, 
1995b). During interphase, the pattern of RB phosphorylation in the cell cycle 
coincides with the model for elevated pol III transcription, this suggests a correlation
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between the phosphorylation of RB and the upregulation of pol III transcription, 
namely phosphorylated RB is unable to repress pol III transcription.
In cancerous cells, as one may have expected, the situation is altered. For 
example in a variety of transformed cells, the RB kinases becomes deregulated, 
ultimately resulting in the inactivation of RB by hyperphosphorylation. In this state 
RB can not act as a cell cycle brake at the restriction point, or inhibit transcription, 
and so cells continuously cycle and display deregulated transcriptional activity. RB 
may become hyperphosphorylated in a variety of ways, such as the overexpression of 
cyclin D l, which is prevalent in many human cancers as a result of gene 
amplification or translocations targeting the cyclin Dl locus. Such overexpression is 
observed in more than 50% of breast cancers, and in esophageal and squamous cell 
carcinomas (Hunter and Pines, 1994; Pines, 1995; Sherr, 1994; Weinberg, 1995). A 
similar means of inactivating RB would be the amplification of cdk4, as observed in 
glioblastomas and some gliomas (He et al., 1994; Schmidt et al., 1994). Alternatively, 
RB hyperphosphorylation can be achieved by the deletion of genes encoding the 
inhibitors of cdk4, such as p i5 and p i6; such mutations are observed in esophageal 
squamous cell carcinomas (Mori et al., 1994; Nobori, 1992). The mutational 
inactivation of pl5 and p i6 presumably mimics the overexpression of cyclin Dl or 
cdk4; the consequence of each is the hyperphosphorylation of RB and subsequent 
physiological inactivation.
In addition to phosphorylation, there are two other means by which RB can 
become physiologically inactivated, namely by mutation and through sequestration
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by a transforming protein. Mutational inactivation of RB has been observed in 
retinoblastomas and osteosarcomas (Weinberg, 1995). Several mutant forms of RB 
have also been isolated from various cell lines and demonstrated to be inactive, 
giving rise to null mutants. The small-cell lung cancer cell line NCI-H209 has been 
shown to express an aberrant, underphosphorylated form of RB (Kaye et al., 1990). 
This mutated RB contains a single point mutation within exon 21, which results in the 
substitution of phenylalanine for cysteine at residue 706 (Kaye et al., 1990). This 
substitution mutation is sufficient to alleviate phosphorylation, prevent binding to the 
viral transforming proteins SV40 large T antigen and adenovirus El A (Kaye et al., 
1990), and abolish RB-mediated repression of pol III transcription (White et al., 
1996).
Examination of two other small-cell lung carcinoma cell lines revealed 
additional mutations in RB. The small-cell lung carcinoma cell line NCI-H69C 
contains an abnormal RB species in which the 38 amino acids of exon 22 have been 
deleted; this form is unable to interact with adenovirus E l A or SV40 large T antigen 
(Horowitz et al., 1990). Another small-cell lung carcinoma cell line, NCI-H1436 
contains a RB form in which the 35 amino acids of exon 21 have been eliminated; 
this RB mutant is also unable to bind to adenovirus El A or SV40 large T antigen 
(Horowitz et al., 1990).
The osteosarcoma cell line SA0S2 contains an abnormal RB protein of 95kD 
(Shew et al., 1990). This protein has a C-terminal truncation resulting from the 
deletion of exons 21-27 (Shew et al., 1990). This RB truncation is not phosphorylated
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and neither does it bind to SV40 large T antigen (Shew et al., 1990). In addition, the 
introduction of wild type RB into SA0S2 cells suppresses their neoplastic phenotype, 
suggesting that the endogenous RB was inactivated (Shew et al., 1990).
The final means by which RB becomes physiologically inactive is through 
sequestration by a transforming protein such as adenovirus El A, SV40 large T 
antigen or human papillomavirus E7 protein (DeCaprio et al., 1988; Dyson et al., 
1989; Vousden, 1995; Whyte et al., 1988).
There are forms of cancer associated with particular transforming viruses. For 
example, HP Vs are associated with 80% of cervical cancer, the second leading cause 
of cancer death in women in the world (Schoell et al., 1999). They are classified as 
high-risk or low-risk types, depending on whether or not they are found in cervical 
cancers (Swan et al., 1994). High-risk HPV types HPV-16, and -18 express 
oncoproteins E6 and E7, which interact strongly with p53 and RB, respectively. The 
binding of E7 to RB has been shown to abolish the interaction between RB and E2F 
(Chellappan et al, 1992). Upon HPV transformation, E7 is expressed and binds RB, 
which disrupts the RB-E2F complex. Hence, E2F is released and can subsequently 
promote cellular proliferation.
Various transformed cell types display abnormally elevated levels of pol III 
activity (White, 1998). This was first observed upon transformation of murine 
fibroblast lines with SV40 (Scott et al., 1983; Singh et al., 1985; Carey et al., 1986b; 
White et al., 1990). This effect is due to the elevated expression of TFIIIC2 and the
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ability of SV40 large T antigen to bind and neutralise RB (White et al., 1990; 
Larminie et al., 1999). It is of interest to note that the level of pol III transcription 
correlates directly with the degree of transformation. Thus, cells which were most 
highly transformed have the greatest level of pol III transcription, whereas those less 
tumorigenic cells show lower levels of pol III activity (Scott et al., 1983; White et al.,
1990).
The work presented here demonstrates that the various ways by which RB 
becomes physiologically inactivated reduce its ability to interact with the BRF 
subunit of TFIIIB. For example, the RB/BRF interaction is severely compromised 
following SV40 transformation. This interaction is also perturbed when RB is 
mutated; the deletion of the C-terminus of RB, or the deletion of 4 amino acids in the 
RB pocket also compromises the ability of RB to interact with BRF. Null mutant 
forms of RB are also shown to be unable to alleviate the association between TFIIIB 
and TFIIIC, or between TFIIIB and pol III, unlike their wild-type counterpart. Lastly, 
the phosphorylation of RB has also been shown to prevent a physical association 
between BRF and RB.
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4.2 Results
4.2.1 The interaction between TFIIIB and RB is deregulated following SV40 
transformation
Previous investigations have shown that in murine fibroblasts RB regulates 
the activity of TFIIIB (Larminie et al., 1997). Immunoprécipitations were undertaken 
in order to determine the effect of SV40 transformation upon the physical association 
between TFIIIB and RB. The BRF subunit of TFIIIB was expressed and radiolabelled 
in vitro using reticulocyte lysate and incubated with whole cell extract. The mixtures 
were then immunoprecipitated using the RB antibody G3-245. The precipitate was 
washed and resolved by SDS-PAGE and visualised by autoradiography (fig 4.1.A). 
As can be seen, significant amounts of BRF were coprecipitated from A31 cell 
extract, an untransformed murine cell line derived from random-bred Swiss mouse 
embryo cultures (Aaronson and Todaro, 1968) (lane 5), This interaction is specific 
and is not due to cross-reaction, since only background levels of BRF were observed 
when the cell extract was replaced by buffer (lane 2). These background levels were 
also observed when RB was coprecipitated from SA0S2 cells (lane 3) which express 
an inactive truncated form of RB (Shew et al., 1990), and SV3T3 C138 cells, a SV40- 
transformed derivative of the A31 cell line (lane 4), even though C138 cells contain 
wild-type full length RB. A similar experiment was carried out with a different 
antibody, wherein reticulocyte lysate containing in vitio translated and radiolabelled 
BRF was incubated with cell extract and immunoprecipitated with the anti-RB 
antibody C-15; the coprecipitated BRF was analysed by SDS-PAGE and
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FIG. 4.1 The BRF subunit of TFIIIB interacts with endogenous RB in A31 cell 
extract, but this interaction is compromised in extracts from SV3T3 C138 and 
€149.
(A) Reticulocyte lysate (1 5 |li1) containing radiolabelled BRF was immunoprecipitated 
in the presence of buffer (20pl) (lane 2), 150pg of SA0S2 cell extract (lane 3), 150|4g 
of €138 cell extract (lane 4), and ISOpg of A31 cell extract (lane 5), using the anti-RB 
antibody G3-245. The precipitated material was resolved on a SDS-7.8% 
polyaciylamide gel and visualised by autoradiography. Lane 1 contains 10% of the 
input of the reticulocyte lysate containing in vitro translated BRF.
(B) 20|.l 1 of buffer (lane 1), 150p.g of A31 cell extract (lane 2) or 150pg of €149 cell 
extract (lane 3), was mixed with 15pi of reticulocyte lysate containing in vitro 
translated BRF and immunoprecipitated using the anti-RB antibody €-15. The 
precipitated material was resolved on a SDS-7.8% polyacrylamide gel and visualised 
by autoradiography.
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visualised by autoradiography (fig. 4.1.B). Once again, a considerable amount of 
BRF was coprecipitated from the A31 whole cell extract (lane 2). Upon replacement 
of the cell extract with buffer, only a background amount of BRF was coprecipitated 
(lane 1). This background level was comparable to that precipitated from SV3T3 
C149 cell extract, another SV40-transformed A31 cell line (lane 3). The difference 
between the parental A31 cell extract and the SV3T3 C138 and C149 cell extracts is 
that the latter have been transformed by SV40. These immunoprécipitation data 
suggest that transformation of a cell line by SV40 compromises the interaction 
between TFIIIB and RB.
Immunoprécipitations were also carried out to assess the effect of SV40 
transformation on the interaction between endogenous TFIIIB and endogenous RB. 
Whole cell extracts were immunoprecipitated with an anti-RB antibody, or an 
irrelevant, negative control antibody against TAF48, a subunit of the pol I 
transcription factor SLl. The precipitated material was resolved by SDS-PAGE and 
the presence of BRF was probed for by western blotting (fig 4.2.A). It can be seen 
that the amount of BRF coprecipitated from the A31 cell extract (lane 4) is greater 
than that coprecipitated from the SV3T3 C138 cell extract (lane 2). Both of these 
interactions are specific, as immunoprécipitation with the anti-TAF48 antibody did 
not coprecipitate BRF (lanes 1 and 3). A similar effect is observed when SV3T3 C149 
cell extracts were immunoprecipitated with anti-RB and anti-TAF48 antibodies (fig. 
4.2.B). Here it shows that RB coprecipitates more BRF from the A31 cell extract 
(lane 4) than from the SV3T3 C149 cell extract (lane 2). Again this interaction is 
specific, as the anti-TAF48 antibody did not coprecipitate BRF (lanes 1 and 3). These
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FIG. 4.2 The association between endogenous TFIIIB and endogenous RB is 
greater in A31 extracts compared to CI38 and CI49 extracts.
(A) 150pg of A31 cell extiact (lanes 3 and 4) and 150pg of C138 cell extract (lanes 1 
and 2) were immunoprecipitated with the anti-RB antibody C-15 (lanes 2 and 4) or 
the anti-TAF48 antibody M-19 (lanes 1 and 3). The coprecipitated material was 
analysed by SDS-7.8% polyacrylamide gel electrophoresis and BRF was visualised 
by western analysis.
(B) 150pg of A31 cell extract (lanes 3 and 4) and 150pg of C149 cell extract (lanes 1 
and 2) were immunoprecipitated with the anti-RB antibody C-15 (lanes 2 and 4), and 
anti-TAF48 antibody M-19 (lanes 1 and 3). The coprecipitated material was resolved 
by SDS-7.8% polyacrylamide gel electrophoresis and the BRF was detected by 
western analysis.
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data confirm those previously observed with the immunoprécipitations using 
radiolabelled BRF, that the interaction between endogenous TFIIIB and endogenous 
RB is severely compromised following transformation by SV40.
4.2.2 The interaction between TFIIIB and RB is diminished in SAOS2 cells but 
not U20S cells
The work described above suggests that transforming proteins bind and 
inactivate RB, resulting in the diminished ability of RB to bind to the BRF subunit of 
TFIIIB. Other RB-inactivating mechanisms were examined for their effect upon the 
RB/BRF interaction, such as mutation or phosphorylation of RB.
The ability of mutant forms of RB to interact with the BRF subunit of TFIIIB 
was investigated by immunoprécipitations. Reticulocyte lysate containing 
radiolabelled BRF was incubated with cell extract and immunoprecipitated with an 
anti-RB antibody. The coprecipitate was analysed by SDS-PAGE and visualised by 
autoradiography (fig. 4.3). As can be seen, a considerable amount of BRF was 
coprecipitated from the U20S cell extract, an osteosarcoma cell line containing wild 
type RB (lane 2). In comparison, BRF coprecipitated from cell extract prepared from 
SAOS2 cells, an osteosarcoma cell line containing an inactive truncated RB (Shew et 
al., 1990), (lane 1) is greatly reduced. These immunoprécipitation data indicate that 
mutational inactivation of RB can prevent it from interacting with the BRF subunit of 
TFIIIB.
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FIG, 4.3 The BRF subunit of TFIIIB interacts with endogenous RB in U20S cell 
extract, but this interaction is compromised in SAOS2 cell extract.
Reticulocyte lysate (ISpl) containing in-vitro translated BRF was incubated with 
150pg of U20S cell extract (lane 3) or 150pg of SA0S2 cell extract (lane 2) and 
immunoprecipitated with the anti-RB antibody G3-245. The coprecipitated material 
was resolved on a SDS-7.8% polyacrylamide gel and visualised by autoradiography. 
Lane 1 contains 10% input of the reticulocyte lysate containing in vitro-translated 
BRF.
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4.2.3 A mutant form of RB from a cervical carcinoma does not interact with 
the BRF subunit of TFIIIB
To further investigate the diminished interaction between mutated forms of 
RB and BRF, cell extracts were prepared from C33A cells. These cells are derived 
from a cervical carcinoma, in which the Rb gene contains a deletion mutation of the 
first four amino acids encoded by exon 20 (Scheffher et al., 1991). The ability of the 
deletion mutant RB to physically associate with the BRF subunit of TFIIIB was 
determined by immunoprécipitations. Whole cell extract prepared from C33A cells 
and HeLa cells were immunoprecipitated with an anti-RB antibody. The 
coprecipitated protein was resolved by SDS-PAGE, and the presence of BRF was 
determined by western analysis (fig. 4.4), As is shown, a greater amount of BRF is 
coprecipitated from extract prepared from HeLa cells, which contain wild type RB 
(lane 1), than extracts prepared from C33A cells, which contain a deletion mutant 
form of RB (lane 2). This interaction is specific, as an irrelevant, negative control 
antibody against TAF48 does not coprecipitate BRF from C33A cell extract (lane 3). 
These immunoprécipitation data therefore suggest that the deletion of four amino 
acids in the pocket domain of RB is sufficient to compromise the ability of RB to 
interact with the BRF subunit of TFIIIB.
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FIG. 4.4 Endogenous BRF and RB interact in HeLa cell extract, but not in C33A 
cell extract.
150pg HeLa cell extract (lane 1) and ISOpg C33A cell extract (lanes 2 and 3) were 
immunoprecipitated with anti-RB antibody C-15 (lanes 1 and 2), or anti-TAF48 
antibody M l9 (lane 3). The coprecipitated material was resolved by SDS-7.8% 
polyaciylamide gel electrophoresis and probed for BRF by western analysis.
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4.2.4 The BRF subunit of TFIIIB does not interact with the RB null mutant 
A21
A pull down assay was carried out to test if  BRF is able to bind to the A21 
null mutant form of RB, from small cell lung carcinoma cell line NCI-H1436 in 
which residues 703-737 are deleted (Horowitz et ah, 1990). A variety of GST fusion 
proteins were expressed, purified and immobilised on glutathione-agarose beads. 
Each of these fusion proteins was incubated with radiolabelled BRF that had been 
expressed in vitro using reticulocyte lysate. The beads were extensively washed and 
the proteins remaining bound were resolved by SDS-PAGE and visualised by 
autoradiography (fig. 4.5.A). As can be seen, GST alone brought down relatively 
little BRF (lane 2), whereas GST-RB (379-928) pulled down a readily detectable 
amount (lane 3). The ability of GST-RB (379-928)A21, to pull down BRF was 
greatly reduced (lane 4). Indeed, when the results were quantitated by using a 
phosphorimager (fig. 4.5.B), GST alone was shown to pull down 6% of the input, in 
comparison to GST-RB (379-928) which pulled down 21% of the input (lanes 1 and 2 
respectively). GST-RB (379-928)A21 pulled down 8% of input, which is comparable 
to the background level observed with GST alone (lane 3 versus lane 1).
The GST pull down data described in chapter 3 suggest that the large pocket 
domain of RB is required for binding to BRF. The presence of the A21 mutation 
within the large pocket domain dramatically reduces the ability of RB to interact with
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FIG. 4.5 The ability of the BRF subunit of TFIIIB to interact with a null mutant 
form of RB is severely compromised.
(A) Reticulocyte lysate containing in vitro-translated BRF (15|l i 1) was incubated in 
the presence of glutathione-agarose beads carrying equal amounts of GST (lane 2), 
GST-RB (379-928) (lane 3), or GST-RB (379-928)A21 (lane 4). After extensive 
washing, the retained protein was resolved by SDS-7.8% polyacrylamide gel 
electi'ophoresis and visualised by autoradiography. Lane 1 shows 10% of the input 
reticulocyte lysate containing in vitro-translated BRF.
(B) The amount of BRF retained on the glutathione-agarose beads was quantitated by 
using a phosphorimager. The values are shown as a percentage of the total input 
bound. GST alone (lane 1), GST-RB (379-928) (lane 2) and GST-RB (379-928)A21 
(lane 3).
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BRF, hence it would appear that an intact large domain is required for this 
interaction.
4.2.5 The RB null mutant A21 does not disrupt the interaction between TFIIIB 
and TFIIIC
The effect of the RB null mutant A21 upon the interaction between 
endogenous TFIIIB and TFIIIC was examined by immunoprécipitations. HeLa 
extract was mixed with GST-RB (379-928) or GST-RB (379-928)A21 and incubated 
with TFIIIC2 antiserum immobilised on protein A beads. After incubation, the 
coprecipitate was extensively washed and resolved by SDS-PAGE and the presence 
of TFIIIB was determined by probing for TBP by western analysis (fig. 4.6). Due to 
the interaction between TFIIIB and TFIIIC, the TFIIIC2 antiserum is able to 
coprecipitate TBP. However, upon the addition of GST-RB (379-928) the ability of 
the TFIIIC2 antiserum to coprecipitate TBP is greatly reduced (lane 4). Strikingly, the 
presence of GST-RB (379-928)A21 in the immunoprécipitation reaction did not 
abolish the ability of the TFIIIC2 antiserum to coprecipitate TBP (lane 5).
Additional immunoprécipitation reactions were undertaken to further 
substantiate these observations. HeLa cell extract was mixed with reticulocyte lysate 
expressing in vitro-translated BRF and purified GST alone, GST-RB (379-928) or 
GST-RB (379-928)A21. These reaction mixtures were immunoprecipitated using
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FIG. 4.6 A null mutant form of RB is not able to disrupt the interaction between 
TFIIIB and TFIIIC2.
HeLa cell extract (150 pg) alone (lanes 2 and 3) or mixed with 200ng of GST-RB 
(379-928) (lane 4) or GST-RB (379-928)A21 (lane 5) was immunoprecipitated using 
affinity-purified TFIIIC2 antiserum 4286 (lanes 3-5), and the corresponding 
preimmune seram (lane 2). The precipitated material was resolved on a SDS-7.8% 
polyaciyamide gel. The presence of TBP was determined by western analysis using 
anti-TBP antibody SL30. Lane 1 shows 20% input of HeLa.
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TFIIIC2 antiserum 4286. The precipitate was washed, resolved by SDS-PAGE and 
visualised by autoradiography (fig. 4.7). As is illustrated, BRF is precipitated in the 
presence of GST (lane 2). Upon inclusion of GST-RB (379-928) in the 
immunoprécipitation reaction, the amount of BRF immunoprecipitated is greatly 
reduced (lane 3). However, the presence of GST-RB (379-928)A21 (lane 4) did not 
compromise the immunoprécipitation of BRF. These immunoprécipitation analyses 
demonstrate that a RB null mutant is not able to disrupt the interaction between 
TFIIIB and TFIIIC, unlike wild-type RB.
4.2.6 RB null mutants do not disrupt the interaction between TFIIIB and pol 
III
Immunoprécipitations were also used to determine the effect of a RB null 
mutant upon the interaction between TFIIIB and pol III. BRF antiserum immobilised 
on protein A beads was incubated with HeLa extract in the presence of GST alone, 
GST-RB (379-928) or GST-RB (379-928)A21. The coprecipitate was washed and a 
random polymerase assay undertaken to detect pol III associated with the precipitated 
material. The addition of GST alone does not affect the interaction between pol III 
and TFIIIB (fig. 4.8.A lane 1). However, the addition of GST-RB (379-928) greatly 
reduced the ability of pol III and TFIIIB to interact (lane 2). The presence of GST-RB 
(379-928)A2I in the immunoprécipitation reaction did not compromise the 
interaction between TFIIIB and pol III (lane 3). The immunoprécipitations suggest
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FIG. 4.7 The RB null mutant A21 cannot compromise the association between 
TFIIIC2 and TFIIIB.
Reticulocyte lysate containing in vitro-translated BRF (15pl) was mixed with 150pg 
HeLa extract (lanes 3 to 5), with the addition of 200ng of GST alone (lane 2), 200ng 
of purified GST-RB (379-928) (lane 3), or 200ng of purified GST-RB (379-928)A21 
(lane 4), then immunoprecipitated with the TFIIIC antiserum 4286. The 
immunoprecipitated material was resolved by SDS-7.8% polyacrylamide gel 
electrophoresis and visualised by autoradiography. Lane 1 shows 10% of the input 
reticulocyte lysate containing in vitro-translated BRF.
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FIG. 4.8 Null mutant forms of RB are not able to disrupt the interaction between 
TFIIIB and pol III.
(A) HeLa cell extract (150 pg) was mixed with 200ng of GST alone (lane 1), GST- 
RB (379-928) (lane 2) or GST-RB (379-928)A21 (lane 3) and immunoprecipitated 
with the BRF antisemm 330. The presence of pol III was detected by a random 
polymerisation assay.
(B) HeLa cell extract (150 pg) mixed with 200ng of GST alone (lane 1), 200ng of 
GST-RB (379-928) (lane 2) or 200ng of GST-RB (379-928)C706F (lane 3) was 
immunoprecipitated with BRF antiserum 330. Pol III activity was detected by random 
polymerisation assay.
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that the ability of RB to disrupt the interaction between TFIIIB and pol III is 
dependent upon wild type RB function, as a RB null mutant was unable to disrupt the 
interaction between TFIIIB and pol III.
This observation was further confirmed by using an alternative RB null 
mutant, namely GST-RB (379-928)C706F. This RB mutant has a point mutation at 
residue 706, at which the cysteine residue had been mutated to phenylalanine (Kaye 
et a l, 1990). One consequence of this substitution is that the mutant is not able to 
repress pol III transcription (White et a l, 1996). As is seen in fig. 4.8.B, the presence 
of GST-RB (379-928)C706F does not abolish the interaction between TFIIIB and pol 
III (lane 3). Again the same pattern is observed for both GST alone and GST-RB 
(379-928) (lanes 1 and 2 respectively), that is GST alone does not abolish the 
interaction between TFIIIB and pol III, whereas GST-RB (379-928) does.
Additional immunoprécipitation reactions were carried out to support these 
findings. Reticulocyte lysate containing in vitro-translated BRF was mixed with 
buffer or HeLa extract with the addition of GST, GST-RB (379-928) or GST-RB 
(379-928)A21. The mixtures were immunoprecipitated with the pol III antiserum 
BN51 113. The precipitate was washed, resolved by SDS-PAGE and visualised by 
autoradiography (fig. 4.9). As can be seen, in the presence of buffer a low, 
background amount of BRF is immunoprecipitated (lane 2). In the presence of HeLa 
extract mixed with purified GST, the amount of BRF immunoprecipitated is greatly 
increased (lane 3). Upon the addition of GST-RB (379-928) into the reaction, the
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FIG. 4.9 The RB null mutant A21 cannot compromise the association between 
pol III and TFIIIB.
Reticulocyte lysate containing in vitro-translated BRF (15pl) was mixed with 20pl 
buffer (lane 2), or ISOpg HeLa extract (lanes 3 to 5), with the addition of 200ng of 
GST (lane 3), 200ng of purified GST-RB (379-928) (lane 4), or 200ng of purified 
GST-RB (379-928)A21 (lane 5), then immunoprecipitated with the pol III antiserum 
BN51 113. The precipitated material was resolved by SDS-7.8% polyacrylamide gel 
electrophoresis and visualised by autoradiography. Lane 1 shows 10% of the input 
reticulocyte lysate containing in vitro-translated BRF.
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amount of BRF immunoprecipitated is greatly reduced (lane 4); in contrast, the 
addition of GST-RB (379-928)A21 (lane 5) did not affect the amount of BRF 
immunoprecipitated. These observations consolidate the previously described data 
wherein RB disrupts the interaction between TFIIIB and pol III. This effect is specific 
to the wild type RB, as RB null mutants are not capable of disrupting this interaction.
4.2.7 Phosphorylation of RB prevents interaction with the BRF subunit of 
TFIIIB
As shown above, the ability of RB to interact with BRF can be diminished by 
transforming proteins or by inactivating mutations; both these forms of RB 
inactivation are prevalent in cancerous cells (Weinberg, 1995). However, another 
form of RB inactivation in cancerous cells exists, namely hyperphosphorylation 
(Hunter and Pines, 1994; Pines, 1995; Sherr, 1994; Weinberg, 1995). Hence, it was 
decided to determine if phosphorylating RB affected its interaction with BRF. RB 
was expressed and radiolabelled in vitro by reticulocyte lysate. This RB was then 
phosphorylated by cdk 4/cyclin D l, cdk 2/cyclin A, and cdk 2/cyclin E. HeLa extract 
was then mixed with lysate expressing either hyperphosphorylated or 
hypopho sphorylated RB and the mixture immunoprecipitated with BRF antiserum 
and its corresponding preimmune. The coprecipitate was resolved by SDS-PAGE and 
visualised by autoradiography (fig. 4.10). The mobility of the RB incubated with cdks
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FIG. 4.10 Hypophosphorylated RB but not hyperphosphorylated RB interacts 
with BRF.
Reticulocyte lysate containing in vitro translated RB, (lanes 3 and 4), or reticulocyte 
lysate containing in-vitro translated RB which had been phosphorylated (lane 5) 
(15(il of each) was mixed with 150pg HeLa extract, and immunoprecipitated with 
BRF antiserum 330 (lanes 4 and 5) and its corresponding preimmune (lane 3). The 
coprecipitate was resolved on a SDS-7.8% polyacrylamide gel and visualised by 
autoradiography. Lanes 1 and 2 show 10% of the input of the reticulocyte lysate 
containing in vitro-translated RB, unphosphorylated (lane 1) and phosphorylated 
(lane 2).
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is slower than that of the RB not incubated with cdks, which suggests that RB has 
been modified, namely by phosphorylation (lane 2 versus lane 1). In its 
hypophosphorylated form, RB is able to interact with BRF (lane 4). However, when 
RB is phosphorylated this binding is not observed (lane 5). These 
immunoprécipitation data indicate that whilst RB is hypophosphorylated it is capable 
of interacting with BRF; however, when RB becomes hyperphosphorylated the 
ability of RB to interact with BRF is abolished.
The data described above demonstrate that the various ways in which RB is 
inactivated in cancerous cells, such as sequestration by a transforming protein, 
mutations, or hyperphosphorylation, can all compromise the ability of RB to interact 
with BRF.
4.3 Discussion
There are various ways the level of pol III transcription can be regulated in 
either a positive or negative fashion. For example, as a cell enters mitosis pol ITT 
transcription has been shown to be repressed in both Xenopus egg extract (Hartl et 
al., 1993) and humans (White et al., 1995a). The level of pol III transcription can also 
be altered in response to viral infection, as seen in cells infected with poliovirus, 
which display a reduced ability to transcribe pol III genes (Fradkin et al., 1987). An
165
Chapter 4 Results
alternative means of regulating pol III transcription is RB-mediated repression (White 
et al., 1996).
In a broad range of cancers and transformed cell lines RB has been inactivated 
either by mutational inactivation, hyperphosphorylation or sequestration by viral 
oncoproteins (Weinberg, 1995). The introduction of wild-type RB into cells lacking 
functional RB has been reported to induce G1 cell cycle arrest, hence RB is believed 
to control cell cycle progression by regulating Gl/S phase transition (Pardee, 1989). 
Until recently it was proposed that the ability of RB to regulate cell cycle progression 
was by binding the pol II transcription factor E2F, thereby making E2F unavailable to 
express genes which promote DNA replication and cell cycle regulation (La Thangue,
1994). This model however does not provide a means for explaining how the loss of 
RB allows tumour cells to increase their biosynthetic capacity, without which an 
increased rate of chromosome duplication would ultimately be lethal (Nasmyth, 
1996). The discovery that RB also regulates pol I and pol III transcription and 
subsequently the expression of rRNA and tRNA genes, respectively (Cavanaugh et 
al., 1995; White et al., 1996), potentially provides an explanation as to how RB also 
regulates the biosynthetic capacity of a cell. The target of RB mediated repression of 
pol III transcription has been demonstrated as being the BRF subunit of TFIIIB 
(Larminie et al., 1997). Hence it was decided to determine if the ability of RB to 
regulate cell cycle progression correlated with its ability to regulate pol III 
transcription by binding to BRF. This was determined by investigating if the loss of 
RB function with regard to cell cycle regulation is also accompanied by the 
diminished ability of RB to interact with BRF.
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It has been well documented that cells transformed with SV40 display elevated 
levels of pol III transcription (Carey et al., 1986b; Scott et al., 1983; Singh et al., 
1985; White et al., 1990), This is due to an increase in the abundance of TFIIICa and 
TFIIICp, and also the release of TFIIIB from RB, upon the sequestration of RB by 
viral large T antigen (Larminie et al., 1999). In untransformed murine fibroblasts, 
TFIIIB is negatively controlled by physically associating with RB. In cells 
transformed by SV40, the amount of TFIIIB associated with RB is dramatically 
reduced (fig. 4.2). Moreover, a specific increase in TFIIIB activity is observed 
(Larminie et al., 1999). These two events could be explained by the partial release of 
BRF from RB, upon viral transformation, resulting in an increase in TFIIIB activity 
(Larminie et al., 1999). It could be that viral transformation altered the levels of 
TFIIIB subunits. However, western analysis demonstrated that the abundance of two 
TFIIIB subunits, TBP and BRF, varied little between A31 extracts and C138 and C149 
extracts (Larminie et al., 1999). Human TFIIIB is not completely characterised; it is 
believed to contain one or more subunit(s) in addition to TBP and BRF (Hernandez, 
1993; Rigby, 1993). Hence, the possibility remains that following SV40 
transformation the abundance of a currently uncharacterised subunit increases. 
Damania et. al. reported an association between T antigen and the BRF subunit of 
TFIIIB (Damania et al., 1998). Immunoprécipitations were carried out to test for 
interaction between T antigen and BRF in C138 and C149 cells, but no association 
was detected. Instead, it appears that SV40 activates TFIIIB by neutralising RB.
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An alternative way by which RB becomes inactivated is by mutation of the RB 
gene. A number of studies have identified and isolated mutated RB from various 
tumourgenic cell lines (Weinberg, 1995). Observations reported here suggest that the 
inability of BRF to interact with mutant RB is not specific to a particular mutant form 
of RB. For example, the ability of BRF to interact with mutated RB present in 
SAOS2 cells (Shew et al., 1990) and C33A cells (Scheffher et al., 1991) is greatly 
reduced compared to cell lines containing wild-type RB, namely U20S and HeLa 
cells respectively. Moreover, as mutant forms of RB are unable to bind BRF, it 
follows they will not perform the functions displayed by wild-type RB, in particular 
compromising the interactions between TFIIIB and TFIIIC and between TFIIIB and 
pol III. Indeed, this was shown to be the case. Two mutant forms of RB, isolated from 
small cell lung carcinoma cell lines, which contain either a point or deletion mutation, 
GST-RB (379-928)C706F (Kaye et al., 1990) or GST-RB (379-928)A21 (Horowitz et 
al., 1990) respectively, were unable to disrupt the interactions between TFIIIB and 
the other components of the initiation complex, namely TFIIIC and pol III. These 
findings demonstrate that a variety of mutant forms of RB are unable to bind BRF. 
Those further investigated were unable to prevent TFIIIB fi*om interacting with the 
other components of the pre-initiation complex hence it would follow that they would 
not be able to repress pol III transcription, as has previously been shown.
The third way by which RB can become inactivated is through 
phosphorylation (Hunter and Pines, 1994; Pines, 1995; Shen\ 1994; Weinberg, 1995). 
In normal cells, RB is silenced by cyclin-dependent kinases, after which it can no
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longer restrain cell cycle progression (Weinberg, 1995). In a vast number of tumour 
cells, RB is physiologically inactivated; hence it can no longer act as a cell cycle 
brake, therefore tumour cells can continuously cycle (Weinberg, 1995). RB can be 
maintained in a phosphorylated state by deregulation of the RB pathway (Weinberg,
1995). As normal cells pass through the cell cycle, the phosphorylation state of RB 
cells oscillates (Weinberg, 1995), as does the level of pol III transcription (White et 
al., 1995b). Hence, it was of interest to determine the effect phosphorylation of RB 
would have on its interaction with BRF. As shown, upon phosphorylation RB is 
unable to bind to BRF. Hence, in cancer cells within which RB is 
hyperphosphorylated, TFIIIB will be released from RB-mediated repression, and will 
be able to promote pol III transcription.
The work presented here demonstrates that the various ways by which RB 
becomes inactivated with regard to its ability to inhibit cell growth also prevent RB 
from interacting with BRF. Thus, a potential correlation exists between the ability of 
RB to bind BRF and to induce cell growth arrest.
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Chapter 5
Characterisation of the interaction between the tumour suppressor 
protein RB and the pol I transcription factor UBF
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5 Characterisation of the interaction between the tumour suppressor
protein RB and the pol I transcription factor UBF
5.1 Introduction
In order for pol I to be recruited to the transcription start sites of class I genes, 
two transcription factors are required, namely SLl and UBF. The human rRNA 
promoter consists of two control sequences, the core and an upstream control element 
(UCE). UBF can recognise both of these promoter sequences. SLl, however, has 
relatively low affinity for the human rRNA promoter and is recruited to the template 
by protein-protein interactions with UBF. This results in an extended region of the 
promoter being protected, as shown by DNase footprinting (Bell et al., 1988; Hempel 
et al., 1996; Learned et al., 1986).
The structural and functional properties of UBF and SLl have been 
investigated, in particular their involvement in the regulation of pol I transcription. 
Pol II and pol III both utilise a transcription factor complex containing TBP and pol I 
is no exception. In this instance the complex is SLl, which in addition to TBP 
contains three TAFs (Comai et al., 1992). Each TAP can bind to the other two and 
TBP (Comai et al., 1994). The properties of the other pol I transcription factor have 
also been elucidated. Xenopus (x) UBF has a dimérisation domain at the amino 
terminus, and an acidic region at the carboxy-terminus. Between these two regions lie 
5 high mobility group (HMG) boxes, which are responsible for binding DNA 
(McStay et al., 1991a). Human (h) UBF has a similar structure, but contains 6 HMG
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boxes (Jantzen et ah, 1992). In all mammalian systems studied to date two forms of 
UBF have been found, UBFl and UBF2 (O'Mahony and Rothblum, 1991). The 
difference between these forms in humans, is a deletion of 35 amino acids from HMG 
box 2 of UBF2.
The level of pol I transcription is regulated throughout the cell cycle and also 
by various proteins. For example, the level of pol I transcription, like pol III, is high 
in S and G2 phase, low in mitosis, then recovers in G l. The repression of pol I 
transcription during mitosis is due to cdc2/cyclin B-directed phosphorylation of the 
TBP-containing complex SLl, which results in dissociation of SLl from UBF (Heix 
et ah, 1998; Kuhn et ah, 1998). Moreover, UBF would also appear to be inactivated 
by phosphorylation during mitosis; during Gl, UBF is reactivated by 
dephosphorylaiton, correlating with the onset of pol I transcription (Klein and 
Grummt, 1999). Alternatively, repression of pol I transcription can be mediated by 
cellular proteins such as p53 (Zhai and Comai, 2000) and RB (Cavanaugh et ah, 
1995; Voit et ah, 1997).
In addition to being down-regulated, pol I transcription can also be enhanced, 
as illustrated upon the discovery that SV40 large T antigen binds to SLl and is 
capable of activating pol I transcription (Zhai et ah, 1997). Furthermore, it is believed 
that UBF can be phosphorylated by a SV40-associated kinase, giving rise to a stable 
association between SLl and UBF, thereby promoting pol I transcription (Zhai and
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Comai, 1999). Other kinases, such as the Gl-specific kinases, cdk4-cyclin Dl and 
cdk2-cyclin E can also phosphorylate and activate UBF (Voit et al., 1999).
As mentioned previously, RB has been shown to be capable of repressing pol 
I transcription. The ability of RB to regulate pol I transcription was first demonstrated 
by Cavanaugh and co-workers (Cavanaugh et al., 1995) who showed that RB 
represses pol I transcription by interacting with UBF (Upstream Binding Factor). 
They showed that upon differentiation of the cell line U937, there is an accumulation 
of RB protein in the nucleoli, the site of pol I transcription, and a decrease in rDNA 
synthesis (Cavanaugh et al., 1995). These observations suggest a correlation between 
the localisation of RB to the nucleoli and the inhibition of pol I transcription. It was 
also shown that upon addition of GST-RB to an in vitro transcription system, pol I 
transcription decreased. In contrast, a GST-RB construct containing a point mutation 
at residue 706 did not decrease pol I transcription, therefore illustrating the 
requirement for an intact pocket domain for RB-mediated pol I repression 
(Cavanaugh et al., 1995). Collectively, these observations suggest that RB represses 
pol I transcription, and this effect is exerted by the ability of RB to target UBF.
The mechanism whereby RB represses pol I transcription was further 
examined, by Voit and co-workers (Voit et al., 1997). They confirmed the previous 
observations of Cavanaugh and co-workers of RB repressing pol I transcription, and 
the ability of UBF and RB to interact (Voit et al., 1997). The UBF-binding site in RB 
was examined by two independent means. Firstly it was shown that the addition of an 
E7 peptide did not relieve RB mediated pol I repression; the conclusion from this was
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that the UBF-binding domain must reside outside the E7-binding domain. The second 
experiment employed various GST-RB fusion protein constructs; each was assayed 
for their ability to repress pol I transcription and interact with UBF. These 
investigations showed that whilst GST-RB (379-928) was able to repress pol I 
transcription and bind UBF, the ability of GST-RB (379-792) to do so was greatly 
reduced (Voit et al., 1997). From these observations, Voit and co-workers concluded 
that the UBF-binding domain in RB resides in the C-terminus of RB, namely residues 
763-928 (Voit et al., 1997). This contrasted with the conclusion of Cavanaugh et al., 
(Cavanaugh et al., 1995) who had suggested that the pocket domain was important 
for binding to UBF.
Further investigations allowed the mechanism whereby RB represses pol I 
transcription to be determined. GST-pull down assays, immunoprécipitation data and 
bandshift assays identified the RB-binding domain in hUBF as being HMG boxes 1 
and 2 (Voit et al., 1997). This work also demonstrated that the presence of RB does 
not disrupt the interaction between UBF and the other pol I transcription factor SLl, 
nor does it disrupt the interaction between UBF and pol I (Voit et al., 1997). Instead, 
the presence of RB greatly perturbs the ability of UBF to interact with DNA (Voit et 
al., 1997).
The work presented below confirms that there is an interaction between 
endogenous RB and endogenous UBF. The human (h) and Xenopus (x) UBF-binding 
domain in RB has been identified, as has the RB-binding domain in xUBF. Lastly, an 
interaction between the other pol I transcription factor SLl and RB has been shown.
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5.2 Results
5.2.1 Endogenous UBF interacts with endogenous RB
In order to investigate if RB and UBF physically associate with one another, 
immunoprécipitations were undertaken. Extract prepared from HeLa cells was 
immunoprecipitated using anti-RB antibodies immobilised on protein A beads. The 
protein retained on the beads was washed extensively, resolved by SDS-PAGE, and 
the presence of UBF was probed for by western analysis (fig. 5.1). The protein A 
alone did not bring down UBF (lane 2). However, the protein A beads coupled to 
anti-RB antibody did coprecipitate UBF (lane 3). These immunoprécipitation data 
suggest that endogenous RB and UBF interact with one another.
5.2.2 Identification of the UBF-binding domain in RB
Having shown that UBF binds RB, it was of interest to determine the sites of 
interaction. To do this, GST-RB (379-928), GST-RB (379-792), and GST-RB (763- 
928) were expressed in bacteria and immobilised on glutathione-agarose beads. 
These beads were incubated with reticulocyte lysate containing radiolabelled hUBF. 
After incubation, the beads were washed and resolved by SDS-PAGE and visualised 
by autoradiography (fig. 5.2.A). The autoradiogram shows that GST alone brings 
down a background amount of hUBF (lane 2), whereas the amount brought down by 
GST-RB (379-928) is much greater (lane 3). Both GST-RB (379-792) (lane 4) and
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FIG. 5.1 Endogenous UBF interacts with endogenous RB.
HeLa cell extract (ISOpg) was immunoprecipitated with beads alone (lane 2) and 
anti-RB antibody G3-245 (lane 3); in addition, beads alone were incubated with 
buffer (lane 1). The precipitated material was resolved by SDS-7.8% polyacrylamide 
gel electrophoresis. The presence of UBF was visualised by western analysis by 
probing with anti-UBF antibody.
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FIG. 5.2 Identification of the hUBF-binding domain in RB.
(A) Reticulocyte lysate containing hUBF (15pl) was incubated with glutathione- 
agarose beads caiTying equal amounts of GST (lane 2), GST-RB (379-928) (lane 3), 
GST-RB (379-792) (lane 4) or GST-RB (763-928) (lane 5). After extensive washing, 
the retained proteins were resolved on a SDS-7.8% polyacrylamide gel and visualised 
by autoradiography. Lane 1 shows 10% of the input reticulocyte lysate containing in 
vitro-translated hUBF.
(B) The results of the GST pull down assay were quantitated by a phosphorimager, 
and plotted as a percentage of input bound.
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GST-RB (763-928) (lane 5) brought down more hUBF than GST alone, but less than 
GST-RB (379-928). These results were quantitated by phosphorimager and plotted on 
a graph as a percentage of input (fig. 5.2.B). From the graph it is evident that the 
binding domain for hUBF in RB resides in the large pocket domain.
The UBF-binding domain in RB was further characterised by utilising the 
Xenopus protein xUBF. Once again a variety of GST fusion proteins (GST, GST-RB 
(379-928), GST-RB (379-792), and GST-RB (763-928)) were expressed and 
immobilised on glutathione-agarose beads. Each of these beads was incubated with 
reticuloctye lysate containing in vitro translated and radiolabelled xUBF. After 
incubation, the beads were washed and the retained protein resolved by SDS-PAGE 
and visualised by autoradiography (fig. 5.3.A). As can be seen, GST alone brings 
down very little xUBF (lane 2), whereas GST-RB (379-928) brings down a readily 
detectable amount ofxUBF (lane 3). GST-RB (379-792) (lane 4) and GST-RB (763- 
928) (lane 5) bring down an amount of xUBF which is only slightly greater than that 
observed with GST alone (lane 2). The results were quantitated by phosphorimager 
and plotted on a graph as a percentage of input bound (fig. 5.3.B). It is clear that the 
large pocket domain of RB is also responsible for xUBF binding.
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FIG. 5.3 Identification of the xUBF-binding domain in RB.
(A) Reticulocyte lysate containing xUBF was incubated with glutathione-agarose 
beads carrying equal amounts of GST (lane 2), GST-RB (379-928) (lane 3), GST-RB 
(379-792) (lane 4) or GST-RB (763-928) (lane 5). After extensive washing, the 
retained proteins were resolved on a SDS-7.8% polyacrylamide gel and visualised by 
autoradiogi-aphy. Lane 1 shows 10% of the input reticulocyte lysate containing in 
viti'o-translated xUBF.
(B) The results of the GST pull down assay were quantitated by a phosphorimager, 
and plotted as a percentage of input bound.
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5.2.3 The presence of a four amino acid deletion mutation in RB is sufficient to 
disrupt its interaction with UBF
As UBF binding was found to require the large pocket of RB, it was decided 
to examine the effect of a four amino acid deletion within the pocket domain of RB. 
Cell extracts prepared from a cervical carcinoma cell line, C33A, which contains RB 
with a deletion of four amino acids (Scheffher et al., 1991), were immunoprecipitated 
with an anti-RB antibody alongside HeLa extract. The coprecipitate was resolved by 
SDS-PAGE and probed for UBF by western analysis (fig. 5.4.). The UBF 
coprecipitated from HeLa cell extract, which contains wild type RB, (lane 1), is a far 
greater amount than that coprecipitated from C33A cell containing a mutant form of 
RB (lane 2). The interaction between UBF and RB is specific, and not due to cross­
reaction, as an irrelevant antibody used as a negative control, (anti-OCT-1, lane 3) did 
not coprecipitate UBF. These immunoprécipitation data suggest that the presence of a 
4 amino acid deletion in the pocket domain of RB is sufficient to compromise the 
interaction between UBF and RB.
5.2.4 Identification of the RB-binding region in xUBF
The identification of the UBF-binding site in RB lead to investigating the 
reciprocal, namely the RB-binding domain in xUBF. GST alone and GST-RB (379-
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FIG. 5.4 Endogenous UBF and RB interact in HeLa cell extract, but this 
interaction is compromised in C33A cell extract.
ISOpg HeLa cell extract (lane 1) and 150pg C33A cell extract (lanes 2 and 3), were 
immunoprecipitated with anti-RB antibody C-15 (lanes 1 and 2) or anti OCT-1 
antibody C-21 (lane 3). The coprecipitated material was resolved by SDS-7.8% 
polyacrylamide gel electrophoresis and probed for UBF by western analysis. Lane 1 
shows 10% of input.
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928) were purified and immobilised on glutathione-agarose beads, and were 
incubated with reticulocyte lysate containing either wild type or truncated mutant 
forms of radiolabelled xUBF (see fig. 5.5 for a schematic representation of the xUBF 
truncated mutants). After incubation, the beads were washed, resolved by SDS-PAGE 
and visualised by autoradiography (fig. 5.6.A). As is shown by the autoradiogram, the 
ability of xUBFWT to bind RB is readily detectable (lane 3). In contrast, xUBFMT13 
(lane 6) and xUBFMT14 (lane 9) bind to GST nearly as well as GST-RB. This 
suggests that HMG boxes 1 and 2, which are lacking in these truncated mutants 
respectively, may contribute to the specific recognition of RB. The ability of the 
XUBFMT15 (lane 9) to interact with RB has not been abolished; indeed, the 
interaction observed is comparable to that seen with xUBFWT. These observations 
suggest that the region deleted from this truncated mutant, namely HMG box 4, is not 
part of the RB-binding domain. The xUBF mutant xUBFMT18, which lacks all 3 
aforementioned HMG boxes (lane 15), is not able to interact with RB. As the HMG 
box 4 was shown not to contribute to the RB-binding capabilities of xUBF, it can be 
concluded that HMG boxes 1 and 2 constitute the RB-binding domain in xUBF. 
These results were quantitated using a phosphorimager, and plotted on a graph as a 
fold increase compared to GST alone (fig. 5.6.B). As is evident from the graph, the 
ability of xUBFMT18 to interact with RB is abolished, whereas the abilities of 
XUBFMT13 and xUBFMT14 to bind RB selectivity were severely compromised. In 
contrast, the ability of xUBFMT15 to interact with RB is comparable to the wild type, 
therefore suggesting that the regions deleted from xUBFMT13, 14 and 18, namely 
HMG boxes 1 and 2, are responsible for binding RB.
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FIG. 5.5 Schematic representation of xUBF truncated mutants.
An illustration of the various xUBF truncations used.
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FIG. 5.6 Identification of the RB-binding region in xUBF.
(A) 15pi of reticulocyte lysate containing xUBFWT (lanes 2 and 3), xUBFMT13 
(lanes 5 and 6), xUBFMT14 (lanes 8 and 9), xUBFMT15 (lanes 11 and 12) or 
xUBFMTlS (lanes 14 and 15) was incubated with glutathione-agarose beads carrying 
equal amounts of GST (lanes 2, 5, 8, 11 and 14) or GST-RB (379-928) (lanes 3, 6, 9, 
12 and 15). After extensive washing, the retained proteins were resolved on a SDS- 
7.8% polyacrylamide gel and visualised by autoradiography. Lanes 1, 4, 7, 10 and 13 
show 10% of input.
(B) The results of the GST pull down assay were quantitated by a phosphorimager, 
and plotted as a fold increase of input bound with respect to GST alone.
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The xUBF mutants discussed above all contain mutations within the N- 
terminal portion of the protein. The contribution of the C-terminal domain towards 
the ability of xUBF to bind RB was also investigated by GST pull down assays. GST 
alone and GST-RB (379-928) were purified and immobilised on glutathione-agarose 
beads and incubated with various xUBF C-terminal truncations. After incubation, the 
proteins retained on the beads were resolved by SDS-PAGE and visualised by 
autoradiography (fig. 5.7.A). As shown, the ability of xUBFMT21 (lane 6) and 
xUBFMTK (lane 9) to bind RB is comparable to that observed with xUBFWT (lane 
3). This shows that the ability of these truncations to interact with RB is not seriously 
compromised by their deleted domains, which suggests that the region between the 
HMG boxes and the acidic tail, as well as the acidic tail itself, do not contribute much 
to the interaction between xUBF and RB. These results were quantitated using the 
phosphorimager, and the results plotted as a fold increase relative to the level 
observed for GST alone (fig. 5.7.B). As is apparent from the graph, the ability of 
these xUBF truncated mutants to interact with RB is only slightly compromised, 
therefore suggesting that these deleted domains do not contribute much to the 
interaction between xUBF and RB. Collectively, these GST pull down assays 
demonstrate that the domains in xUBF which are responsible for the interaction 
between xUBF and RB are the HMG boxes 1 and 2 located in the N-terminal half of 
xUBF. In contrast, the ability of xUBFMTlS to interact with RB is comparable to the 
wild type, therefore suggesting that the regions deleted from xUBFMTlS, 14 and 18, 
namely HMG boxes 1 and 2, are responsible for binding RB.
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FIG. 5.7 Identification of the RB-binding region in C-terminal truncated xUBF.
(A) 15pi of reticulocyte lysate containing xUBFWT (lanes 2 and 3), xUBFMT21 
(lanes 5 and 6), or xUBFMTK (lanes 8 and 9) was incubated with glutathione-agarose 
beads canying equal amounts of GST (lanes 2, 5 and 8) or GST-RB (379-928) (lanes 
3, 6 and 9). After extensive washing, the retained proteins were resolved on a SDS- 
7.8% polyacrylamide gel and visualised by autoradiography. Lanes 1, 4 and 7 show 
10% of the input reticulocyte lysate containing in vitro-translated xUBFs.
(B) The results of the GST pull down assay were quantitated by a phosphorimager 
and plotted as a fold increase of input bound with respect to GST alone.
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5.2.5 Endogenous SLÏ interacts with endogenous RB
The tumour suppressor protein RB has been shown to interact with the pol I 
transcription factor UBF. Hence it was of interest to determine if  RB can also be 
found associated with the other pol I transcription factor SLl. The potential physical 
association between RB and SLl was investigated by immunoprécipitations. Extracts 
prepared from HeLa cells were incubated with anti-SLl antibodies immobilised on 
protein A beads. After washing, the proteins retained on the beads were resolved by 
SDS-PAGE and the presence of RB determined by western analysis (fig 5.8). It can 
be observed that the anti-TAF48 antibodies coprecipitated RB (lanes 3 and 4). These 
interactions are specific, as the negative control did not coprecipitate RB (lane 2). 
These immunoprécipitation data suggest that cellular SLl can be found in complex 
with endogenous RB.
5.3 Discussion
Pol I transciption can be regulated in a positive or negative fashion by a 
variety of means. Of particular interest with regard to these studies are the effects of 
RB upon pol I transcription, and the proteins which it targets in order to produce 
these effects.
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FIG. 5.8 Endogenous SLl interacts with endogenous RB.
HeLa cell extract (150pg) was immunoprecipitated with the anti-TAF48 antibody C- 
19 (lane 3), the anti-TAF48 antibody M-19 (lane 4), and the BRF preimmune (lane 
2). The precipitated material was resolved by SDS-7.8% polyacrylamide gel 
electrophoresis. The presence of RB was visualised by western analysis by probing 
with anti-RB antibody IF8. Lane 1 shows 10% of HeLa input.
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As shown above and by work undertaken by Cavanaugh and colleagues using 
immunoprécipitation analyses, endogenous UBF and RB can interact (Cavanaugh et 
al., 1995). With regard to the ability of an E7 peptide to disrupt the interaction 
between UBF and RB, conflicting data have been reported. Cavanaugh et. al. 
demonstrated that the addition of an E7 peptide greatly reduced the ability of UBF to 
interact with RB in immunoprécipitation analysis and GST-pull down assays. 
However, Voit et. al. reported that in a reconstituted transcription system the E7 
peptide did not relieve RB-mediated repression, implying that the addition of this 
peptide did not alleviate the interaction between RB and UBF (Voit et al., 1997). The 
E7 protein binds to a domain in RB referred to as the small pocket; as its addition did 
not disrupt the UBF/RB interaction, they concluded that the UBF-binding domain in 
RB resides outside the small pocket, namely towards the C-terminus of RB (Voit et 
al., 1997).
In order to define the UBF-binding domain within RB, a variety of RB 
constructs were utilised for in vitro interaction analysis. These studies suggest that the 
UBF-binding domain in RB is the large pocket domain for both hUBF and xUBF.
The identification of the UBF-binding domain in RB is of interest as it may 
allow for a correlation between the ability of RB to repress pol I transcription by 
interacting with UBF, and the ability of RB to prevent cell growth. The sequestration 
of E2F by RB makes E2F unavailable to promote the expression of genes required for 
DNA replication (e.g. dihydro folate reductase and thymidine kinase) and cell cycle 
regulation, (e.g. cyclin E, cyclin A, cdc2, p i07 and E2F). This was believed to be the
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mechanism of RB-mediated cell cycle arrest (Weinberg, 1995). This model, however, 
does not explain the increased biosynthesis observed in tumours that lack functional 
RB. More recently, it has been proposed that RB functions not only by controlling the 
expression of genes required for DNA synthesis and cell cycle regulation, but also by 
controlling the expression of genes required for promoting cell growth (Nasmyth, 
1996). The designation of the UBF-binding domain in RB by Voit et al (1997) is 
inconsistent with a correlation between the ability of RB to arrest cell growth and its 
ability to regulate rRNA synthesis. The data presented by Cavanaugh et al (1995) 
defining the large pocket domain as the site recognised by UBF, and by Hannan et al. 
(2000a) showing a functional A/B pocket is required for the RB/UBF interaction, 
provide a direct correlation between the ability of RB to bind UBF and repress pol I 
transcription, and its ability to inhibit cell growth, inasmuch as both functions reside 
in the large domain of RB.
To delineate the regions in xUBF responsible for binding RB, a variety of 
xUBF constructs were utilised (fig. 5.1) (McStay et al., 1991a). Many proteins which 
bind RB have been shown to bear the LXCXE motif, such as adenovirus El A 
(Whyte et al., 1988), SV40 large T antigen (DeCaprio et al., 1988), and HPV 16 E7 
(Dyson et al., 1989). Transcription factors that bind RB do not necessarily display 
this motif. For example, the pol II transcription factor E2F does not bear an LXCXE 
motif (La Thangue, 1994), neither does the pol III transcription factor BRF (Larminie 
and White, 1998). Nevertheless, the first step in elucidating the RB-binding domain 
in UBF was to determine if UBF had a LXCXE motif. In hUBF, residues 307 to 311, 
which reside in HMG box 3, contain a LXCXE motif (McStay et al., 1991a). In
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xUBF residues 307 to 311, which are encompassed by HMG domain 4, contain an 
altered LXCXE motif, in which the L residue is replaced by M (McStay et al., 
1991a). It was previously reported that the RB-binding domain in hUBF consists of 
HMG boxes 1 and 2 (Voit et al., 1997). As shown above, not only does xUBF bind 
RB, but also the binding domain for RB in xUBF mirrors that observed for hUBF, 
namely HMG boxes 1 and 2. Neither of these HMG boxes in hUBF or xUBF include 
the LXCXE motif, therefore suggesting that this motif present in these proteins does 
not contribute to the interaction with RB.
The region of UBF, which is sufficient for DNA sequence specificity is HMG 
box 1 (Jantzen et al., 1992). It is therefore possible that RB represses pol I 
transcription by binding the HMG boxes 1 and 2 and thereby preventing them from 
binding DNA. The addition of RB has been shown to prevent UBF from binding 
cruciform DNA in bandshifr assays, and ribosomal DNA in DNase footprinting 
experiments (Voit et al., 1997). These experiments demonstrate that the binding of 
RB to UBF prevents UBF from associating with DNA, Indeed, the addition of RB did 
not disrupt the interaction between UBF and pol I; it also did not affect the interaction 
between UBF and a subunit of SLl, TAF95 (Voit et al., 1997). The SLl binding site 
in UBF has been mapped to multiple sites in the C-terminal half of UBF (Jantzen et 
al., 1992), which is physically distinct from the RB-binding domain. Hence, it is 
feasible that the interaction between UBF and SLl is not disrupted by RB. As 
discussed above, the TAF48 subunit of SLl was able to coprecipitate with RB; 
whether this was via association with UBF, or due to the ability of RB to target SLl 
independently from UBF cannot be concluded from this experiment. The available
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data therefore suggest that RB represses pol I transcription by binding UBF and 
preventing it from binding DNA, but without disrupting interactions with the other 
pol I transcription factor SLl or pol I itself. This mechanism of RB mediated 
repression of transcription is different from that observed for pol III, in which RB 
targets TFIIIB and prevents it from binding other transcription factors (Sutcliffe et al., 
2000). It also differs from that observed for pol II, wherein RB binds E2F, blocking 
its interaction with basal transcription factors (Ross et al, 1999).
It would be of interest to determine if RB could target SLl independently of 
UBF, and the consequences of such an interaction for pol I transcription. This might 
lead to an alternative model regarding RB-mediated regulation of pol I activity.
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Chapter 6
The pocket proteins pl07 and pl30 interact with both BRF and UBF
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6 The pocket proteins pl07 and pl30 interact with both the BRF and UBF
6 Introduction
The product of the Rb susceptibility gene, RB, belongs to a family of proteins 
called the pocket proteins. The two other pocket proteins, p i07 and p i30, are related 
in sequence and function to RB (Ewen et al., 1991; Hannon et al., 1993; Li et al., 
1993; Mayol et al., 1993; Zhu et al., 1993).
pl07 and pl30 are 30-35 % identical to RB, but show greater homology 
between each other, namely 50% amino acid identity (Grana et al., 1998; Mulligan 
and Jacks, 1998). These proteins display similar functions to RB, some are identical, 
whilst others appear to be related. Like RB, p i07 and p i30 are able to bind the 
products of DNA tumour viruses (Dyson, 1998; Herwig and Strauss, 1997; Mulligan 
and Jacks, 1998; Taya, 1997), and mediate arrest of cell cycle progression upon 
overexpression in particular cell types (Claudio et al., 1994; Qin et al., 1992; Zhu et 
al., 1993). They are also able to complex with E2F. However, whereas RB-E2F 
complexes are found in G1 (Hiebert et al., 1992), complex formation between E2F 
and the remaining pocket proteins occurs at other points during the cell cycle. For 
example, the binding of p i07 to E2F is found at the Gl-S boundary (Schwarz et al., 
1993), whilst pl30 coupled to E2F is detected in GO-Gl (Cobrinik et al., 1993). In 
addition, the E2F family member for which p i07 and p i30 have a preference to bind 
is different from that of RB. pl07 and pl30 prefer E2F4 and 5 (Beijersbergen et al., 
1994; Ginsberg et al., 1994; Hijmans et al., 1995; Vairo et al., 1995), whilst RB
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prefers E2F1, 2 and 3 (Lees et a l, 1993). Another interesting difference is the 
composition of the pocket protein-E2F complex; RB complexes to E2F alone, in 
contrast E2F4 and 5 complex to p i07 and p i30 in the presence of cyclin A-cdk2 or 
cyclin E-cdk2 (Cobrinik et a l, 1993; Li et a l, 1993; Shirodkar et a l, 1992), Hence, 
whilst p i07 and p i30 are able to mimic some functions of RB, such as binding E2F 
family members and cell cycle arrest, they clearly also display some peculiarities of 
function.
There is considerable redundancy between the various pocket proteins and 
this is well illustrated by studies characterising the phenotype of knock-out mice. 
Animals which lack either p i07 or p i30 develop normally, but animals which lack 
both of these proteins die within hours of being bom (Cobrinik et a l, 1996). In 
contrast, animals lacking RB die at midgestation, displaying defects in neurogenesis 
and erythropoiesis (Clarke et a l, 1992; Jacks et a l, 1992; Lee et a l, 1992). Thus it 
would appear that p i07 and p i30 are not able to undertake all the functions 
performed by RB. Furthermore, whilst RB has been shown to be a tumour suppressor 
suffering from mutational inactivation in a vast cross-section of tumours, the same 
can not be said for the other pocket proteins (Weinberg, 1995). No examples of 
naturally occurring mutations of p i07 have been found in human cancers. In the 
instance of p i 30, the chromosome area to which it is mapped is reported to be deleted 
in a variety of cancers. Moreover, one mutant form of p i30 has been identified in a 
small-cell lung cancer cell line (Helin et a l, 1997).
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As p i07 and p i30 are able to undertake some of the functions of RB, it was 
decided to determine if they were also able to assume other activities, such as binding 
the factors RB targets in order to repress pol I and pol III transcription. The work 
presented below demonstrates that like RB, p i07 and p i30 are able to interact with 
BRF, and that this interaction occurs at physiological ratios. It also shows that p i07 
and p i30, as has been demonstrated for RB, are able to interact with the pol I 
transcription factor UBF.
6.2 Results
6.2.1 Recombinant p i07 and pl30 interact with the BRF subunit of TFIIIB
Since RB has been shown to interact with the BRF subunit of TFIIIB, it was 
of interest to determine if the other members of the pocket protein family, p i07 and 
pi 30, could do the same. In order to investigate if recombinant p i07 and p i30 could 
interact with BRF, GST alone, GST-RB (379-928), GST-pl07 and GST-pl30 were 
purified and immobilised on glutathione-agarose beads. Reticulocyte lysate 
expressing radiolabelled BRF was added to each of these beads and the mixtures 
incubated. After incubation, the beads were washed, and the protein retained by the 
beads was visualised by SDS-PAGE and autoradiography (fig. 6.1). As can be seen 
from the autoradiogram, both GST-pl07 (lane 4) and GST-pl30 (lane 5) retained 
BRF with an efficiency comparable with that observed for GST-RB (lane 3). GST 
alone (lane 2) retained only a small background amount of BRF. Hence, the retention
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FIG. 6.1 Recombinant pl07 and pl30 interact with the BRF subunit of TFIIIB.
Reticulocyte lysate containing radiolabelled BRF (15pl) was incubated in the 
presence of glutathione beads carrying equal amounts of GST alone (lane 2) GST-RB 
(379-928) (lane 3) GST-107 (lane 4) and GST-pl30 (lane 5). Proteins retained after 
extensive washing were resolved on a SDS-7.8% polyacrylamide gel and visualised 
by autoradiography. Lane 1 shows 10% of the input of reticulocyte lysate containing 
in vitro-translated BRF.
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of BRF is specific to the pocket protein portion of the fusion protein. These data 
suggest that both p i07 and p i30 can interact with BRF.
6.2.2 Endogenous pl07 and pl30 can interact with the BRF subunit of TFIIIB
Immunoprécipitations were undertaken in order to determine if  endogenous 
p i07 and p i30 could interact with BRF. BRF expressed in vitro using reticulocyte 
lysate was mixed with HeLa cell extract and the mixture immunoprecipitated with a 
variety of antibodies immobilised on protein A beads. The precipitated material was 
examined for the presence of BRF by SDS-PAGE and autoradiography (fig. 6.2). As 
is shown, the antiserum specific for RB (lane 2), p i07 (lane 3) and p i30 (lane 4) each 
coprecipitated readily detectable amounts of BRF. This effect was demonstrated to be 
specific, as the control antiserum against TAF48 (lane 5) was not observed to 
coprecipitate BRF.
6.2.3 Endogenous p i07 and pl30 interact with endogenous BRF
To test for association of p i07 and p i30 with TFIIIB at physiological ratios, 
an immunoprécipitation was undertaken to determine if endogenous p i07 and p i30 
could interact with endogenous BRF. HeLa cell extract was subjected to 
immunoprécipitation using a range of antibodies immobilised on protein A beads. 
The coprecipitated material was resolved by SDS-PAGE and the presence of BRF
198
Chapter 6 Results
FIG. 6.2 Endogenous pl07 and pl30 interact with the BRF subunit of TFIIIB.
Reticulocyte lysate (15 pi) containing in vitro-translated BRF was mixed with HeLa 
cell extract (ISOpg) and the mixture was immunoprecipitated with anti-RB antibody 
C-15 (lane 2), anti-pl07 antibody C-18 (lane 3), anti-pl30 antibody C-20 (lane 4) and 
anti-TAF48 antibody C-19 (lane 5). The material retained after extensive washing 
was resolved by SDS-7.8% polyacrylamide gel electrophoresis and visualised by 
autoradiography. Lane 1 shows 10% input of the reticulocyte lysate containing 
radiolabelled BRF.
199
3
Q.
O
m
ŒI
H
Z
<
N
O
a .I
h"
Z
<
Oco
Q.
■
H
Z
<
00
T f
u_
?
z<
BRF
160kD
105kD
• i w  , . v - c W f
75kD
1 2 3 4
Chapter 6 Results
determined by western analysis (fig. 6.3.A). This figure demonstrates that antibodies 
raised against either RB (lane 3), p i07 (lane 1) or p i30 (lane 5) were all able to 
coprecipitate BRF. Once again, the antibody against the TAF48 subunit of SLl (lanes 
2 and 4) was unable to coprecipitate BRF, thus illustrating the specificity of the 
interaction. From these immunoprécipitation data it can be concluded that 
endogenous p i07 and p i30 interact with endogenous BRF.
The reciprocal experiments were also undertaken, immunoprecipitating with 
antiserum against BRF or the corresponding preimmune as a negative control. The 
coprecipitated material was analysed for the presence of pocket proteins by western 
blotting and probing for pl07 (fig. 6.3.B) or pl30 (fig. 6.3.C). As shown, both pl07 
and p i30 are coprecipitated with the BRF antiserum, but not with the preimmune 
control. These immunoprécipitation data confirm the previous observations that p i07 
and p i30 form a physical association with BRF at physiological ratios.
6.2.4 Recombinant p i 30 interacts with hUBF
It has been demonstrated that the two pocket proteins p i 07 and p i30 are able, 
like RB, to interact with the BRF subunit of TFIIIB. Hence it was decided to 
determine if p i 07 and p i 30 were also able to undertake another characteristic of RB, 
namely to interact with the pol I transcription factor UBF. The initial step in these 
investigations was to determine if recombinant p i30 could interact with hUBF. This 
was undertaken by purifying GST alone, GST-RB (379-928) and GST-pl30 and
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FIG. 6.3 Endogenous pl07 and pl30 interact with endogenous BRF.
(A) HeLa cell exti'act (150 p.g) was immunoprecipitated by anti-pl07 antibody (lane 
1), anti-RB antibody (lane 3), anti-pl30 antibody (lane 5) æid anti-TAF48 antibody 
(lanes 2 and 4). The coprecipitated material was resolved by SDS-7.8% 
polyaciylamide gel electrophoresis and probed for BRF by western blotting using the 
anti-BRF antisemm 128.
(B) HeLa cell extract (150 p,g) was immunoprecipitated with anti-BRF antiserum 128 
(lane 1) or preinnnune serum (lane 2). The coprecipitated material was resolved on a 
SDS-7.8% polyacrylamide gel and analysed by western blotting with the anti-pl07 
antibody SD9.
(C) HeLa cell exti'act (150 p,g) was immunoprecipitated with anti-BRF antiserum 128 
(lane 2) or preimmune serum (lane 1). The coprecipitated material was resolved on a 
SDS-7.8% polyactylamide gel and analysed by western blotting with the anti-Rb2 
antibody against p i30.
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immobilising them on glutathione-agarose beads. These beads were incubated with 
radiolabelled hUBF expressed in vitro by reticulocyte lysate. After incubation, the 
beads were washed and the retained protein analysed by SDS-PAGE and 
autoradiography (fig. 6.4.). As is illustrated, GST-RB retains readily detectable 
amounts of hUBF (lane 3). GST-pl30 does not retain as much hUBF as GST-RB 
(compare lanes 4 and 3), although it does retain more than GST alone (compare lanes 
4 and 2). This pull down suggests that whilst GST-pl30 may not retain hUBF to the 
same efficiency as GST-RB, there does appear to be an interaction which warrants 
further investigation.
6.2.5 Endogenous pl07 and pl30 interact with endogenous UBF
Immunoprécipitations were undertaken to establish an interaction between 
endogenous p i30 and UBF. HeLa cell extract was immunoprecipitated with a range 
of antibodies immobilised on protein A beads. The coprecipitated material was 
examined for the presence of UBF by western blotting and probing for UBF (fig. 6.5). 
The antisera against p i30 (lane 5) and RB (lane 4) coprecipitate UBF, therefore 
illustrating a physical association between p i30 and UBF at physiological ratios. The 
interaction was shown to be specific, as an irrelevant antiserum against the 
transcription factor OCT-1 (lane 6) was not able to precipitate UBF.
The ability of p i07 to interact with UBF was also investigated by 
immunoprecipitating HeLa cell extract with a variety of antibodies immobilised on
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FIG. 6.4 Recombinant pl30 interacts with the pol I transcription factor UBF.
Reticulocyte lysate containing radio labelled UBF was incubated in the presence of 
glutathione beads carrying equal amounts of GST alone (lane 2), GST-RB (379-928) 
(lane 3) and GST-pl30 (lane 4). Proteins retained after extensive washing were 
resolved by SDS-7.8% polyacrylamide gel electrophoresis and visualised by 
autoradiography. Lane 1 shows 10% of the input of reticulocyte lysate containing in 
vitro-translated UBF.
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FIG. 6.5 Endogenous p i30 interacts with endogenous UBF.
HeLa cell exti'act (150 pg) was immunoprecipitated using anti-OCT-1 antibody C-21 
(lane 6), anti-RB antibody C-15 (lane 4), anti-pl30 antibody C-20 (lane 5) or beads 
alone (lane 3). The coprecipitated material was resolved on a SDS-7.8% 
polyaciylamide gel and probed for UBF by western blotting using the anti-UBF 
antiserum 131. Lanes 1 and 2 show 10% and 25%, respectively, of the input of HeLa 
cell extract.
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protein A beads. The coprecipitated material was analysed for UBF by western 
blotting (fig. 6.6). The antiserum against p i07 (lane 3) coprecipitates UBF, therefore 
suggesting that at physiological ratios p i07 and UBF interact with one another. This 
interaction is specific, as antiserum against OCT-1 (lane 4) does not coprecipitate 
UBF.
6.3 Discussion
RB has been shown to target specific pol I and pol III transcription factors, 
namely UBF (Cavanaugh et ah, 1995) and BRF, respectively. Like RB, p i07 and 
pl30 have been shown to bind to the pol II transcription factor E2F (Grana et ah,
1998), hence their ability to bind BRF and UBF was investigated.
The pocket proteins p i07 and p i30 were both shown to bind BRF. This 
interaction was demonstrated to occur with endogenous proteins by 
coimmunoprecipitation and cofractionation data (Sutcliffe et ah, 1999). The binding 
of p i07 and p i30 to BRF was shown to be of functional significance, as the 
overexpression of both pi 07 and p i 30 in vivo inhibited pol III transcription (Sutcliffe 
et ah, 1999). In addition, the inclusion of either p i07 or p i30 in a reconstituted in 
vitro transcription system repressed pol III transcription from a range of promoter- 
types (Sutcliffe et ah, 1999). The E7 oncoprotein of human papillomavirus type 16 
has been shown to bind RB and prevent it from binding other cellular targets. In
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FIG. 6.6 Endogenous p i07 interacts with endogenous UBF.
HeLa cell exti'act (150 pg) was immunoprecipitated using anti-OCT-1 antibody C-21 
(lane 4), and anti-pl07 antibody C-18 (lane 3). The coprecipitated material was 
resolved by SDS-7.8% polyacrylamide gel electrophoresis and probed for UBF by 
western blotting using the anti-UBF antiserum 131. Lanes 1 and 2 show 10% and 
25% of the input of HeLa cell extract, respectively.
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addition to relieving RB-mediated pol III repression, E7 was shown to overcome pol 
III repression imposed by p i07 and p i30, as demonstrated by overexpressing wild 
type E7 in SA0S2 cells which lack a functional RB protein (Sutcliffe et al., 1999). 
Further evidence regarding the ability of p i07 and p i30 to regulate pol III activity 
was observed using mouse embryonic fibroblasts from p i 07 and p i30 double 
knockout mice. Northern blot analysis showed that the p i07 and p i30 null cells 
displayed slightly elevated B2 transcript expression. Moreover, upon serum 
withdrawal the level of B2 RNA expression in the p i07 and p i 30 null cells was 
approximately twice that observed in the heterozygous counterpart (Sutcliffe et ah, 
1999).
These observations provide additional evidence that p i07 and p i30 make a 
significant contribution to the control of pol III transcription in vivo. A model of how 
RB mediates repression of pol III transcription has been proposed. This model 
postulates that upon binding the general factor TFIIIB, RB does not disrupt the multi­
subunit complex of TFIIIB, but instead prevents it from interacting with other 
members of the initiation complex, namely TFIIIC and pol III (Sutcliffe et al, 2000). 
As pl07 and pl30 are both capable of repressing pol III transcription (Sutcliffe et ah,
1999), and display significant homology to RB (Grana et ah, 1998; Mulligan and 
Jacks, 1998), it would be reasonable to speculate that pl07 and pl30 repress pol III 
transcription in a similar fashion to RB.
The ability of p i07 and p i 30 to bind TFIIIB and regulate pol III transcription 
instigated investigations regarding the ability of p i 07 and p i 30 to perform another RB
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function, namely the targeting of UBF and regulation of pol I transcription, p i30 has 
been demonstrated by pull-down assays and immunoprécipitations to form a physical 
association with UBF, consistent with previous observations (Hannan et al., 2000a). 
Furthermore, p i30 has been shown to repress pol I activity (I. Grummt; personal 
communication), probably via its interaction with UBF. In addition, these studies have 
shown a physical association between p i07 and UBF. This conflicts with the findings 
of Voit et. al. (1997) and Hannan et al. (2000a) who have previously demonstrated 
that p i07 is not capable of binding UBF (Hannan et al., 2000a) or inhibiting pol I 
transcription in vitro (Voit et al., 1997). Therefore, the question remains as to what, if 
any, is the functional significance of p i 07 binding to UBF
The ability of RB, pl07 and pl30 to arrest cell cycle progression is suggested 
to be due to these proteins sharing particular cellular targets. Recent studies have 
demonstrated that like RB, p i07 and p i30 are able to repress pol III activity and 
probably also pol I transcription, p i07 and p i30 are therefore able to control cellular 
biosynthesis by regulating the expression of tRNA and rRNA genes.
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In 1996 White et al (White et ah, 1996) showed that RB was able to act as a 
general repressor of pol III transcription. In addition, they showed that the large 
pocket domain of RB was responsible for repressing pol III transcription, and that 
mutations within the domain alleviated this inhibitory effect (White et ah, 1996).
Further studies were undertaken by Larminie et al (Larminie et ah, 1997) in 
order to elucidate the target for RB within the pol III transcription machinery. It was 
reasoned that as RB is a general repressor of pol III transcription, it most likely 
targets a general component of the pol III apparatus. Indeed, this hypothesis was 
correct, as it was shown that RB specifically targets the general transcription factor 
TFIIIB (Larminie et ah, 1997).
TFIIIB is a multisubunit complex, which contains TBP (Hernandez, 1993; 
Rigby, 1993) and TAFs. One of these TAFs has been shown to be homologous to the 
pol II transcription factor TFIIB, and is called BRF (Buratowski and Zhou, 1992; 
Colbert and Hahn, 1992; Khoo et ah, 1994; Lopez-de-Leon et ah, 1992; Mital et ah, 
1996; Wang and Roeder, 1995). The next question to be answered was which subunit 
of TFIIIB does RB target in order to repress pol III transcription. Previous work had 
demonstrated that TBP did not interact with RB (Weintraub et ah, 1995). In addition, 
purified TBP could not rescue RB-mediated pol III repression (Larminie et ah, 1997). 
Therefore, the ability of RB to interact with the other characterised subunit of TFIIIB, 
that is BRF, was investigated.
210
Chapter 7 Conclusions
The work presented here clearly demonstrates that there is an interaction 
between RB and BRF, and thereby identifies BRF as a subunit of TFIIIB recognised 
by RB. Since it is feasible that mammalian TFIIIB contains additional subunits yet to 
be identified, it is possible that RB also recognises one of these.
In addition to establishing a physical association between BRF and RB, the 
binding interfaces on each protein have been mapped. The BRF-binding domain has 
been demonstrated to be the large pocket domain of RB. This finding is of great 
significance, as it provides a direct relationship between the large pocket of RB 
repressing pol III transcription (Larminie et al., 1997; White et al., 1996) and binding 
BRF. This suggests that by binding BRF, the large pocket domain of RB is able to 
mediate repression of pol III transcription. Moreover, the ability of RB to restrain cell 
growth (Qin et al., 1992) and bind BRF are both attributable to the large pocket 
domain. These observations suggest that the ability of RB to bind BRF and repress 
pol III transcription may contribute to its ability to inhibit cellular growth.
The reciprocal binding interface was also determined; namely the RB-binding 
region in BRF was shown to be the direct repeats in the TFIIB homologous amino- 
terminal half. This interesting discovery has several implications; firstly, the region in 
BRF that binds tightly to TBP is in the carboxy-terminal half, in both yeast 
(Kassavetis, 1998; Khoo et al., 1994) and human (fig 3.17). RB and TBP recognise 
distinct regions in BRF. Hence, it was expected that the binding of the former should 
not affect the association of the latter. Indeed, in the presence of RB the interaction 
between BRF and TBP is not abolished. The second implication of this work regards
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the direct repeats recognised by RB. BRF is the subunit of TFIIIB which forms 
contacts with both TFIIIC (Kassavetis et al., 1991; Kassavetis et al., 1992) and pol III 
(Khoo et al., 1994). Moreover, the location of these contacts has been mapped to the 
direct repeats (Kassavetis, 1998; Khoo et al., 1994). Hence, it was expected that upon 
binding BRF, RB would prevent TFIIIB from associating with TFIIIC, pol III or 
both. Work shown here indicates that the presence of RB abolishes the interaction 
between TFIIIB and TFIIIC, and between TFIIIB and pol III.
As mentioned previously, an intact large pocket domain of RB mediates 
binding and repression of E2F and cell growth suppression activities (Qin et al., 
1992). Mutations in the RB pocket domain occur naturally in tumours, resulting in 
inactivation of these frmctions (Horowitz et al., 1990). Indeed, naturally occurring 
deletions of the RB pocket (deletion of exon 21 and 22 (Horowitz et al., 1990)) 
alleviate the ability of RB to repress pol III transcription (White et al., 1996). 
Moreover, a point mutation in the pocket domain which causes a substitution at 
residue 706 from cysteine to phenylalanine (Kaye et al., 1990) abolishes the ability of 
RB to repress pol III transcription (White et al., 1996). Hence, it was decided to 
determine if these naturally occurring RB mutants were unable to repress pol III 
transcription as they are unable to bind BRF and prevent TFIIIB from interacting 
with both TFIIIC and pol III.
The work presented here indicates that a naturally occurring RB mutant 
(deletion of exon 21 (Horowitz et al., 1990)) is unable to interact with BRF. 
Subsequent investigations demonstrated that this mutant is also unable to disrupt the
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association between TFIIIB and TFIIIC, and between TFIIIB and pol III. 
Furthermore, another naturally occurring RB mutant, which contains a point mutation 
in the pocket domain (Kaye et ah, 1990), is also unable to abolish the interaction 
between TFIIIB and pol III. Similar findings were observed in tumourigenic cell lines 
in which the large pocket of RB was mutated. The deletion of exons 21-27 (Shew et 
al., 1990), or of four amino acids at the beginning of exon 20 (Scheffher, et al., 1991) 
abrogated the ability of RB to interact with BRF. These findings demonstrate that the 
presence of mutations within the pocket domain abolish the ability of RB to bind and 
repress TFIIIB. RB is a recognised tumour suppressor protein and as such it is able to 
restrain cell growth (Weinberg, 1995). Hence, these findings suggest that RB- 
mediated growth control may entail inhibition of polymerase III transcription.
In addition to mutational inactivation there are two other ways, found in 
cancerous cells, which inactivate RB: sequestration by viral oncoproteins and 
hyperphosphorylation. Previous work has demonstrated that cell lines transformed by 
Simian virus 40 display elevated pol III transcription levels in comparison to the 
untransformed parental cell line (White et al., 1990). Work shown here demonstrates 
that the association between BRF and RB is reduced in a cell line transformed with 
SV40 compared to the untransformed parental cell line. This suggests that upon 
transformation, the sequestration of RB by a viral oncoprotein compromises the 
association between BRF and RB, so that BRF is released and is now able to promote 
pol III transcription (Larminie et ah, 1999). It must be highlighted, however, that the 
oncoprotein binding and inactivation of RB is not the sole mechanism whereby SV40
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transformation up-regulates pol III transcription; in addition, abnormally high levels 
of TFIIIC2 expression are observed (Larminie et ah, 1999).
The third mechanism of RB inactivation observed in human cancer is 
hyperphosphorylation (Weinberg, 1995). The phosphorylation status of RB oscillates 
throughout the cell cycle, the majority of RB becoming phosphorylated during the 
last third of the G1 phase (Weinberg, 1995). Such phosphorylation prevents RB from 
interacting with a variety of cellular proteins, such as E2F (Chellappan et ah, 1991). 
As RB has now been shown able to repress all three nuclear RNA polymerases 
(Cavanaugh et ah, 1995; Kouzarides, 1995; White et ah, 1996), it was of interest to 
determine if hyperphosphorylation of RB abolished its ability to interact with BRF, as 
it does for E2F. Data shown here illustrate that hyperphosphorylation of RB disrupts 
its ability to interact with BRF. This observation provides a strong correlation 
between the inactivation of RB during late Gl, and the up-regulation of pol III 
transcription observed at the Gl/S transition (White et ah, 1995b). It suggests that the 
release of BRF from RB upon hyperphosphorylation of the latter promotes the 
elevated levels of pol III transcription observed. The pathway by which RB is 
phosphorylated is compromised in a variety of human cancers, such as breast and 
esophageal carcinomas. Disruption of this pathway ultimately gives rise to an inactive 
hyperphosphorylated form of RB (Weinberg, 1995). As this form is prevalent in 
tumourigenic cells, and is unable to bind BRF, this would suggest that the inability of 
RB to bind and repress TFIIIB via BRF contributes to the unrestrained growth 
associated with these cells. Therefore, these results demonstrate that the three ways
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RB is inactivated in human cancers can all compromise its ability to interact with 
BRF; hence, TFIIIB is not repressed and is able to promote pol III transcription.
As mentioned previously, in 1995 Cavanaugh et at showed that RB was able 
to repress pol I transcription, by targeting UBF (Cavanaugh et al., 1995). These 
studies confirm the previous observation of a physical association between RB and 
both UBF splice variants (Cavanaugh et al., 1995; Voit et al., 1997). They also 
identify the binding regions involved in this interaction. The large pocket domain of 
RB is bound by UBF; this agrees with former investigations that the large pocket is 
required to be intact for this interaction (Cavanaugh et al., 1995). This domain of RB 
has also been identified as being responsible for growth suppression (Qin et al., 
1992). Hence, the finding that this domain is also responsible for binding and 
repressing UBF suggests that repression of pol I transcription might contribute to this 
effect. The RB-binding domain in UBF was determined as HMG boxes 1 and 2, 
thereby substantiating previous work (Voit et al., 1997).
In addition to binding UBF, RB was also shown to bind the other pol I 
transcription factor SLl. This is consistent with the model for RB-mediated pol I 
repression, whereby RB binds UBF and prevents it from binding DNA, but not the 
other members of the pre-initiation complex, namely SLl and pol I (Voit et al., 
1997).
RB belongs to a family of proteins called the pocket proteins; the other two 
members, p i07 and p i30, display similar but not identical sequence homologies and
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functional properties (Grana et al., 1998; Mulligan and Jacks, 1998). Hence, it was of 
interest to determine if, like RB, p i07 and p i30 were both able to interact with the 
pol I and pol III transcription factors which RB targets to mediate its effect. As shown 
here, p i07 and p i30 were both able to interact with BRF and UBF. Moreover, p i07 
and p i30 are both able to repress pol III transcription (Sutcliffe et al., 1999). 
Recently, p i 30 has been shown to repress pol I transcription (I. Grummt, personal 
communication), but it is less clear whether p i07 is also able to repress pol I 
transcription.
In summary, RB is able to interact with both BRF and UBF. For both these 
interactions, the large domain of RB needs to be intact. This provides a correlation 
between repression of pol I and pol III and the ability of RB to mediate growth 
suppression. RB represses pol III transcription by binding BRF, and preventing 
TFIIIB from associating with TFIIIC or pol III. Inactivation of RB by 
hyperphosphorylation, viral oncoprotein sequestration or mutations disrupts the 
ability of RB to interact with BRF. Furthermore, inactivating mutations compromise 
the ability of RB to disrupt TFIIIB from associating with TFIIIC and pol III. RB also 
represses pol I transcription by binding the HMG boxes 1 and 2 of UBF. This agrees 
with previous observations whereby RB represses pol I transcription by binding UBF 
and preventing it from contacting DNA, but not disrupting it from associating with 
SLl or pol I. Lastly, the pocket proteins, p i07 and p i30 are both able to mimic 
particular functions of RB, as they both interact with BRF and UBF.
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